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Potential of human bone marrow derived stem cells combined with 
chitosan based biodegradable scaffolds for bone tissue engineering 
 
ABSTRACT 
 Bone tissue engineering has emerged as a promising alternative in cases of 
bone loss, overcoming problems of rejection and donor scarcity associated to the 
clinical used bone grafts (autografts, allografts and xenografts). By combining three-
dimensional structures (3D) – scaffolds, autologous cells and growth factors, bone 
tissue engineering seeks to achieve a long lasting and fully functional regeneration of 
bone. The selected scaffold should be biodegradable, allowing cells to adhere, 
proliferate and differentiate into the osteogenic phenotype, producing a mineralized 
extracellular matrix (ECM), to be later implanted into the bone defect. The rate of 
degradation of the scaffold should, therefore, be compatible to the rate of neo-tissue 
ingrowth. 
 The rationale of the experimental work of this thesis was designed to study a 
bone tissue engineering strategy by combining chitosan based scaffolds and human 
bone marrow mesenchymal stem cells (hBMSCs), aiming bone tissue regeneration. 
 Blends of chitosan with different types aliphatic polyesters were produced by 
extrusion. Afterwards, scaffolds were produced by compression molding followed by 
salt leaching. Several scaffolds formulations were produced and subjected to 
cytotoxicity and cytocompatibility tests, allowing selecting the most suitable 
formulation in terms of biological response. From the results obtained, the chitosan-
poly(butylene succinate) (PBS) formulation presented the most promising results in in 
vitro cell studies with relevant cell lines. To understand why this formulation has 
enhanced cell performance, several formulations using different percentages of 
chitosan (0, 25 and 50%) and PBS (100, 75 and 50%) were used to produce 
scaffolds. The influence of chitosan content was evaluated with hBMSCs in vitro. All 
in vitro results evidenced a better performance for the highest chitosan containing 
scaffolds, as for cell adhesion and proliferation, as for osteogenic differentiation. 
Scaffolds containing chitosan (50% chitosan-50% PBS) and without chitosan (100% 
PBS) were implanted in different anatomic regions (cranial defect, auricular pocket 
and submuscular) of rats. The tissue response was evaluated by studying the 
inflammatory response to the implanted scaffolds. Again, scaffolds with higher 
chitosan amounts evidenced superior results, with a mild inflammatory response 
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without cell necrosis, in vivo, as compared to PBS scaffolds, that evidenced tissue 
necrosis in all implantation regions. 
 A different morphology of chitosan-PBS scaffolds was developed by fiber 
bonding to improve the porous structure. These scaffolds were clearly non-cytotoxic 
and cytocompatible. Furthermore, chitosan-PBS scaffolds seeded and cultured with 
hBMSCs in osteogenic conditions, showed an excellent cell performance. 
 The biodegradation of chitosan-PBS scaffolds was assessed in vitro using 
enzymes responsible for the degradation of chitosan (lysozyme) and PBS (lipase), in 
similar concentrations to the ones found in human body. The cocktail of both 
enzymes induced a superior effect on the scaffolds biodegradation. The in vivo 
biodegradation and biocompatibility of the scaffolds were evaluated. The in vivo 
model applied to this study was the rat subcutaneous model. Results showed that the 
in vivo degradation was much slower than in vitro. The host tissue response was the 
typically associated with biomaterialsʼ implantation, with the presence of foreign body 
giant cells and an inflammatory response that progressed over time. The in vivo 
response was similar to those observed for biodegradable fixation devices or 
bioresorbable sutures. 
 The final study included in this thesis was performed to confirm the tissue 
engineering strategy followed in this work. The potential of chitosan-PBS scaffolds 
combined with hBMSCs, as previously demonstrated, was studied in a relevant 
animal model. A critical size cranial defect in nude mice was used. This model 
allowed evaluating the in vivo matured construct using human cells. The results 
showed that constructs were able to promote bone regeneration in a superior level 
than scaffolds without cells. The strategy followed under the scope of this PhD thesis 
was successfully validated in this small animal model, using a combination of 
chitosan-poly(butylene succinate) scaffolds with hBMSCs.  
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Potencial de células estaminais de medula óssea associadas a 
scaffolds biodegradáveis à base de quitosano para engenharia de 
tecido ósseo. 
 
RESUMO 
 A área de engenharia de tecidos ósseos surgiu como uma alternativa de 
tratamento em casos clínicos de perdas ósseas, evitando problemas de rejeição e 
morbidez associada a enxertos ósseos obtidos do próprio paciente. Combinando 
estruturas tridimensionais (3D) porosas, células autólogas e factores de crescimento, 
a engenharia de tecidos ósseos visa encontrar soluções para a regeneração de osso 
neste tipo de pacientes. O suporte 3D seleccionado deverá ser biodegradável, 
permitindo a adesão, proliferação e diferenciação osteogénica das células, de forma 
a produzir uma matriz extracelular mineralizada, sendo posteriormente implantada 
no defeito ósseo. A taxa de degradação do suporte 3D poroso deverá ser compatível 
com a taxa de regeneração do tecido ósseo. 
 O objectivo do trabalho experimental desenvolvido nesta tese foi planeado 
de forma validar uma estratégia de engenharia de tecidos ósseos, através da 
combinação de suportes 3D porosos biodegradáveis à base de quitosano e células 
estaminais adultas de origem humana obtidas a partir de medula óssea.  
 Neste trabalho foram produzidas várias misturas de quitosano com 
diferentes tipos de poliésteres alifáticos usando a técnica de extrusão. Usando estas 
misturas desenvolveram-se suportes tridimensionais que foram processados por 
moldação por compressão com partículas de sacrifício de sal. As misturas 
produzidas foram avaliadas em termos de citotoxicidade e citocompatibilidade. Desta 
forma, foi possível seleccionar a formulação mais adequada em termos de resposta 
biológica. A formulação de quitosano e polibutileno succinato (PBS) foi a formulação 
seleccionada para posterior desenvolvimento da estratégia de engenharia de 
tecidos. Por ter tido consistentemente os melhores resultados biológicos in vitro, a 
mistura seleccionada foi usada para produzir suportes porosos contendo diferentes 
percentagens de quitosano (0, 25 and 50%) e PBS, de forma a estudar a importância 
do quitosano nas formulações. A influência da percentagem de quitosano nos 
suportes porosos foi avaliada através de estudos in vitro com culturas primárias de 
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células estaminais mesenquimais de origem humana. Os resultados celulares 
obtidos mostraram um melhor desempenho em termos de adesão e proliferação, 
assim como na diferenciação osteogénica das células nos suportes 3D com maior 
percentagem de quitosano. Tendo-se observado uma maior eficácia no desempenho 
biológico dos suportes porosos contendo quitosano, interessava confirmar estes 
resultados in vivo, tendo como controlo suportes sem quitosano, só com PBS. 
Suportes porosos sem quitosano e com quitosano (50%), uma vez que foram 
aqueles para os quais se obteve o pior e o melhor comportamento celular in vivo 
respectivamente, foram implantados em diferentes regiões anatómicas (defeito 
craniano, implantação auricular e submuscular) em ratos. A resposta inflamatória foi 
avaliada, tendo os suportes porosos com quitosano evidenciado uma resposta 
inflamatória moderada, não se observando necrose celular. Suportes porosos com 
apenas PBS na sua constituição, mostraram necrose celular em todos os locais 
anatómicos implantados.  
 O passo seguinte passou por optimizar a morfologia  dos suportes, tendo 
sido neste caso desenvolvida uma estrutura porosa de malha de fibras de quitosano 
e PBS, por compressão a quente. Estes suportes porosos foram avaliados e 
confirmou-se também que não eram citotóxicos e que eram citocompatíveis. 
Adicionalmente, foram cultivadas células primárias humanas de medula óssea 
nestas estruturas tridimensionais, em condições de diferenciação osteogénica, 
mostrando um excelente desempenho in vitro. A biodegradação destes suportes 
porosos de quitosano-PBS foi estudada usando enzimas responsáveis pela 
degradação do quitosano (lisozima) e PBS (lipase) em concentrações idênticas às 
encontradas no corpo humano. Os resultados obtidos mostraram que um cocktail 
das duas enzimas teve um efeito pronunciado no que respeita à taxa de degradação 
dos suportes porosos. O estudo foi complementado pela análise da biodegradação e 
biocompatibilidade dos suportes tridimensionais in vivo. O modelo in vivo escolhido 
para este estudo foi o implante subcutâneo em ratos. Os resultados obtidos 
mostraram que a taxa de degradação in vivo foi consideravelmente menor 
comparativamente com os estudos efectuados in vitro. A resposta in vivo foi 
semelhante à observada em implantes de placas de fixação óssea biodegradáveis 
ou em suturas bioabsorvíveis.  
 O último estudo incluído nesta tese foi realizado para confirmar a estratégia 
de engenharia de tecidos proposta neste trabalho: a associação de suportes porosos 
biodegradáveis de quitosano e PBS e células estaminais humanas de medula óssea 
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diferenciadas para a linhagem osteogénica. O potencial desta estratégia foi 
estudado num modelo animal relevante: um defeito craniano de tamanho crítico em 
ratinhos imunocomprometidos. Este modelo permitiu avaliar o efeito da implantação 
dos suportes porosos cultivados com células humanas naqueles defeitos ósseos. Os 
resultados obtidos mostraram que esta associação de suportes porosos de 
quitosano-PBS com células humanas pré-cultivados in vitro em condições 
osteogénicas, promoveram regeneração óssea de uma forma mais significativa 
quando comparados com suportes porosos implantados sem células. A estratégia de 
engenharia de tecidos seguida no âmbito desta tese de doutoramento, através da 
combinação de suportes porosos de quitosano-PBS e células estaminais humanas 
de medula óssea foi validada com sucesso neste modelo animal de pequeno porte.
 xvi 
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STRUCTURE OF THE THESIS 
 
 This thesis is divided in six sections containing eight chapters, being five of 
them experimental work. The structure of the thesis was adopted having in mind the 
final objective of this PhD research, leading to a successful bone tissue engineering 
strategy. The experimental part was divided in 3 sections, 3, 4 and 5. In each of 
these sections it is described each one of the phases of the work developed in this 
thesis. The contents of each section are summarized below. 
 
 
SECTION 1 (Chapter I) 
 Chapter I is based on a review paper, presenting an overview on bone tissue 
engineering using chitosan based scaffolds. Bone biology is briefly analyzed to clarify 
the role of the various components required to achieve a successful bone tissue 
engineering strategy. These components are discussed in detail, covering from the 
type of scaffold to the in vivo proof of concept. The choice of cells, type of biomaterial 
used to produce the scaffold and its in vivo validation, as well as the type of animal 
models are also presented. In all these aspects, a special attention was given to 
chitosan as a suitable biomaterial to produce scaffolds for bone tissue engineering. It 
is also included a review of the literature on the different types of chitosan processing 
methodologies. The review also discusses the reports in vitro and in vivo on bone 
tissue engineering strategies using chitosan. 
 
 
SECTION 2 (Chapter II) 
 Chapter II presents the materials and experimental procedures used in the 
present thesis. This chapter contains additional information about the experimental 
methods used in the various chapters of the thesis. Furthermore, it aims also at 
providing a general framework for the testing of new tissue engineering strategies in 
a comprehensive and structured way.  
 
 
SECTION 3 (Chapters III and IV)  
 Chapter III describes the in vitro testing of scaffolds produced with various 
chitosan-polyester formulations (PBS, PCL and PBTA) using in all cases the same 
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percentage of chitosan (50% wt). The scaffolds were processed by compression 
molding and particulate leaching. The eventual cytotoxicity of extracts from the 
scaffolds is evaluated with a L929 cell line. This chapter also presents the results of 
the first biological evaluation of these scaffolds, by using a mouse MSC cell line 
(BMC9) to select the most adequate scaffold formulation for bone tissue engineered 
applications. These in vitro results evidenced a superior performance for chitosan-
poly(butylene succinate) scaffolds. The next step aimed at clarifying why this specific 
scaffold formulation evidenced a superior cell performance. 
 
 Chapter IV presents further in vitro studies using primary cultures of human 
MSCs differentiated into the osteogenic lineage on scaffolds produced with different 
chitosan percentages (0, 25 and 50%). The in vitro results allowed concluding that 
chitosan containing scaffolds have stronger biological performance than 100% PBS 
scaffolds. This work also reports an experimental design to assess the in vivo effect 
of the chitosan, by implanting the scaffolds without and with 50% chitosan. The trend 
already observed in vitro was further confirmed in vivo, showing that the chitosan 
containing scaffolds elicit a milder inflammatory response and no signs of tissue 
necrosis when compared with scaffolds of PBS (without chitosan). 
 
 
SECTION 4 (Chapters V and VI) 
 Chapter V reports the results of the in vitro testing of scaffolds produced by 
fiber bonding, with an optimized porous morphology and with the formulation having 
the strongest performance in previous experiments (chitosan-PBS 50% wt). These 
scaffolds have enhanced porosity and interconnectivity, facilitating the cell ingrowth. 
In fact, the previous in vitro results obtained in chapter IV evidenced some difficulty of 
the cells to penetrate the porous structure of the scaffolds produced by compression 
molding/salt leaching. The results obtained in vitro using human MSCs differentiated 
into the osteogenic lineage evidenced a superior cell ingrowth throughout the entire 
scaffolds structure. This evidence showed that the optimized morphology indeed was 
able to facilitate the cell migration into the porous structure of the scaffold. 
  
 Chapter VI reports the results of the study of the biodegradation of the 
scaffolds previously tested in chapter V, both in vitro and in vivo. The in vitro studies 
were intended to model the degradation in vivo, using specific enzymes. The 
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selected enzymes (lysozyme and lipase) are known to degrade the two polymers 
used to produce the scaffolds. The concentrations of enzymes used in vitro were 
similar to those found in the human serum, to predict the degradation of the 
developed scaffolds. The in vivo analysis was performed to assess the 
biodegradation of the scaffolds and to compare its kinetics with the one obtained in 
the in vitro results. Furthermore, it was also evaluated the tissue response to the 
implantation of the new scaffold morphology, comparing the inflammatory response 
with the one previously obtained for the scaffolds with similar composition but with 
different porous morphology. 
 
 
SECTION 5 (Chapter VII) 
 Chapter VII describes the in vivo validation of the tissue engineering strategy 
proposed in this thesis. After studying the in vitro performance and the in vivo tissue 
response of the developed scaffolds, in the context of bone tissue engineering, it was 
necessary to demonstrate if the strategy would be effective in a relevant in vivo 
model. For that, it was used an orthotopic model in the calvaria of nude mice to verify 
if pre-cultured human bone MSCs on chitosan-PBS scaffolds were able to stimulate 
bone regeneration in vivo. The scaffolds used in this model were produced by 
compression molding and salt leaching, being the preferred morphology enabling 
producing a scaffold with the geometry required to fit into the bone defect used.  
 
 
SECTION 6 (Chapter VIII) 
 Chapter VIII contains the general conclusions and final remarks regarding 
the series of studies performed under the scope of this thesis. It is intended to 
provide a general summing up of the conclusions extracted in the various sections 
and allowing a complete analysis of the progress obtained in the framework of this 
thesis.  
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CHAPTER I 
 
INTRODUCTION 
 
Chitosan based scaffolds for bone tissue engineering applications 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: Costa-Pinto AR, Reis RL, Neves NM. “Chitosan based 
scaffolds for bone tissue engineering applications” 2010; Submitted. 
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CHAPTER I 
INTRODUCTION 
 
ABSTRACT 
 As life expectancy increases, malfunction or loss of tissue caused by injury or disease 
leads to reduced quality of life in many patients at significant socio-economic cost. Even 
though major progresses have been made in the field of bone tissue engineering during the 
last few years, current therapies such as bone grafts still have limitations. Current research 
on biodegradable polymers is emerging, combining these structures with osteogenic cells, as 
an alternative to autologous bone grafts.  
 Different types of biodegradable materials have been proposed to be used as three-
dimensional (3D) porous scaffolds for bone tissue engineering. Among them, natural 
polymers are one of the most attractive options, mainly due to their similarities with 
extracellular matrix (ECM), chemical versatility, good biological performance and inherent 
cellular interactions. In this review, special attention is given to chitosan as a biomaterial for 
bone tissue engineering. An extensive literature survey was performed about the processing 
of chitosan scaffolds and its biological performance in vitro as well as its in vivo bone 
regeneration potential.  
 The present review also aims to offer the reader a general overview on all 
components needed to engineer new bone tissue, giving a brief background on bone biology, 
followed by an explanation of all components in bone tissue engineering, as well as 
describing different tissue engineering strategies. Moreover, it will be exploited the typical 
model to evaluate the in vitro functionality of a tissue engineered construct and the in vivo 
models to assess the potential to regenerate bone tissue.  
 
1. INTRODUCTION 
 Bone tissue, when injured, leads to dramatic changes in the quality of life of patients. 
It can limit the ability to perform basic tasks, such as walking and frequently causes social 
and psychological problems. The current clinical available solutions for these problems rely 
on bone graft transplants (autologous, allogenous and xenogenic), bone transport methods 
(Ilizarov technique) and implants based on different types of materials. More than 2.2 million 
bone graft procedures (autologous bone graft and banked bone) take place annually 
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worldwide (1, 2). Those procedures ensure adequate bone healing in many skeletal 
problems, such as non-union fractures, cervical and lumbar spine fusion, joint arthrodesis or 
revision arthroplasty. Bone grafting is a strong and mature business generating sales of more 
than $2.5 billion a year (3). Autografts are considered the gold standard for bone repair. 
However, some complications may occur, such as bone non-unions and blood loss, which 
increases the need for blood transfusions (4-7). Moreover, besides being an expensive 
procedure, there is a limited supply of tissue and it causes significant donor site morbidity (6, 
8). Allografts are typically non-vital (dead) bone harvested from a cadaver and then 
processed using a freeze-drying method that extracts all the water via a vacuum drying 
process. These type of grafts avoid donor site morbidity, but present a potential risk for 
disease transmission and severe immune response by the patient (9). Similar to allogeneic 
bone, xenogenic bone is non-vital bone derived from other species, mainly from bovine 
origin. Because the potential for immune rejection and contamination by viral proteins is 
higher in bovine bone than in human cadaver bone, xenograft material is processed at very 
high temperatures. The Ilizarov methodology consists of an osteotomy followed by bone 
distraction by extendable fixation devices. This technique avoids problems related with the 
osteointegration of bone grafts, but requires longer periods of treatment (12-18 months) and 
can be quite painful for the patient (10). The aforementioned limitations justify the need to 
develop new therapies using alternative concepts that are currently the focus of intense 
research efforts. 
 Bone has a notable regenerative ability but a considerable amount of bone loss or the 
development of an adverse microenvironment can hinder this capacity, such in cases of 
severe trauma, developmental deformities, revision surgeries and tumor resection (11, 12). In 
these cases, bone tissue engineering holds the promise of great therapeutic potential (13). 
Bone tissue engineering may constitute the needed breakthrough technology to solve the 
problem of bone shortage in various destructive clinical conditions and deformities, by 
providing functional tissue engineered biological substitutes (14). The most promising 
strategy used in this field is based on the seeding and in vitro culture of primary osteoblasts 
or adult stem cells, differentiated into the osteogenic phenotype on three-dimensional (3D) 
scaffolds (synthetic, natural or ceramics). These constructs will be further implanted into a 
bone defect. The cells will synthesize the ECM of the new bone tissue, while the scaffold will 
provide the adequate 3D environment for the cells to adhere, proliferate and differentiate. 
The scaffolds will be not only temporary 3D supports for the cells to create new bone, but 
also space filling and local controlled release devices of signaling molecules. To accomplish 
all these goals, the scaffold should meet stringent requirements, such as biodegradability at 
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such rate that is compatible to the rate of new tissue formation. Other important properties 
include the biocompatibility with host tissues, non-toxicity and non-immunogenicity, 
appropriate mechanical properties, adequate porosity and morphology (15-17). All these 
properties are essential to facilitate and guide cell ingrowth, transport of gases, metabolites, 
nutrients and signaling molecules, both within the scaffold and between the scaffold and the 
native local environment. 
 The selection of the most suitable material to produce a scaffold to be used in bone 
tissue engineering applications is a determinant step, since its properties will determine its 
final characteristics. Biodegradable polymers, either synthetic or natural, are the most 
appropriate substrates for the cells to attach, grow and maintain a differentiated phenotype. 
In the last years, natural origin polymers have been increasingly proposed for the referred 
application. In our group, we have been working with natural based polymers, such as starch 
(18-22), chitosan (23-27), gellan gum (28-31), soy (32) or silk (33, 34). Our strategy is to 
mimic nature and, for that, we have been using those polymers to design functional 
microenvironments stimulating tissue morphogenesis. In particular, chitosan has shown an 
excellent combination of properties and it has been demonstrated that it is a suitable 
biomaterial to develop scaffolds for bone tissue engineering. Chitosan can be used either 
alone (23, 35-41) or in combination with other biodegradable polymers, such as aliphatic 
polyesters (25, 42-47), other natural polymers such as starch (26, 48, 49) or silk (50, 51), or 
with ceramics, such as hydroxyapatite (HA) (24, 52-60). 
 This manuscript aims to provide an overview of the most important concepts in bone 
tissue engineering and a review on chitosan based scaffolds proposed in the literature to 
regenerate bone tissue. The potential of this biomaterial as a suitable substrate to support 
osteogenic differentiation of mesenchymal stem cells (MSCs) will also be explored. 
 
2. BRIEF OVERVIEW OF BONE BIOLOGY 
 Bone is a dynamic and complex tissue evolving and adapting to various stimuli 
throughout the entire lifetime (61). It plays crucial roles in both mechanical support and 
mineral homeostasis (62). Within a skeletal element, there are different morphologies of 
bone, such as cortical and trabecular bone. Cortical bone is a compact structural tissue, with 
only 10% porosity, being 80% of the mass of an adult human skeleton. Trabecular bone is a 
spongy structure with 50-90% porosity, filled with bone marrow. The majority of bones are 
covered by a highly vascularized fibrous connective tissue, the periosteum (63). Five different 
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cell types are involved in bone maintenance and remodeling: MSCs, bone-lining cells, 
osteoblasts, osteocytes and osteoclasts. Within the bone structure, MSCs are found in the 
bone marrow (64-67) and also in the periosteum (68). The bone marrow is composed of 
hematopoietic tissue and the supporting stroma (69). Marrow stromal cells, originally thought 
to only contribute to the hematopoietic microenvironment, later came to the center stage with 
the recognition of being the stem/progenitor cells of skeletal tissues (65). Human autologous 
bone marrow associated with macroporous hydroxyapatite scaffolds were implanted in large 
bone segmental defects and shown to promote bone regeneration (70). After a 7 years follow 
up (71), the patients presented a complete healing of the defects. Bone-lining cells are flat 
cells that cover all bone surfaces and are believed to have origin from osteoblasts that 
become inactive (72, 73). These cells form an important cellular barrier that divides the 
canalicular network (where osteocytes are present) from other fluids (63). Osteoblasts are 
cells derived from MSCs that synthesize the osteoid (non-mineralized organic matrix of the 
bone, i.e. type I collagen, osteocalcin, osteopontin, bone sialoproteins and bone 
morphogenetic proteins) (74). Osteoblasts also have an active role in the vascularization 
process by secreting morphogens that activate angiogenesis by signaling endothelial cells 
(75-77). Osteocytes are terminally differentiated osteoblasts entrapped within the bone ECM, 
that are involved in the maintenance of ECM and calcium homeostasis (63). Osteocytes are 
also the cells sensing mechanical stress and communicating signals for bone remodeling 
and tissue maintenance (78). The fifth cell type is the osteoclast, responsible for bone 
resorption that is the first stage of the bone remodeling process, followed by bone 
homeostasis. These cells are large multinucleated cells differentiated from a fraction of 
monocytes found in the peripheral blood (63).  
 As many other connective tissues, one of the main components of bone is its ECM, 
that in this case is mineralized. Bone ECM is composed of 35% of organic matrix and 65% of 
mineral matrix. The most abundant mineral in bone ECM is HA, a calcium phosphate 
crystallized at the surface of collagen fibrils, required to resist to bending and compression 
stresses (61). The organic matrix is mainly proteic composed of type I collagen (90%) and 
the remaining fraction includes up to 200 other non-collagenous proteins, such as 
glycoproteins, proteoglycans, integrin-binding proteins and growth factors (61). 
 Bones are developed by two main processes: intramembranous and endochondral 
ossification (79, 80). Intramembranous ossification is a process that generates flat bones and 
the skull structure. In this pathway, the embryonic mesenchyme condenses and develops in 
primary ossification centers, which will eventually fuse to form a network of anastomosing 
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interconnected trabeculae made of woven bone (79). After that, periosteum is formed at the 
surface of trabeculae, further mineralized and part of the intertrabecular connective tissue is 
transformed in hematopoietic tissue (80). Finally, the woven bone is remodeled into a 
lamellar type of bone (81). Endochondral ossification is an osteogenic process through which 
long bones, vertebrae and pelvis are generated from their precursor cartilaginous tissue. 
(82). This process starts in the fetus stage where MSCs differentiate into chondrocytes, 
converting the condensed mesenchyme into a cartilaginous model of bone that will expand in 
its extremities, while becoming hypertrophic in the center. These hypertrophic chondrocytes 
will promote primary ossification by secreting molecules (such as alkaline phosphatase, type 
X collagen or vascular endothelial growth factor - VEGF) that will induce calcification of 
cartilage. This tissue will be resorbed, becoming a structure onto which progenitor cells 
differentiate into osteoblasts that start to deposit osteoids. After birth, the secondary 
ossification centers are developed at the extremity of long bones allowing the development 
and growth of bone structure (81). 
 
3. BONE TISSUE ENGINEERING STRATEGIES 
 Bone has an intrinsic self-ability to regenerate, but over a large defect, inherent 
osseous processes are not able to repair the defect during the patient´s lifetime (83). 
Furthermore, diseased bones do not heal properly, and under certain pathological conditions 
start damaging themselves (83-85). Tissue engineering has emerged as a possible solution 
for these clinical conditions. Several strategies can be employed to develop new bone tissue. 
Those strategies may involve the use of an ECM-like structure (scaffold), cells, and/or growth 
factors. These three basic components need to be well synchronized in order to achieve a 
successful tissue engineering therapy. The strategy used for a specific bone defect must be 
adapted to the clinical state of the patient. There are three main approaches originally 
described for tissue engineering: 1) to use engineered matrices alone, in order to guide 
tissue regeneration; 2) to inject autologous, allogeneic, or xenogeneic cells alone; 3) to 
develop constructs of cells seeded on those matrices (14). The first method involves 
implanting the scaffold at the site of interest, allowing host cells to migrate from the 
surrounding tissues to colonize the scaffold. The second strategy has the advantage of 
involving minimal surgical invasion and cells can be manipulated by recombinant gene 
technology or clonal expansion prior to injection or infusion. However, this methodology has 
limitations for bone critical size defects, due to the absence of the supporting matrix to keep 
cells at the defect site. In the last approach, cells are seeded onto scaffolds (construct) and 
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later implanted into the bone defect. Usually constructs are produced ex vivo prior to 
transplantation to a bone defect and over time cells will synthesize a new ECM, as the 
scaffold degrades, creating a new functional tissue. This review will focus on the third tissue 
engineering strategy, exploring the potential use of autologous stem cells cultured onto 
biodegradable scaffolds that will act as extracellular matrices, supporting cell growth and 
tissue development.  
 
4. NATURAL BASED POLYMERS FOR SCAFFOLD DESIGN  
 Nature offers a remarkable set of materials with great potential to be used in different 
fields. The study and use of natural materials comes from ancient times, such as cellulose, 
that is used to produce paper or silk to produce clothes. In medicine for example, chitosan is 
used as wound dressing material and collagen as a substitute in reconstructive surgery. 
Today, powerful tools are available and the micro and nanostructures of these materials were 
already clarified. The new level of knowledge brought new opportunities to develop materials 
for other applications, such as scaffolds for tissue engineering. Great efforts have been made 
to recapitulate the key features of bone ECM by developing structures that mimic this 
naturally occurring matrix. ECM plays an important role over cell activities, modulating their 
behavior (86). One difficulty in developing such scaffolds is the complexity to recreate a 
similar microenvironment to the tissue of interest. A simple approach to mimic nature is to 
use naturally occurring materials. Moreover, natural polymers have different functions, such 
as the role of polysaccharides in the cell membranes, intracellular communication and 
storage, or proteins that are structural materials and catalysts (enzymes) (87). Natural 
polymers such as starch (18-20, 22, 88-90) or chitosan (91-94) have been described as 
biocompatible, biodegradable and having tailored degradation rate (88, 92). Some 
drawbacks of these biomaterials are the limited mechanical properties and processability or 
variability between different batches (15). Examples of natural polymers commonly used to 
produce scaffolds are collagen (95-99), hyaluronan (100, 101), alginate (102), silk (50, 103, 
104) and chitosan (23, 37, 41). These polymers can be combined with other synthetic 
materials, to improve their processability and mechanical properties. Combinations with HA 
(105), aliphatic polyesters (25, 27, 106, 107) or composites of different natural polymers (26, 
48) have also been described. Herein a special focus will be given to the natural 
polysaccharide chitosan, the deacetylated product of chitin obtained from the exoskeleton of 
crustaceans. 
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5. CHITOSAN AS A NATURAL ORIGIN BIOPOLYMER 
 The history of chitosan dates back from the 19th century when Rouget discussed its 
deacetylated form (108). Chitosan is a linear polysaccharide, obtained from the deacetylation 
of chitin, the primary structural polymer of the exoskeleton of crustaceans, cuticles of insects 
and cell wall of fungi (109, 110). Chitosan is composed of glucosamine and N-acetyl 
glucosamine with β (1-4) link (111). Chitosan is the common name for the family of 
deacetylated chitins, with different degrees of deacetylation. By definition, when the number 
of N-acetyl glucosamine units is higher than 50%, the polymer is considered chitin. On the 
other hand, when the number of N-glucosamine units is superior, its name is chitosan (112). 
The molecular weight of chitosan may range from 300 to more than 1,000 kDa, depending on 
its origin and on the preparation method (35). The solubility of chitosan depends on the free 
amino and N-acetyl groups, being soluble in acidic pH (35). The cationic nature of chitosan 
allows electrostatic interactions with anionic glycosaminoglycans (GAGs) and proteoglycans. 
Natural polymers are known to influence cell morphology, modulation and differentiation 
(113, 114), as referred previously. This property is of crucial importance in tissue engineering 
field, because GAGs molecules modulate the action of several cytokines and growth factors 
(115).  
 Chitosan presents a wide range of properties that makes it suitable for tissue 
engineering applications, namely its biodegradability (91, 116, 117), biocompatibility (93, 94, 
118-120), antibacterial activity (121-123), wound healing properties (124-130) and easy 
accessibility.  
 Chitosan can be hydrolyzed by chitosanases (131), which are absent in mammals. It 
is well documented that lysozyme is responsible for the biodegradation of chitosan in vitro 
(91, 92, 132, 133). The degradation rate of chitosan is inversely related to the degree of 
deacetylation (132), which represents the proportion of N-acetyl-D-glucosamine units to the 
total number of units (131). Lysozyme is ubiquitous in the human body (134). It is found in 
lacrimal gland, middle ear, nose, bronchus, bronchiole, bone marrow and digestive tract 
(135). Lysozyme has an important role in inflammatory response, being secreted by 
macrophages, monocytes, and granulocytes (136, 137). Monocytes and macrophages are 
the main contributors to the presence of lysozyme in human serum in concentrations 
between 7 and 13 mg/L (134).  
 Chitosan has intrinsic anti-microbial properties against several microorganisms, 
namely fungi and bacteria (138). The accurate mechanism is still unknown, although its 
CHAPTER I. Introduction  
 12 
cationic nature associates with anions in bacteria cell wall, suppressing biosynthesis and 
also disrupting the mass transport across the cell wall, leading to the death of bacteria (138). 
  Chitosan has been described as a potent wound healing accelerator (139), and to 
possess immunological activity, by activating macrophages (140), to produce cytokines (141) 
and to inhibit infection (142).  
 One of the most important characteristics of chitosan, for tissue engineering 
applications, is its ability to be shaped into various structures, such as microspheres (143), 
paste (144), membranes (113), sponges (37, 145-148), fibers (27, 38, 149) and porous 
scaffolds (25, 27, 56, 150, 151). Several processing methodologies have been used to 
produce chitosan porous scaffolds and will be herein further discussed in detail. 
Nevertheless, before describing the scaffolds processing techniques, it is important to 
underline the properties that a scaffold must possess to be successfully applied in bone 
tissue engineering applications. 
 
6. SCAFFOLD REQUIREMENTS FOR BONE TISSUE ENGINEERING 
 Bone is a 3D tissue and cells alone do not grow in a 3D manner in vitro. For that 
reason, a tridimensional structure is required to support the formation of new functional bone 
tissue. This structure should provide a suitable environment for cell attachment, proliferation, 
differentiation and ECM deposition. The in vitro cultured constructs, when implanted into the 
defect must be vascularized and osteointegrated into the host bone (152). The 3D structures 
should be biocompatible, i.e., not evoking an immune response when implanted in the host 
tissue. When a scaffold is implanted into the defect to restore bone functionality, it should 
activate the healing mechanisms (inflammatory response). The time course of healing is 
influenced by interactions between blood, scaffold surface and degradation products, which 
are released from the scaffold and therefore, influencing biocompatibility. The ideal scaffold 
should degrade in a rate compatible with the rate of bone growth, physically creating open 
space for the new bone formation, until full regeneration is achieved. The process of polymer 
degradation follows the mechanisms through which polymer chains are cleaved into 
oligomers and finally to monomers, that can be metabolized by natural mechanisms (153). If 
a biological process mediates the degradation process, it is designated by biodegradation 
(153). Several factors influence the kinetics of degradation: type of chemical bonds, pH, 
polymer composition, crystallinity, molecular weight, porosity, water uptake and anatomical 
location of the implant (153). Ideally, natural pathways of the animal body should eliminate 
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the degradation products. 
 As previously discussed, bone is a highly vascularized tissue, relying on the 
interactions between bone cells and blood vessels. In this way, angiogenesis and 
neovascularization play a crucial role in bone repair, and should be taken into account when 
designing a scaffold. Angiogenesis is mainly characterized by the protrusion and outgrowth 
of capillary buds and sprouts from pre-existing blood vessels, while neovascularization 
comprises the formation of functional microvascular networks with red blood cell perfusion 
(154). Both processes are required to ensure successful engraftment of the construct into the 
surrounding host tissue. A vascular network can be included in a biodegradable and 
biocompatible scaffold by microfabrication techniques (155). The main property of the 
scaffold that is directly related to vascularization is its porosity (156). Scaffolds should have 
highly interconnected porosity to promote cell ingrowth and distribution throughout the matrix, 
as well as facilitating the development of neovascularization. The minimum pore size is 
considered to be approximately 100-150 μm (157), due to cell size, migration requirements 
and fluid transport. However, due to vascularization requirement, pore sizes were shown to 
affect the course of osteogenesis (156). Large pores rapidly become well-vascularized 
leading to direct osteogenesis (158, 159). In contrast, small pores lead to hypoxic conditions, 
which tend to induce the development of osteochondral process, before osteogenesis 
occurs. The porosity strongly influences scaffold mechanical properties. High porosity and 
pore size facilitates tissue ingrowth, but the consequence is a drastic reduction of mechanical 
properties, compromising the structural integrity of the scaffold (160). The mechanical 
properties of a scaffold should be compatible with those of the native tissue, maintaining its 
structural integrity after implantation (161). In general, the scaffold should be strong enough 
to not only resist to stresses that may cause important dimensional changes, but also to 
overcome the contraction that will exist during the in vivo tissue healing. Scaffold integrity is 
critical, since cells and tissue remodeling are important to achieve stable biomechanical 
environment and vascularization at the host site. The topography and surface chemistry of 
the scaffold play a crucial role in its performance, since those are the first elements that cells 
recognize when in contact with the scaffold surface. The type of proteins that will adsorb to 
the surface of the material, hydrophilicity or hydrophobicity will modulate to a great extent the 
protein adsorption, which will influence cell activity upon seeding (162).  
 The methodology used to produce scaffolds for bone tissue engineering must not 
adversely affect biocompatibility or physical and chemical properties of the biomaterials used. 
Different scaffold batches should exhibit minor variations in their properties, when processed 
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with similar processing parameters and conditions (163). Different processing methodologies 
for chitosan based scaffolds were already reported in the literature and will be further 
discussed in detail.  
 
7. CHITOSAN SCAFFOLDING METHODOLOGIES 
 The most common processing methodology described for chitosan scaffolds is 
freeze-drying. This process consists in the lyophilization of a frozen chitosan solution, where 
the chitosan acetate salt is induced by the freezing conditions to phase-separate from the ice 
crystal phase. The ice phase is further sublimated, producing a porous structure (24, 35, 37, 
51, 56, 148, 151, 160, 164-175). In most cases, the scaffolds can still have chitosan acetate 
that will cause fast swelling and subsequently dissolution in a neutral aqueous medium. This 
can be overcomed by crosslinking upon immersion in sodium hydroxide (35, 169), sodium 
sulfate (38), tripolyphosphate (37, 148), ethanol series (35), or with a combination of 
crosslinking with rehydration (164). The freeze-drying technique requires a very tight control 
of the temperature. If the temperature is not sufficiently low, the matrix will not become rigid 
enough to support the interfacial tension caused by the evaporation of the solvent without 
collapsing, creating a surface skin. Another limitation of the structures produced by this 
technique is that the size of the pores is not very large. Also the mechanical properties of the 
porous structures are very limited, even after cross-linking. Due to the susceptibility of freeze-
drying methodology, solvent exchange phase separation has been proposed as an 
alternative methodology. This technique is based in the gelation of a solution of chitosan 
using an alkaline solution below its gelation point (26, 36, 53, 176). In freeze-drying process, 
the choice of the solvent is limited, since the solvent vapor pressure at the drying 
temperature (usually low) must be high enough to allow its removal (36). With this alternative 
method, less time consuming and more economic, the choice of the solvent is wider (36).  
 Another processing methodology of chitosan is wet spinning, allowing producing 
fibers. Due to the strong inter-chain forces derived from the hydroxyl and amino groups, 
chitosan tends to degrade at temperatures below its melting temperature, limiting its 
processability by melt or dry spinning methods (38, 41, 149, 177-179). Basically, chitosan is 
dissolved in a solution of diluted acetic acid. This solution is spun through a spinneret into a 
coagulation bath, in this way producing fibers. Chitosan can also be processed by 
electrospinning into a nanofiber mesh scaffold. This method uses an electrical field created 
between a collector and a capillary connected to a reservoir with the polymer solution. The 
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elongation of the drop of solution caused by the electrical field leads to the formation of very 
thin fibers with nanometer scale diameters. Electrospinning of pure chitosan (39, 180-183) is 
considered to be quite difficult, since the resulting chitosan salt is soluble in water. Its stability 
in solution requires neutralization or crosslinking in a post-processing stage that frequently 
has an impact in the morphology of the mesh. Several studies report the blending of chitosan 
with other polymers, being easier to process by electrospinning, namely silk fibroin (184), 
poly(ethylene oxide) (PEO) (185, 186), poly(vinyl alcohol) (PVA) (187), collagen (188) or 
polycaprolactone (189).  
 Less conventional is the particle aggregation method (Figure 1) proposed by 
Malafaya et al. (23). This process relies on the bioadhesive character of chitosan that confers 
a strong bonding between individual particles. The scaffolds produced by this method have 
shown very interesting mechanical properties. In another study, chitosan-poly(lactic-co-
glycolic acid) (PLAGA) microspheres were molded by mixing them with acetic acid solution, 
in a stainless steel mold (190). 
 
 
Figure 1. Micro computed tomography image of a cross-section of chitosan scaffolds 
obtained by particle aggregation method (A) and interface between particles stained with 
eosin (B).  
 
 Rapid prototyping is a processing route enabling also to develop chitosan porous 
scaffolds. This methodology is based on the production of a 3D physical model from 
computer aided design data (CAD software), which is generated in a layer-by-layer 
deposition process (150, 191). Theoretically, a great variety of morphologies and shapes can 
be created by different variants of these techniques, and the scaffolds will be highly 
reproducible.   
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 Our group developed different chitosan based scaffolds by melt based routes (42, 
44). The vast majority of the processing methods used to produce chitosan scaffolds involve 
the use of solvents. Those solvents are frequently harmful for cells, because residual solvent 
may be entrapped in the scaffold and these are toxic for the cells. We developed various 
blends of chitosan with different aliphatic polyesters. Those blends can be processed by 
compression molding followed by salt leaching (42) and by melt spinning and fiber bonding 
(27, 44) into porous scaffolds with different morphologies and mechanical properties (Figure 
2).  
 
 
Figure 2. Chitosan based scaffolds produced by compression molding followed by particle 
leaching (A) and fiber bonding (B) methodologies. 
 
 A systematic list of various porous scaffold compositions using chitosan, the 
processing methods used to obtain the scaffolds and the in vitro evaluation with different cell 
types is provided in Table I. It is clear from the table that the most used processing method to 
obtain chitosan-based porous scaffolds is freeze drying or freeze related processes. The 
main reason is probably the simplicity of the process.  
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Table I. Survey of in vitro studies with chitosan based scaffolds proposed in the literature for 
bone tissue engineering applications. 
Scaffold structure Processing method Cell type (source) References 
Chitosan scaffolds 
Chitosan scaffolds 
Freeze drying - (35) 
Chitosan-TCP sponges Freeze drying Fetal rat calvaria cells (148) 
Chitosan-gelatin scaffolds Freeze drying - (164) 
Chitosan-TCP sponges Freeze drying MG63 human cell line (192) 
Chitosan-HA scaffolds RP and Freeze drying - (150) 
Chitosan-calcium phosphate scaffolds Freeze drying MG63 human cell line (56) 
Chitosan scaffolds Freeze gelation ROS 17/2.8 cells (36) 
Chitosan sponges Freeze drying Rat calvaria cells (37) 
Chitosan fiber mesh scaffolds Wet spinning Human SAOS-2 cell line (38) 
Chitosan scaffolds Freeze drying MG63 human cell line (165) 
Chitosan-silk scaffold Freeze drying - (51) 
Chitosan scaffolds RP Porcine BMSCs (191) 
Chitosan scaffolds Electrospinning - (39) 
Chitosan-gelatin scaffolds Freeze drying HUVECs (193) 
Chitosan scaffolds Precipitation/Particle 
aggregation 
ADAS (23) 
Chitosan sponges Freeze drying MG63 human cell line (167) 
CPC-Chitosan scaffold Cement/Particle leaching MG63 human cell line (194) 
Chitosan-starch scaffolds Solvent-exchange phase 
separation 
- (48) 
Chitosan scaffolds with HA formation Freeze drying Human SAOS-2 cell line (169) 
Chitosan-nanoHA scaffolds Freeze drying MC3T3-E1 cell line (168) 
Chitosan-coralline scaffolds Freeze drying CRL-12424 cell line (170) 
HA-chitosan scaffold Freeze drying Goat bone marrow cells (24) 
Chitosan-gelatin scaffolds Freeze gelation hBMSCs (53) 
BCP-chitosan scaffolds Freeze drying MC3T3-E1 cell line (171) 
Chitosan-PLAGA scaffolds Particle aggregation MC3T3-E1 cell line (195) 
Chitosan gelatin/montmorillonite scaffolds Freeze drying Rat stromal cells TC1 (172) 
Chitosan scaffolds Freeze gelation - (40) 
Chitosan and chitosan-starch scaffolds Freeze gelation Human SAOS-2 cell line (26) 
Chitosan-collagen sponges Freeze drying Rat BMSCs (173) 
Chitosan-PBS/PBTA/PCL Compression molding/salt 
leaching 
Mouse BMC-9 cell line (25) 
Chitosan scaffolds Wet spinning Mouse osteoblast 7F2 cell line (41) 
Chitosan-PBS scaffolds Melt spinning/fiber bonding Human BMSCs (27) 
Chitosan-PBS/PCL/PBTA/PBSA Compression molding/salt 
leaching 
- (42) 
Chitosan-PCL scaffolds Electrospinning MC3T3-E1 cell line (189) 
Chitosan scaffolds Freeze drying MC3T3-E1 cell line (175) 
PLGA-chitosan scaffolds Freeze drying Human BMSCs (174) 
Chitosan sponges Freeze drying Chicken embryo chondrocytes (196) 
Chitosan and chitosan-starch + lysozyme scaffolds Freeze gelation Rat BMSCs (197) 
PCL-chitosan Solvent casting/salt leaching/ 
freeze-drying 
Rat osteoblasts (46) 
HA-Hydroxyapatite; TCP-Tricalcium phosphate; RP-Rapid prototyping; PLLA-Poly(L-lactic acid); ROS-Rat ostosarcoma cells; HUVECs- Human 
Umbilical Vein Endothelial Cells; ADAS-Adipose derived stem cells; CPC-Calcium phosphate cement; BCP- biphasic calcium phosphate; PLAGA-
Poly(lactic acid-glycolic acid); PBS-Poly(butylene succinate); PCL-Polycaprolactone; PBTA-Poly (butylene terephtalate adipate); PBSA-
Poly(butylene succinate adipate); PLGA-Poly(L-glycolic acid. 
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8. IN VITRO CELLULAR APPROACH IN BONE TISSUE ENGINEERING  
 The development of new scaffolds follows a typical evaluation routine. The first step is 
the assessment of the eventual cytotoxicity. This initial screening is based on the use of 
extracted leachables from the scaffold, i.e., substances that leach out of the biomaterials. 
These leachables are added in defined concentrations to standard culture medium and 
placed in contact with a cell line for a determined period of time. After this, cell viability and 
cell morphology are evaluated to determine the eventual toxicity to the cells. The use of cell 
lines is recommended in a first stage, given that these cells are reproducible and can be 
expanded into large numbers. Cell lines, such as mouse fibroblast cells (L929) or human 
osteosarcoma cells (SAOS-2), are frequently used. If the scaffolds show no signs of cell 
cytotoxicity or morphology changes, the next step involves direct contact assays with an 
appropriate cell type to evaluate the cytocompatibility and phenotype functionality. A valid 3D 
construct for bone tissue engineering applications should have a positive outcome from this 
sequence of initial in-vitro tests.  
 
8.1. SELECTION OF CELLS  
 The cell source should be ideally non-immunogenic, easily available, non-
tumorogenic and with defined and adequate characteristics. It should be expandable into 
large numbers and have demonstrated osteogenic potential. Autologous cells, from each 
patient, are the most preferred (198-202). These cells may be isolated from a biopsy of tissue 
(e.g. cartilage, bone, skin) from the patient. The tissue obtained is dissociated and the 
isolated cells are expanded in culture for later implantation into the same patient (29, 70, 
198). The use of autologous cells eliminates the risk of immune rejection, avoiding the need 
of using immunosuppressive drugs. For bone tissue engineering applications, osteoblasts 
are the most obvious selection, since those cells are responsible for the bone formation (74). 
However, these cells have limited availability since the number of cells that are obtained after 
the isolation procedure is low and the expansion rate is slow (203). In the last years, stem 
cells appeared as a valid alternative (203). The term stem cell is used to describe 
undifferentiated cells with ability to self-renew and maintain itself for long periods of time 
keeping its multilineage differentiation capacity (65). Stem cells can be classified as 
embryonic or adult. Embryonic stem cells (ESCs) are pluripotent cells derived from the inner 
cell mass of the blastocyst stage of an embryo (204). These cells possess long-term 
proliferation potential and are able to differentiate into all the types of somatic cells in the 
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organism. Nevertheless, ethical issues regarding its source restrain its use in regenerative 
medicine. Adult stem cells (ASCs) are a valid and alternative option to ESCs. These cells can 
be isolated from different adult tissue sources such as bone marrow (65), peripheral blood 
(205), adipose tissue (206), or fetal tissues such as umbilical cord (207), amniotic fluid (208) 
or placenta (209). ASCs are multipotential cells, capable of differentiating into several cell 
lineages such as osteoblasts, chondrocytes and adipocytes (210). Recent reports sustain the 
plasticity of these cells, i.e. the ability of differentiate into other cell types rather than the ones 
they are committed (211).  
  The process of osteogenic differentiation of stem cells may be achieved by expanding 
the cells in standard culture medium, supplemented with β-glycerophosphate (212), ascorbic 
acid (213), and dexamethasone (67, 213). These agents activate the osteogenic commitment 
of stem cells. Culture of osteogenic cells depends on the adequate supplementation of their 
growth medium with a source of inorganic phosphate (214), β-glycerophosphate, a non 
physiological organic substrate of alkaline phosphatase (ALP) (215), in order to produce 
mineralized ECM. Ascorbic acid is essential for the survival of human osteoblasts in vitro 
(216). This osteogenic inducing agent is required for collagen synthesis and alkaline 
phosphatase activity (213). Dexamethasone is a glucocorticoid that increases the expression 
of several genes associated with osteogenic differentiation (217). Moreover, the timing, size 
and number of bone like nodules is affected by the dose of dexamethasone used (218). 
Osteogenic medium can also be supplemented with growth factors, naturally existent in the 
bone structure, such as bone morphogenic proteins (BMPs) fibroblast growth factors (FGFs), 
platelet derived growth factor (PDGF), transforming growth factor beta (TGF-β) and insulin 
growth factors (IGFs) (219-226). The process of osteogenic differentiation is coordinated and 
involves three main stages: i) cell proliferation; ii) ECM deposition and maturation; and iii) 
mineralization (227). During cell proliferation, growth genes are expressed (228). 
Immediately following the down-regulation of the proliferation, the expression of ALP 
increases (227). During this period, the ECM undergoes a series of events that renders it 
competent for mineralization (ECM maturation and hydroxyapatite formation) (228). After this 
stage ECM becomes mineralized (227, 228). With the onset of mineralization, the ECM 
protein genes become up-regulated, like osteopontin and osteocalcin that are increasingly 
expressed with the accumulation of mineral (227). ALP activity prior to the onset of the 
mineralization suggests that this enzyme is involved in the preparation of the ECM for 
mineral deposition (227). This enzyme is considered to be an early marker of osteogenic 
differentiation and used to assess in vitro the osteogenic differentiation (20, 229, 230). The 
mineral content of the bone ECM can be qualitatively assessed by alizarin red or von Kossa 
CHAPTER I. Introduction  
 20 
staining and the calcium content can be quantitatively assessed. This information can be 
complemented by the analysis of the mineral fraction by energy dispersive spectroscopy to 
detect the presence of calcium and phosphorous elements, thin-film X-ray diffraction to 
analyze the crystallinity of the ECM and Fourier-transformed spectroscopy to detect the 
carbonate and phosphate groups (27, 231). 
 
8.2. In vitro studies with chitosan as a biomaterial 
 It is well accepted that the cells strongly interact with their environment, namely with 
neighboring cells, ECM and the surface to which they adhere (232). Chitosan as a 
biomaterial, like previously mentioned, has an analogous structure to the GAGs present in 
the ECM of connective tissues. Several studies describe the positive influence of chitosan 
over cell attachment, proliferation and over the osteogenic differentiation of MSCs (Table I). 
Mouse MSCs in contact with a chitosan suspension were shown to facilitate its osteogenic 
differentiation, when compared to cells seeded onto polystyrene culture wells (233). Lahiji et 
al. reported that chitosan, coated in coverslips, is an appropriate substrate for the growth of 
human osteoblasts and chondrocytes (110). Poly(D,L-lactic acid) (PDLLA) films modified with 
chitosan solution evidenced improved cell adhesion, proliferation, and biosynthetic activity, 
using human osteoblasts (234). Moreover, neonatal rat calvaria osteoblasts proliferate at 
superior rates on titanium surfaces coated with chitosan compared with titanium alone (235). 
In fact, coating of titanium pins with chitosan, induced minimal inflammatory response and a 
positive healing of a rabbit tibia bone defect (236). MC3T3-E1 osteoblast-like cells 
proliferated and evidenced increased ALP activity, as well as up-regulation of osteogenic 
genes expression in composite chitosan/poly(lactide-co-glicolic acid) (PLAGA) scaffolds as 
compared to PLAGA scaffolds (190). Chitosan–collagen sponges with higher concentration 
of chitosan positively promoted osteoblastic differentiation of BMSCs and improved the 
mechanical and physical properties of the matrices (173). Previous studies from our group, 
using flat discs obtained by injection molding composed of chitosan-PBS and PBS blends, 
showed that chitosan had a positive effect on osteoblast like cells (237). Furthermore, in 
literature, PCL nanofibrous scaffolds containing chitosan, revealed that stem cells adhered, 
proliferated and expressed phenotypic markers of osteogenic differentiation in a superior way 
when compared to nanofibrous scaffolds alone (189, 238). The ability of chitosan to support 
cell adhesion and influence osteogenic differentiation of cells can be attributed to its chemical 
properties.  
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  The in vitro testing systems are inevitably limited in their capacity to recreate the 
complex in vivo environment. Therefore, these tests are unable to predict accurately the in 
vivo performance, particularly in the context of tissue engineering and regeneration of 
functional tissues. Thus, in a later stage of development it is critical to test the developed 
strategies in vivo. 
 
9. IN VIVO ANIMAL MODELS 
 The general trend in bone tissue engineering after successful in vitro testing of the 
constructs is to implant the tissue-engineered construct into a relevant animal model. First, it 
is necessary to obtain a proof of concept of the tissue engineering strategy, in vivo. For this, 
an ectopic model in a small animal (mouse or rat) is commonly used. The constructs are 
implanted into a non-bone related anatomic location of the animal body (90, 239-241). These 
areas can be intraperitoneal, intramuscular, mesenteric or subcutaneous. This model is also 
interesting to determine if a scaffold has adequate properties namely porosity and 
interconnectivity, to allow tissue ingrowth and neovascularization. It is important to conclude 
about the biodegradation of the implanted material, in terms of degradation products and also 
the host immune response. If the aim is to use human cells, nude mouse/rat models are the 
most commonly used, because these animals do not have thymus, being unable to produce 
mature T lymphocytes, compromising the immune system. Therefore, its immune system is 
not able to react against xenogeneic cells (89, 220, 242). The purpose of using such model is 
to conclude about the ability of the tissue-engineered constructs to form ectopic bone and 
also to verify about osteoinductivity, i.e. the ability of the scaffold to induce proliferation of 
undifferentiated stem cells, as well as their differentiation into the osteogenic lineage (243-
245).  
 The in vivo approach should mimic as close as possible the real clinical situation. 
Frequently, it is created an intraosseous wound that will not heal spontaneously during the 
lifetime of the animal (critical size defect) (83). The minimum size considered being a critical 
size defect is not absolute clear. The defect cannot be defined only by size, it is dependent 
on various variables, such as type of specie, anatomic location, among many others (246). 
Guidelines are available for the dimensions of implants based on the size of the animal, type 
of bone chosen and on the implant design to avoid pathological fracture of the test location 
(247). It is important to include controls in the experimental design. These controls should be 
of a material already in clinical use and also a control consisting of an empty defect, to prove 
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that the bone defect is not able to regenerate by itself (247). There are several types of bone 
defects that can be used, such as cranial, segmental, partially cortical and cancellous bone. 
These locations can be subjected to load or non-load bearing (e.g. femur or calvarial, 
respectively). The type of animal can be small (mouse or rat) (90, 104, 226, 248, 249) or 
large (rabbit, sheep, goat, dogs or primates) (146, 198, 250-255). Typically, researchers start 
with a smaller model mainly with less costs involved but also because it is easier to compare 
results between a wealth of experiments reported in the literature. One of the most accepted 
non-loading bearing models is the calvaria bone defect. This bone is a flat bone, allowing the 
creation of a uniform circular defect, and has an adequate size for easy surgical procedure 
and specimen handling. The dura mater and the overlying skin provide fixation of the 
scaffold. The model has been systematically studied and is very well established (83, 84, 
256, 257). This model can be performed in small animals using rat (258, 259) or mouse (226, 
248). It can be also applied to large animals, like rabbit (260-262) or sheep (202).  
 The last stage of preclinical trials of a bone tissue engineering strategy should be 
performed in animals that are believed to be more similar to humans, in terms of metabolism, 
physiology, anatomy, etc. Bones of small animals are more reactive to specific stimuli and 
are not subjected to comparable stresses. For example, a femur defect in rats (263-265) is 
believed to heal faster that in larger animals (256). However, in a study where the authors 
compared the bone ingrowth using the same chamber, in rats and in goats, no significant 
differences were observed between the two animals (266). In vivo experimentation design is 
therefore not an easy task, it is necessary to balance all the variables and decide which 
animal models suits better the specific goals of the experiment. Surgeries involving load-
bearing conditions, involving stabilization with internal or external fixation devices, require the 
presence of experts to perform the surgery. The maintenance of the animals is expensive 
and variations within the same group may be larger as compared to those that are found in 
small laboratory animals. A countless number of variables need to be addressed to assure 
that the chosen model is the most appropriate for testing a specific situation. Consequently, 
variables should be minimized and very well controlled to reduce the random effects and to 
ensure as much as possible statistical significance. It is also very important to moderate the 
number of variables, such as physical condition of the animal (nutritional status, diet, age, 
sex), anesthesics and analgesics, type of bone defect (location, use of fixation) and, finally, 
the methodologies used to assess the sample collection and characterization. Despite the 
issues aforementioned, the final pre-clinical tests should be performed in large animals, 
subjected to load bearing comparable to the human case. For this proposes, the sheep or 
goat may be a good option. Both have a similar metabolism and bone remodeling rate to 
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humans, as well as a comparable weight (12, 18, 199, 202, 252). 
 
9.1. In vivo bone regeneration studies with chitosan material 
  As described before, chitosan is already used in medicine, as a biomaterial for 
wound dressings. However, there are several reports in the literature showing the ability of 
chitosan to be used as material to regenerate bone (Table II). The first report describing the 
attempt to in vivo regenerate bone using chitosan structures dates back from 1988 (113), 
when Muzzarelli and colleagues implanted chitosan membranes and chitosan ascorbate gel 
into cranial defects in cats. Their findings suggested that chitosan seems to induce some 
type of stimulatory and/or attractive effect over the stromal cells of the surrounding tissues.  
 
Table II. Survey of in  vivo studies with chitosan based scaffolds proposed in the literature for 
bone tissue engineering applications. 
Scaffold structure Processing method Cell type 
(source) 
Animal model References 
Methylpyrrolidinone chitosan 
sponges 
Freeze drying - Human, dental application (145) 
Methylpyrrolidinone chitosan 
sponges 
Freeze drying - Rabbit, tibia defect (146) 
Modifyed chitosan with 
imidazole groups sponges 
Freeze drying - Sheep, femur defect (147) 
Chitosan-HA membranes Paste - Rat, implanted over calvaria (267) 
Chitosan-PLLA scaffolds Freeze drying Rat calvaria cells Rat, Calvaria defect (268) 
Chitosan-gelatin-TCP 
scaffolds 
Freeze drying - Subcutaneous implantation (151) 
Chitosan membrane Wet spinning - Dog, dental application (149) 
Chitosan nanofiber 
membrane 
Electrospinning MG63 human 
cell line 
Rabbit, calvaria defect (182) 
Chitosan-alginate scaffold Freeze drying MG63 human 
cell line 
Rat, intramuscular (166) 
Chitosan scaffolds Particle agregation - Rat, intramuscular (269) 
Chtosan-nanoHA Particle agregation Human fetal 
osteoblasts 
Rat, Calvaria defect (54) 
Chitosan-silk scaffolds Freeze gelation - Sheep, rib defect (50) 
Chitosan gel Freeze drying-dilution 
in acetic acid 
- Rat, Calvaria defect (270) 
Chitosan-PLAGA scaffolds Particle agregation - Rabbit, ulna segmental 
defect 
(271) 
            HA-Hydroxyapatite; TCP-Tricalcium phosphate; PLLA-Poly(L-lactic acid); 
 The subsequent studies from the same authors describe the use of methylpirrolidone 
CHAPTER I. Introduction  
 24 
chitosan in defects created in the tibia of rabbits (146) and in the femoral head of sheep 
(147). These studies confirmed the previous results (113) about the possible stimulatory 
and/or attractive effect of chitosan over cells. Chitosan has been also used as carrier for 
growth factors, such as platelet-derived growth factor-BB (PDGF-BB) to promote bone 
formation in a calvaria critical sized defect in rats (221, 268). Osteoconductive 
chitosan/tricalcium phosphate (TCP) sponges promoted osseous healing of the rat calvarial 
defects as compared to controls (without scaffolds) and the addition of PDGF-BB to the 
carrier further enhanced bone regeneration, favoring its osteoinductivity (268). These authors 
observed that chitosan/TCP sponge with PDGF-BB promoted more bone formation of the 
defects as compared to chitosan-TCP without the bioactive agents (221). PDGF growth 
factor is produced by platelets, osteoblasts and monocytes/macrophages and it is believed to 
have a role in the migration of MSCs to the wounding sites (272). Electrospun chitosan 
nanofiber membranes evidenced new bone formation at four weeks in calvaria defects of 
rabbits when compared to the controls (empty bone defects), where only soft tissue formation 
was observed (182). Chitosan combined with nano-hydroxyapatite in the form of 
microspheres were implanted in rat calvaria defects for twelve weeks, being able to promote 
bone regeneration (54). Moreover, chitosan-PLAGA microspheres conjugated in a scaffold 
by particle aggregation, with or without heparin and recombinant human bone morphogenetic 
protein 2 (rhBMP-2) showed to promote bone regeneration in vivo (271). More pronounced 
results were obtained for the scaffolds with the incorporated growth factor (271). A study by 
Ríos and co-workers (50) used a model mimicking the clinical bone free flaps, by flap 
prefabrication technique, which involves the design of the desired tissue at an ectopic site in 
the patient own body. This study used chambers containing silk fibroin-chitosan scaffolds 
implanted on top of the grafted periosteum over the latissimus dorsi muscle of sheeps (50). 
Bone grafts were used as positive controls and empty defects as negative controls. The 
authors found that the same amount of bone was regenerated in the defects with the tested 
scaffolds, as for the defects with the bone grafts (50). 
 
10. CONCLUSIONS AND FINAL REMARKS 
 The developments in bone tissue engineering were considerable but there is not yet a 
tissue-engineered product that has reached clinical application. Both cells and biomaterial 
components need to be optimized to produce a functional bone tissue engineered therapy. 
 New stem cell sources are being explored, such as the extra-embryonic tissues, 
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placenta, amniotic fluid or umbilical cord. These stem cells have been shown to express 
pluripotent markers and low immunogenicity, evidencing a more primitive state. These cells 
are usually discarded, which make these sources attractive candidates for tissue engineering 
applications. Moreover, the low immunogenic potential could enable the use of these cells as 
an allogenic cell source for successful bone repair. 
 A new generation of biodegradable natural biomaterials is emerging, being chitosan 
one of the most interesting. Chitosan has been extensively studied as a biomaterial for bone 
tissue engineering scaffolding, but in practice it is still and only used as a wound dressing 
and hemostatic agent in medicine. Several morphologies can be successfully obtained by 
different processing techniques, which turn this material attractive for this end. Although 
several studies reporting the biological enhancement by chitosan and its influence over 
osteogenic differentiation and bone regeneration, still remains unclear the mechanism of 
action. It is worthwhile to continue to pursuit research over this interesting natural polymer in 
order to clarify its function over cell performance, as well as, to improve the scaffold 
processing methodologies, that will lead to the clinical use in the bone regeneration field. 
 
 
ACKNOWLEDGEMENTS 
 This review was supported by the FCT grant (SFRH/24735/2005) attributed to Ana 
Costa-Pinto. The authors will also want to acknowledge the precious help of Ana M. Martins 
in the revision of the manuscript. 
CHAPTER I. Introduction  
 26 
REFERENCES 
 
1. Muschler GF, Negami S, Hyodo A, Gaisser D, Easley K, Kambic H. Evaluation of 
Collagen Ceramic Composite Graft Materials in a Spinal Fusion Model. Clinical Orthopaedics 
and Related Research. 1996;328:250-60. 
2. Lewandrowski K-U, Gresser J, Wise DL, Trantolo DJ. Bioresorbable bone graft 
substitutes of different osteoconductivities: a histologic evaluation of osteointegration of 
poly(propylene glycol-co-fumaric acid)-based cement implants in rats. Biomaterials. 
2000;21(8):757-64. 
3. Desai B. Osteobiologics. Am J Orthop. 2007;36:8-11. 
4. Muramatsu K, Doi K, Ihara K, Shigetomi M, Kawai S. Recalcitrant posttraumatic 
nonunion of the humerus: 23 patients reconstructed with vascularized bone graft: 23 patients 
reconstructed with vascularized bone graft. Acta Orthopaedica Scandinavica. 2003;74(1):95 - 
7. 
5. Al-Sayyad M, Abdulmajeed T. Fracture of the anterior iliac crest following autogenous 
bone grafting. Saudi Med J. 2006;27(2):254-8. 
6. Chou L, Mann R, Coughlin M, Mcpeake W, Mizel M. Stress fracture as a complication 
of autogenous bone graft harvest from the distal tibia. Baltimore: Williams &amp; Wilkins; 
2007. 
7. Pritsch T, Bickels J, Wu C-C, Squires H, Malawer M. The Risk for Fractures after 
Curettage and Cryosurgery Around the Knee. Clinical Orthopaedics and Related Research. 
2007;458:159-67  
8. Chen Y-C, Chen C-H, Chen P-L, Huang I-Y, Shen Y-S, Chen C-M. Donor site 
morbidity after harvesting of proximal tibia bone. Head & Neck. 2006;28(6):496-500. 
9. Laurencin C, Khan Y, El-Amin SF. Bone graft substitutes. Expert Review of Medical 
Devices. 2005;3(1):49-57. 
10. Ilizarov G. The Tension-Stress Effect on the Genesis and Growth of Tissues: Part I. 
The Influence of Stability of Fixation and Soft-Tissue Preservation. Clinical Orthopaedics and 
Related Research. 1989;238:249-81. 
11. Perka C, Schultz O, Spitzer R-S, Lindenhayn K, Burmester G-R, Sittinger M. 
Segmental bone repair by tissue-engineered periosteal cell transplants with bioresorbable 
fleece and fibrin scaffolds in rabbits. Biomaterials. 2000;21(11):1145-53. 
12. Gugala Z, Gogolewski S. Healing of critical-size segmental bone defects in the sheep 
tibiae using bioresorbable polylactide membranes. Injury. 2002;33(Supplement 2):71-6. 
13. Cook D, Salkeld S, Rueger D. Comparison of osteoinductive and osteoconductive 
biomaterials in healing large segmental bone defects.  American Academy of Orthopaedic 
Surgeons1995. 
14. Langer R, Vacanti J. Tissue engineering. Science. 1993;260(5110):920-6. 
15. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials. 
2000;21(24):2529-43. 
16. Hutmacher DW, Schantz JT, Lam CXF, Tan KC, Lim TC. State of the art and future 
directions of scaffold-based bone engineering from a biomaterials perspective. JTERM. 
2007;1(4):245-60. 
17. Bonfield W. Designing porous scaffolds for tissue engineering. Phil Trans R Soc 
2006;364:227-32. 
18. Mendes S, Reis R, Bovell Y, Cunha A, Van Blitterswijk CA, de Bruijn J. 
Biocompatibility testing of novel starch-based materials with potential application in 
orthopaedic surgery: a preliminary study. Biomaterials. 2001;22:2057-64. 
19. Salgado A, Gomes M, Chou A, Coutinho O, Reis R, Hutmacher D. Preliminary study 
on the adhesion and proliferation of human osteoblasts on starch-based scaffolds. Materials 
Science and Engineering C. 2002;20(2002):27-33. 
 CHAPTER I. Introduction 
 27 
20. Gomes M, Sikavitsas V, Behravesh E, Reis R, Mikos A. Effect of flow perfusion on the 
osteogenic differentiation of bone marrow stromal cells cultured on starch-based three-
dimensional scaffolds. J Biomed Mater Res. 2003;67A:87-95. 
21. Salgado A, Coutinho O, Reis R. Novel Starch-Based Scaffolds for Bone Tissue 
Engineering: Cytotoxicity, Cell Culture, and Protein Expression. Tissue Engineering. 
2004;10(3/4):465-74. 
22. Gomes ME, Godinho JS, Tchalamov D, Cunha AM, Reis RL. Alternative tissue 
engineering scaffolds based on starch: processing methodologies, morphology, degradation 
and mechanical properties. Materials Science and Engineering C. 2002;20:19-26. 
23. Malafaya P, Pedro A, Peterbauer A, Gabriel C, Redl H, Reis RL. Chitosan particles 
agglomerated scaffolds for cartilage and osteochondral tissue engineering approaches with 
adipose tissue derived stem cells. Journal of Materials Science: Materials in Medicine. 
2005;16:1077-85. 
24. Oliveira J, Rodrigues M, Silva S, Malafaya P, Gomes M, Viegas C, et al. Novel 
hydroxyapatite/chitosan bilayered scaffold for osteochondral tissue-engineering applications: 
Scaffold design and its performance when seeded with goat bone marrow stromal cells. 
Biomaterials. 2006;27(36):6123-37. 
25. Costa-Pinto A, Correlo V, Sol P, Bhattacharya M, Charbord P, Delorme B, et al. 
Adhesion, Proliferation, and Osteogenic Differentiation of a Mouse Mesenchymal Stem Cell 
Line (BMC9) Seeded on Novel Melt-Based Chitosan/Polyester 3D Porous Scaffolds. Tissue 
Engineering. 2008;14(6):1049-52. 
26. Martins A, Santos M, Azevedo H, Malafaya P, Reis R. Natural origin scaffolds with in 
situ pore forming capability for bone tissue engineering applications. Acta Biomaterialia. 
2008;4:1637-45. 
27. Costa-Pinto A, Correlo V, Sol P, Bhattacharya M, Charbord P, Delorme B, et al. 
Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells Seeded on Melt 
Based Chitosan Scaffolds for Bone Tissue Engineering Applications. Biomacromolecules. 
2009. 
28. Oliveira J, Santos T, Martins L, Picciochi R, Marques A, Castro A, et al. Gellan Gum 
Injectable Hydrogels for Cartilage Tissue Engineering Applications: In vitro Studies and 
Preliminary In vivo Evaluation. Tissue Engineering Part A. 2010;16(1):343-53. 
29. Oliveira J, Gardel L, Rada T, Martins L, Gomes M, Reis R. Injectable gellan gum 
hydrogels with autologous cells for the treatment of rabbit articular cartilage defects. Journal 
of Orthopaedic Research. 2010;28(9):1193-9. 
30. Oliveira JT, Martins L, Picciochi R, Malafaya PB, Sousa RA, Neves NM, et al. Gellan 
gum: A new biomaterial for cartilage tissue engineering applications. Journal of Biomedical 
Materials Research Part A. 2010;93A(3):852-63. 
31. Silva NA, Salgado AJ, Sousa RA, Oliveira JT, Pedro AJ, Leite-Almeida H, et al. 
Development and Characterization of a Novel Hybrid Tissue Engineering Based Scaffold for 
Spinal Cord Injury Repair. Tissue Engineering Part A. 2010;16(1):45-54. 
32. Silva SS, Santos MI, Coutinho OP, Mano JF, Reis RL. Physical properties and 
biocompatibility of chitosan/soy blended membranes. Journal of Materials Science: Materials 
in Medicine. 2005;16(6):575-9. 
33. Silva SS, Maniglio D, Motta A, Mano JF, Reis RL, Migliaresi C. Genipin-Modified Silk-
Fibroin Nanometric Nets. Macromolecular Bioscience. 2008;8(8):766-74. 
34. Silva SS, Motta A, Rodrigues MT, Pinheiro AFM, Gomes ME, Mano JF, et al. Novel 
Genipin-Cross-Linked Chitosan/Silk Fibroin Sponges for Cartilage Engineering Strategies. 
Biomacromolecules. 2008;9(10):2764-74. 
35. Madihally S. Porous chitosan scaffolds for tissue engineering. Biomaterials. 1999;20  
1133-42. 
36. Ho MH, Kuo PY, Hsieh HJ, Hsien TY, Hou LT, Lai JY, et al. Preparation of porous 
scaffolds by using freeze-extraction and freeze-gelation methods. Biomaterials. 2004 
Jan;25(1):129-38. 
CHAPTER I. Introduction  
 28 
37. Seol YJ, Lee JY, Park YJ, Lee YM, Young K, Rhyu IC, et al. Chitosan sponges as 
tissue engineering scaffolds for bone formation. Biotechnology letters. 2004 Jul;26(13):1037-
41. 
38. Tuzlakoglu K, Alves CM, Mano JF, Reis RL. Production and characterization of 
chitosan fibers and 3-D fiber mesh scaffolds for tissue engineering applications. Macromol 
Biosci. 2004 Aug 9;4(8):811-9. 
39. Geng X, Kwon O-H, Jang J. Electrospinning of chitosan dissolved in concentrated 
acetic acid solution. Biomaterials. 2005;26(27):5427-32. 
40. Hsieh C-Y, Tsai S-P, Ho M-H, Wang D-M, Liu C-E, Hsieh C-H, et al. Analysis of 
freeze-gelation and cross-linking processes for preparing porous chitosan scaffolds. 
Carbohydrate Polymers. 2007;67(1):124-32. 
41. Heinemann C, Heinemann S, Bernhardt A, Worch H, Hanke T. Novel Textile Chitosan 
Scaffolds Promote Spreading, Proliferation, and Differentiation of Osteoblasts. 
Biomacromolecules. 2008;9(10):2913-20. 
42. Correlo V, Boesel L, Pinho E, Costa-Pinto A, Alves da Silva M, Bhattacharya M, et al. 
Melt-based compression-molded scaffolds from  chitosan–polyester blends and composites: 
Morphology and mechanical properties. J Biomed Mater Res A. 2009;91A(2):498-504. 
43. Costa-Pinto AR, Correlo VM, Sol PC, Bhattacharya M, Charbord P, Delorme B, et al. 
Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells Seeded on Melt 
Based Chitosan Scaffolds for Bone Tissue Engineering Applications. Biomacromolecules. 
2009;10(8):2067-73. 
44. Correlo VM, Costa-Pinto AR, Sol P, Covas JA, Bhattacharya M, Neves NM, et al. Melt 
Processing of Chitosan-Based Fibers and Fiber-Mesh Scaffolds for the Engineering of 
Connective Tissues. Macromolecular Bioscience. 2010. 
45. Cao W, Wang A, Jing D, Gong Y, Zhao N, Zhang X. Novel biodegradable films and 
scaffolds of chitosan blended with poly(3-hydroxybutyrate). Journal of biomaterials science. 
2005;16(11):1379-94. 
46. Wu H, Wan Y, Dalai S, Zhang R. Response of rat osteoblasts to 
polycaprolactone/chitosan blend porous scaffolds. Journal of Biomedical Materials Research 
Part A. 2009;92A(1):238-45. 
47. Sarasam A, Madihally SV. Characterization of chitosan-polycaprolactone blends for 
tissue engineering applications. Biomaterials. 2005 Sep;26(27):5500-8. 
48. Nakamatsu J, Torres FG, Troncoso OP, Min-Lin Y, Boccaccini AR. Processing and 
Characterization of Porous Structures from Chitosan and Starch for Tissue Engineering 
Scaffolds. Biomacromolecules. 2006;7(12):3345-55. 
49. Baran ET, Mano JF, Reis RL. Starch-chitosan hydrogels prepared by reductive 
alkylation cross-linking. J Mater Sci Mater Med. 2004 Jul;15(7):759-65. 
50. Ríos CN, Skoracki RJ, Miller MJ, Satterfield WC, Mathur AB. In vivo Bone Formation 
in Silk Fibroin and Chitosan Blend Scaffolds via Ectopically Grafted Periosteum as a Cell 
Source: A Pilot Study. Tissue Engineering Part A. 2009;15(9):2717-25. 
51. Gobin AS, Froude VE, Mathur AB. Structural and mechanical characteristics of silk 
fibroin and chitosan blend scaffolds for tissue regeneration. J Biomed Mater Res A. 2005 Sep 
1;74(3):465-73. 
52. Manjubala I, Woesz A, Pilz C, Rumpler M, Fratzl-Zelman N, Roschger P, et al. 
Biomimetic mineral-organic composite scaffolds with controlled internal architecture. Journal 
of Materials Science: Materials in Medicine. 2005;16(12):1111-9. 
53. Zhao F, Grayson WL, Ma T, Bunnell B, Lu WW. Effects of hydroxyapatite in 3-D 
chitosan-gelatin polymer network on human mesenchymal stem cell construct development. 
Biomaterials. 2006 Mar;27(9):1859-67. 
54. Chesnutt BM, Yuan Y, Buddington K, Haggard WO, Bumgardner JD. Composite 
Chitosan/Nano-Hydroxyapatite Scaffolds Induce Osteocalcin Production by Osteoblasts In 
vitro and Support Bone Formation In vivo. Tissue Engineering Part A. 2009;15(9):2571-9. 
 CHAPTER I. Introduction 
 29 
55. Finisie MR, Josue A, Favere VT, Laranjeira MC. Synthesis of calcium-phosphate and 
chitosan bioceramics for bone regeneration. Anais da Academia Brasileira de Ciencias. 2001 
Dec;73(4):525-32. 
56. Zhang Y, Ni M, Zhang M, Ratner B. Calcium phosphate-chitosan composite scaffolds 
for bone tissue engineering. Tissue Eng. 2003 Apr;9(2):337-45. 
57. Xu HH, Takagi S, Quinn JB, Chow LC. Fast-setting calcium phosphate scaffolds with 
tailored macropore formation rates for bone regeneration. J Biomed Mater Res A. 2004 Mar 
15;68(4):725-34. 
58. Correlo VM, Boesel LF, Bhattacharya M, Mano JF, Neves NM, Reis RL. 
Hydroxyapatite reinforced chitosan and polyester blends for biomedical applications. 
Macromolecular Materials and Engineering  2005;290(12):1157-65. 
59. Zhang Y, Xu HH, Takagi S, Chow LC. In-situ hardening hydroxyapatite-based scaffold 
for bone repair. J Mater Sci Mater Med. 2006;17(5):437-45. 
60. Mukherjee DP, Tunkle AS, Roberts RA, Clavenna A, Rogers S, Smith D. An animal 
evaluation of a paste of chitosan glutamate and hydroxyapatite as a synthetic bone graft 
material. J Biomed Mater Res B Appl Biomater. 2003;67(1):603-9. 
61. Rodan GA. Introduction to bone biology. Bone. 1992;13(Supplement 1):S3-S6. 
62. Weiner S, Wagner H. The material bone: structure mechanical function relations. 
Annu Rev Mater Sci 1998;28:271-98. 
63. Jee W. Integrated bone tissue physiology: anatomy and physiology. In: Cowin SC, 
editor. Bone mechanics handbook. 4th ed. Boca Raton: CRC press; 2001. 
64. Friedenstein A, Deriglasova U, Kulagina N, Panasuk A, Rudakowa S, Luriá E, et al. 
Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in 
vitro colony assay method. Exp Hematol. 1974;2(2):83-92. 
65. Owen M. Marrow Stromal Stem Cells. J Cell Sci Suppl. 1988;10:63-76. 
66. Simmons P, Torok-Storb B. CD34 Expression by Stromal Precursors in Normal 
Human Adult Bone Marrow Blood. 1991;11:2848-53. 
67. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI. Characterization of cells with 
osteogenic potential from human marrow. Bone. 1992;13(1):81-8. 
68. Nakahara H, Goldberg VM, Caplan AI. Culture-expanded human periosteal-derived 
cells exhibit osteochondral potential in vivo. Journal of Orthopaedic Research. 1991;9(4):465-
76. 
69. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone Marrow Stromal Stem Cells: 
Nature, Biology, and Potential Applications. Stem cells. 2001;19:180-92. 
70. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov S, Mukhaev V, Lakroukov A, et 
al. Repair of large bone defects with the use of autologous bone marrow stromal cells. New 
England Journal of Medicine. 2001;344(5):385-6. 
71. Marcacci M, Kon E, Moukhachev V, Lavroukov A, Kutepov S, Quarto R, et al. Stem 
Cells Associated with Macroporous Bioceramics for Long Bone Repair: 6- to 7-Year Outcome 
of a Pilot Clinical Study. Tissue Engineering. 2007;13(5):947-55. 
72. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, et al. 
Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841-
6. 
73. Zhang J, Niu C, Ye L, Huang H, He X, Tong W-G, et al. Identification of the 
haematopoietic stem cell niche and control of the niche size. Nature. 2003;425(6960):836-41. 
74. Robey P, Termine J. Human bone cells in vitro. Calcified Tissue International. 
1985;37(5):453-60. 
75. Fuchs S, Hofmann A, Kirkpatrick CJ. Microvessel-Like Structures from Outgrowth 
Endothelial Cells from Human Peripheral Blood in 2-Dimensional and 3-Dimensional Co-
Cultures with Osteoblastic Lineage Cells. Tissue Engineering. 2007;13(10):2577-88. 
76. Unger RE, Sartoris A, Peters K, Motta A, Migliaresi C, Kunkel M, et al. Tissue-like 
self-assembly in cocultures of endothelial cells and osteoblasts and the formation of 
CHAPTER I. Introduction  
 30 
microcapillary-like structures on three-dimensional porous biomaterials. Biomaterials. 
2007;28(27):3965-76. 
77. Santos MI, Unger RE, Sousa RA, Reis RL, Kirkpatrick CJ. Crosstalk between 
osteoblasts and endothelial cells co-cultured on a polycaprolactone-starch scaffold and the in 
vitro development of vascularization. Biomaterials. 2009;30(26):4407-15. 
78. Nomura S, Takano-Yamamoto T. Molecular events caused by mechanical stress in 
bone. Matrix Biology. 2000;19(2):91-6. 
79. Kronenberg HM. Developmental regulation of the growth plate. Nature. 
2003;423(6937):332-6. 
80. Horton W. The biology of bone growth. Growth Genet Horm. 1990;6(2):1-3. 
81. Bruder S, Caplan A. Cellular and molecular events during embryonic bone 
development. Cellular and molecular events during embryonic bone development. 1989;20(1-
4):65-71. 
82. Bianco P, Cancedda F, Riminucci M, Cancedda R. Bone Formation via Cartilage 
Models: The "Borderline" Chondrocyte. Matrix Biology. 1998;17:185-92. 
83. Schmitz J, Hollinger J. The Critical Size Defect as an Experimental Model for 
Craniomandibulofacial Nonunions. Clinical Orthopaedics and Related Research. 
1986;205:299-308. 
84. Hollinger JO, Kleinschmidt JC. The Critical Size Defect as an Experimental Model To 
Test Bone Repair Materials. Journal of Craniofacial Surgery. 1990;1(1):60-8. 
85. Aaboe M, Pinholt E, Hjorting-Hansen E. Healing of experimentally created defects: a 
review. Br J Oral Maxillofac Surg. 1995;33(5):312-8. 
86. Pham QP, Kurtis Kasper F, Scott Baggett L, Raphael RM, Jansen JA, Mikos AG. The 
influence of an in vitro generated bone-like extracellular matrix on osteoblastic gene 
expression of marrow stromal cells. Biomaterials. 2008;29(18):2729-39. 
87. Kaplan D. Biopolymers from renewable resources. New York: Springer; 1998. 
88. Azevedo HS, Gama FM, Reis RL. In vitro Assessment of the Enzymatic Degradation 
of Several Starch Based Biomaterials. Biomacromolecules. 2003;4(6):1703-12. 
89. Mendes SC, Bezemer J, Claase MB, Grijpma DW, Bellia G, Degli-Innocenti F, et al. 
Evaluation of two biodegradable polymeric systems as substrates for bone tissue 
engineering. Tissue Engineering. 2003;9:S91-S101. 
90. Salgado A, Coutinho O, Reis R, Davies J. In vivo response to starch-based scaffolds 
designed for bone tissue engineering applications. J Biomed Mater Res A. 2006;80:983-9. 
91. Tomihata K, Ikada Y. In vitro and in tivo degradation of films of chitin and its 
deacetylated derivatives. Biomaterials. 1997;18:261-8. 
92. Varum K, Myhr M, Hjerde R, Smidsrod O. In vitro degradation rates of partially N-
acetylated chitosans in human serum. Carbohydrate res. 1997;299:99-101. 
93. Molinaro G, Leroux JC, Damas J, Adam A. Biocompatibility of thermosensitive 
chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials. 
Biomaterials. 2002;23(13):2717-22. 
94. Rucker M, Laschke MW, Junker D, Carvalho C, Schramm A, Mulhaupt R, et al. 
Angiogenic and inflammatory response to biodegradable scaffolds in dorsal skinfold 
chambers of mice. Biomaterials. 2006;27(29):5027-38. 
95. Xiao Y, Young WG, Bartold PM. Tissue engineering for bone regeneration using 
osteoblasts in collagen scaffolds. J Dent Res. 2002 Mar;81:0851. 
96. Sachlos E, Reis N, Ainsley C, Derby B, Czernuszka JT. Novel collagen scaffolds with 
predefined internal morphology made by solid freeform fabrication. Biomaterials. 
2003;24(8):1487-97. 
97. Xiao Y, Qian H, Young WG, Bartold PM. Tissue engineering for bone regeneration 
using differentiated alveolar bone cells in collagen scaffolds. Tissue Engineering. 
2003;9(6):1167-77. 
 CHAPTER I. Introduction 
 31 
98. George J, Kuboki Y, Miyata T. Differentiation of mesenchymal stem cells into 
osteoblasts on honeycomb collagen scaffolds. Biotechnol Bioeng. [Article]. 2006;95(3):404-
11. 
99. Schneider RK, Puellen A, Kramann R, Raupach K, Bornemann J, Knuechel R, et al. 
The osteogenic differentiation of adult bone marrow and perinatal umbilical mesenchymal 
stem cells and matrix remodelling in three-dimensional collagen scaffolds. Biomaterials. 2010 
Jan;31(3):467-80. 
100. Lisignoli G, Fini M, Giavaresi G, Nicoli Aldini N, Toneguzzi S, Facchini A. 
Osteogenesis of large segmental radius defects enhanced by basic fibroblast growth factor 
activated bone marrow stromal cells grown on non-woven hyaluronic acid-based polymer 
scaffold. Biomaterials. 2002;23(4):1043-51. 
101. Kim J, Kim IS, Cho TH, Lee KB, Hwang SJ, Tae G, et al. Bone regeneration using 
hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal 
stem cells. Biomaterials. 2007;28(10):1830-7. 
102. Abbah S, Lu W, Chan D, Cheung K, Liu W, Zhao F, et al. Osteogenic behavior of 
alginate encapsulated bone marrow stromal cells: An in vitro study. Journal of Materials 
Science: Materials in Medicine. 2008;19(5):2113-9. 
103. Li C, Vepari C, Jin H-J, Kim HJ, Kaplan DL. Electrospun silk-BMP-2 scaffolds for bone 
tissue engineering. Biomaterials. 2006;27(16):3115-24. 
104. Meinel L, Betz O, Fajardo R, Hofmann S, Nazarian A, Cory E, et al. Silk based 
biomaterials to heal critical sized femur defects. Bone. 2006;39(4):922-31. 
105. Bakos D, Soldan M, Hernandez-Fuentes I. Hydroxyapatite-collagen-hyaluronic acid 
composite. Biomaterials. 1999;20(2):191-5. 
106. Solchaga LA, Temenoff JS, Gao JZ, Mikos AG, Caplan AI, Goldberg VM. Repair of 
osteochondral defects with hyaluronan- and polyester-based scaffolds. Osteoarthritis 
Cartilage. 2005;13(4):297-309. 
107. Schumann D, Ekaputra AK, Lam CXF, Hutmacher DW. Biomaterials/scaffolds. Design 
of bioactive, multiphasic PCL/collagen type I and type II-PCL-TCP/collagen composite 
scaffolds for functional tissue engineering of osteochondral repair tissue by using 
electrospinning and FDM techniques. Methods Mol Med. 2007;140:101-24. 
108. Rouget C. Des substances amylacées dans les tissus des animaux, spécialement 
des Articulés (chitine). CR Acad Sci Ser III. 1859;48:792-5. 
109. Suh. Application of chitosan-based polysaccharide biomaterials in cartilage tissue 
engineering: a review. Biomaterials. 2000;21:2589-98. 
110. Lahiji A, Sohrabi A, Hungerford DS, Frondoza CG. Chitosan supports the expression 
of extracellular matrix proteins in human osteoblasts and chondrocytes. J Biomed Mater Res. 
2000;51(4):586-95. 
111. Kurita K. Chemistry and application of chitin and chitosan. Polymer Degradation and 
Stability. 1997;59(1-3):117-20. 
112. Shi C, Zhu Y, Ran X, Wang M, Su Y, Cheng T. Therapeutic Potential of Chitosan and 
Its Derivatives in Regenerative Medicine. Journal of Surgical Research. 2006;133(2):185-92. 
113. Muzzarelli R, Baldassarre V, Conto F, Ferrara P, Biagini G, Gazzanelli G, et al. 
Biological activity of chitosan: ultrastructural study. Biomaterials. 1988;9(3):247-52. 
114. Denuziere A, Ferrier D, Damour O, Domard A. Chitosan-chondroitin sulfate and 
chitosan-hyaluronate polyelectrolyte complexes: biological properties. Biomaterials. 
1998;19(14):1275-85. 
115. Di Martino A, Sittinger M, Risbud MV. Chitosan: a versatile biopolymer for orthopaedic 
tissue-engineering. Biomaterials. 2005;26(30):5983-90. 
116. Nordtveit RJ, VArum KM, Smidsrd O. Degradation of partially N-acetylated chitosans 
with hen egg white and human lysozyme. Carbohydrate Polymers. 1996;29(2):163-7. 
117. Kjell M. Varum, Mildrid M. Myhr, Ragnhild J.N. Hjerde, Smidsrod O. In vitro 
degradation rates of partially N-acetylated chitosans in human serum. Carbohydrate res. 
1997;299:99-101. 
CHAPTER I. Introduction  
 32 
118. Lu F, Cao Z, Zhuang Z, Mou ZX, Feng X. [Biodegradation and biocompatibility of a 
chitosan film]. Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = 
Shengwu yixue gongchengxue zazhi. 1998 Jun;15(2):183-5. 
119. Laschke MW, Strohe A, Scheuer C, Eglin D, Verrier S, Alini M, et al. In vivo 
biocompatibility and vascularization of biodegradable porous polyurethane scaffolds for 
tissue engineering. Acta Biomaterialia. 2009;5(6):1991-2001. 
120. Spin-Neto R, de Freitas RM, Pavone C, Cardoso MB, Campana-Filho SP, 
Marcantonio RA, et al. Histological evaluation of chitosan-based biomaterials used for the 
correction of critical size defects in rat's calvaria. J Biomed Mater Res A. 2010;93(1):107-14. 
121. Muzzarelli R., Tarsi R, Filippini O, Giovanetti E, Biagini G, Varaldo PE. Antimicrobial 
properties of N-carboxybutyl chitosan. Antimicrobial agents and chemotherapy. 
1990;34(10):2019-23. 
122. Loke WK, Lau SK, Yong LL, Khor E, Sum CK. Wound dressing with sustained anti-
microbial capability. J Biomed Mater Res. 2000;53(1):8-17. 
123. No HK, Park NY, Lee SH, Meyers SP. Antibacterial activity of chitosans and chitosan 
oligomers with different molecular weights. International journal of food microbiology. 
2002;74(1-2):65-72. 
124. Sall KN, Kreter JK, Keates RH. The effect of chitosan on corneal wound healing. 
Annals of ophthalmology. 1987;19(1):31-3. 
125. Biagini G, Bertani A, Muzzarelli R, Damadei A, DiBenedetto G, Belligolli A, et al. 
Wound management with N-carboxybutyl chitosan. Biomaterials. 1991 Apr;12(3):281-6. 
126. Okamoto Y, Shibazaki K, Minami S, Matsuhashi A, Tanioka S, Shigemasa Y. 
Evaluation of chitin and chitosan on open would healing in dogs. J Vet Med Sci. 
1995;57(5):851-4. 
127. Ueno H, Yamada H, Tanaka I, Kaba N, Matsuura M, Okumura M, et al. Accelerating 
effects of chitosan for healing at early phase of experimental open wound in dogs. 
Biomaterials. 1999;20(15):1407-14. 
128. Peh K, Khan T, Ch'ng H. Mechanical, bioadhesive strength and biological evaluations 
of chitosan films for wound dressing. J Pharm Pharm Sci. 2000;3(3):303-11. 
129. Mi FL, Shyu SS, Wu YB, Lee ST, Shyong JY, Huang RN. Fabrication and 
characterization of a sponge-like asymmetric chitosan membrane as a wound dressing. 
Biomaterials. 2000;22(2):165-73. 
130. Azad AK, Sermsintham N, Chandrkrachang S, Stevens WF. Chitosan membrane as a 
wound-healing dressing: characterization and clinical application. J Biomed Mater Res B 
Appl Biomater. 2004;69(2):216-22. 
131. Chatelet C, Damour O, Domard A. Influence of the degree of acetylation on some 
biological properties of chitosan films. Biomaterials. 2001;22(3):261-8. 
132. Pangburn SH, Trescony PV, Heller J. Lysozyme degradation of partially deacetylated 
chitin, its films and hydrogels. Biomaterials. 1982;3(2):105-8. 
133. Sashiwa H, Saimoto H, Shigemasa Y, Ogawa R, Tokura S. Lysozyme susceptibility of 
partially deacetylated chitin. International Journal of Biological Macromolecules. 
1990;12(5):295-6. 
134. Hankiewicz J, Swierczek E. Lysozyme in human body fluids. Clinica Chimica Acta. 
1974;57(3):205-9. 
135. Muzzarelli RAA. Biochemical significance of exogenous chitins and chitosans in 
animals and patients. Carbohydrate Polymers. 1993;20(1):7-16. 
136. Torsteinsdottir I, Hakansson L, Hallgren R, Gudbjornsson B, Arvidson N-G, Venge P. 
Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. 
Rheumatology. 1999 December 1, 1999;38(12):1249-54. 
137. TeijÛn C, Olmo R, Dolores Blanco M, Romero A, MarÌa TeijÛn J. Effects of lead 
administration at low doses by different routes on rat spleens. Study of response of splenic 
lymphocytes and tissue lysozyme. Toxicology. 2003;191(2-3):245-58. 
 CHAPTER I. Introduction 
 33 
138. Rabea EI, Badawy MET, Stevens CV, Smagghe G, Steurbaut W. Chitosan as 
Antimicrobial Agent: Applications and Mode of Action. Biomacromolecules. 2003;4(6):1457-
65. 
139. Prudden JF, Migel P, Hanson P, Friedrich L, Balassa L. The discovery of a potent 
pure chemical wound-healing accelerator. The American Journal of Surgery. 
1970;119(5):560-4. 
140. Peluso. Chitosan-mediated stimulation of macrophage function. Biomaterials. 
1994;15:1215-20. 
141. Mori. Effects of chitin and its derivatives on the proliferation and cytokine production 
of fibroblasts in vitro. Biomaterials. 1997;18:947-51. 
142. Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. Immunological activity 
of chitin and its derivatives. Vaccine. 1984 Mar;2(1):93-9. 
143. Jameela SR, Misra A, Jayakrishnan A. Cross-linked chitosan microspheres as 
carriers for prolonged delivery of macromolecular drugs. Journal of biomaterials science. 
1994;6(7):621-32. 
144. Maruyama M, Ito M. In vitro properties of a chitosan-bonded self-hardening paste with 
hydroxyapatite granules. J Biomed Mater Res. 1996;32(4):527-32. 
145. Muzzarelli RA, Biagini G, Bellardini M, Simonelli L, Castaldini C, Fratto G. 
Osteoconduction exerted by methylpyrrolidinone chitosan used in dental surgery. 
Biomaterials. 1993;14(1):39-43. 
146. Muzzarelli RA, Zucchini C, Ilari P, Pugnaloni A, Mattioli Belmonte M, Biagini G, et al. 
Osteoconductive properties of methylpyrrolidinone chitosan in an animal model. Biomaterials. 
1993;14(12):925-9. 
147. Muzzarelli RA. Stimulatory effect on bone formation exerted by a modified chitosan. 
Biomaterials. 1994;15(13):1075-81. 
148. Lee YM, Park YJ, Lee SJ, Ku Y, Han SB, Choi SM, et al. Tissue engineered bone 
formation using chitosan/tricalcium phosphate sponges. Journal of periodontology. 
2000;71(3):410-7. 
149. Yeo Y-J, Jeon D-W, Kim C-S, Choi S-H, Cho K-S, Lee Y-K, et al. Effects of chitosan 
nonwoven membrane on periodontal healing of surgically created one-wall intrabony defects 
in beagle dogs. Journal of Biomedical Materials Research. 2004;72B(1):86-93. 
150. Ang TH, Sultana FSA, Hutmacher DW, Wong YS, Fuh JYH, Mo XM, et al. Fabrication 
of 3D chitosan-hydroxyapatite scaffolds using a robotic dispensing system. Materials Science 
and Engineering: C. 2002;20(1-2):35-42. 
151. Yin Y, Ye F, Cui J, Zhang F, Li X, Yao K. Preparation and characterization of 
macroporous chitosan-gelatin/beta-tricalcium phosphate composite scaffolds for bone tissue 
engineering. J Biomed Mater Res A. 2003 ;67(3):844-55. 
152. Burg KJL, Porter S, Kellam JF. Biomaterial developments for bone tissue engineering. 
Biomaterials. 2000;21(23):2347-59. 
153. Gopferich A. Mechanisms of polymer degradation and erosion. Biomaterials. 
1996;17(2):103-14. 
154. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 
2000;6(4):389-95. 
155. Borenstein JT, Weinberg EJ, Orrick BK, Sundback C, Kaazempur-Mofrad MR, 
Vacanti JP. Microfabrication of Three-Dimensional Engineered Scaffolds. Tissue 
Engineering. 2007;13(8):1837-44. 
156. Mastrogiacomo M, Scaglione S, Martinetti R, Dolcini L, Beltrame F, Cancedda R, et 
al. Role of scaffold internal structure on in vivo bone formation in macroporous calcium 
phosphate bioceramics. Biomaterials. 2006;27(17):3230-7. 
157. Klawitter J, Hulbert S. Application of porous ceramics for the attachment of load 
bearing internal orthopedic applications. Journal of Biomedical Materials Research. 
1971;5(6):161-229. 
CHAPTER I. Introduction  
 34 
158. Lewandrowski K-U, Gresser JD, P.Bondre S, Silva AE, Wise DL, Trantolo DJ. 
Developing porosity of poly(propylene glycol-co-fumaric acid) bone graft substitutes and the 
effect on osteointegration: A preliminary histology study in rats. Journal of Biomaterials 
Science, Polymer Edition. 2000;11:879-89. 
159. Gomes M, Holtorf H, Reis R, Mikos AG. Influence of the Porosity of Starch-Based 
Fiber Mesh Scaffolds on the Proliferation and Osteogenic Differentiation of Bone Marrow 
Stromal Cells Cultured in a Flow Perfusion Bioreactor. Tissue Engineering. 2006;12(4):801-9. 
160. Zhang Y, Zhang M. Three-dimensional macroporous calcium phosphate bioceramics 
with nested chitosan sponges for load-bearing bone implants. J Biomed Mater Res. 
2002;61(1):1-8. 
161. Yang S, Leong K-F, Du Z, Chua C-K. The Design of Scaffolds for Use in Tissue 
Engineering. Part I. Traditional Factors. Tissue Engineering. 2004;7(6):679-89. 
162. Boyan BD, Hummert TW, Dean DD, Schwartz Z. Role of material surfaces in 
regulating bone and cartilage cell response. Biomaterials. 1996;17(2):137-46. 
163. Leong KF, Cheah CM, Chua CK. Solid freeform fabrication of three-dimensional 
scaffolds for engineering replacement tissues and organs. Biomaterials. 2003;24(13):2363-
78. 
164. Shen F, Cui YL, Yang LF, Yao KD, Dong XH, Jia WY, et al. A study on the fabrication 
of porous chitosan/gelatin network scaffold for tissue engineering. Polymer International. 
2000;49(12):1596-9. 
165. Zhang Y, Zhang M. Cell growth and function on calcium phosphate reinforced 
chitosan scaffolds. Journal of materials Science: materials in medicine. 2004;15:255-60. 
166. Li Z, Ramay HR, Hauch KD, Xiao D, Zhang M. Chitosan-alginate hybrid scaffolds for 
bone tissue engineering. Biomaterials. 2005;26(18):3919-28. 
167. Amaral IF, Sampaio P, Barbosa MA. Three-dimensional culture of human osteoblastic 
cells in chitosan sponges: the effect of the degree of acetylation. J Biomed Mater Res A. 
2006;76(2):335-46. 
168. Kong L, Gao Y, Lu G, Gong Y, Zhao N, Zhang X. A study on the bioactivity of 
chitosan/nano-hydroxyapatite composite scaffolds for bone tissue engineering European 
Polymer Journal. 2006;42(12):3171-9. 
169. Manjubala I, Scheler S, Bˆssert J, Jandt KD. Mineralisation of chitosan scaffolds with 
nano-apatite formation by double diffusion technique. Acta Biomaterialia. 2006;2(1):75-84. 
170. Gravel M, Gross T, Vago R, Tabrizian M. Responses of mesenchymal stem cell to 
chitosan–coralline composites  microstructured using coralline as gas forming agent 
Biomaterials. 2006;27:1899-906. 
171. Sendemir-Urkmez A, Jamison RD. The addition of biphasic calcium phosphate to 
porous chitosan scaffolds enhances bone tissue development in vitro. Journal of Biomedical 
Materials Research Part A. 2007;81A(3):624-33. 
172. Zheng JP, Wang CZ, Wang XX, Wang HY, Zhuang H, Yao KD. Preparation of 
biomimetic three-dimensional gelatin/montmorillonite-chitosan scaffold for tissue engineering. 
Reactive and Functional Polymers. 2007;67(9):780-8. 
173. Arpornmaeklong P, Pripatnanont P, Suwatwirote N. Properties of chitosan-collagen 
sponges and osteogenic differentiation of rat-bone-marrow stromal cells. International 
Journal of Oral and Maxillofacial Surgery. 2008;37(4):357-66. 
174. Kuo Y-C, Yeh C-F, Yang J-T. Differentiation of bone marrow stromal cells in 
poly(lactide-co-glycolide)/chitosan scaffolds. Biomaterials. 2009;30(34):6604-13. 
175. Akman AC, Tigli RS, Gumusderelioglu M, Nohutcu RM. Bone morphogenetic protein-
6-loaded chitosan scaffolds enhance the osteoblastic characteristics of MC3T3-E1 cells. Artif 
Organs. 2010;34(1):65-74. 
176. Hsieh Chien-Yang, Tsai Sung-Pei, Ho Ming-Hwa, Wang Da-Ming, Liu Chung-En, 
Cheng-Hsuan, et al. Analysis of freeze-gelation and cross-linking processes for preparing 
porous chitosan scaffolds. 2007;67:9. 
 CHAPTER I. Introduction 
 35 
177. Knaul JZ, Hudson SM, Creber KAM. Improved mechanical properties of chitosan 
fibers. Journal of Applied Polymer Science. 1999;72(13):1721-32. 
178. Hirano S. Wet-spinning and applications of functional fibers based on chitin and 
chitosan. Macromolecular Symposia. 2001;168(1):21-30. 
179. Tuzlakoglu K, Reis R. Formation of bone-like apatite layer on chitosan fiber mesh 
scaffolds by a biomimetic spraying process. Journal of Materials Science: Materials in 
Medicine. 2007;18(7):1279-86. 
180. Duan B, Dong C, Yuan X, Yao K. Electrospinning of chitosan solutions in acetic acid 
with poly(ethylene oxide). Journal of Biomaterials Science, Polymer Edition. 2004;15:797-
811. 
181. Ohkawa K, Cha D, Kim H, Nishida A, Yamamoto H. Electrospinning of Chitosan. 
Macromolecular Rapid Communications. 2004;25(18):1600-5. 
182. Shin SY, Park HN, Kim KH, Lee MH, Choi YS, Park YJ, et al. Biological evaluation of 
chitosan nanofiber membrane for guided bone regeneration. Journal of periodontology. 
2005;76(10):1778-84. 
183. De Vrieze S, Westbroek P, Van Camp T, Van Langenhove L. Electrospinning of 
chitosan nanofibrous structures: feasibility study. Journal of Materials Science. 
2007;42(19):8029-34. 
184. Park WH, Jeong L, Yoo DI, Hudson S. Effect of chitosan on morphology and 
conformation of electrospun silk fibroin nanofibers. Polymer. 2004;45(21):7151-7. 
185. Subramanian A, Lin HY, Vu D, Larsen G. Synthesis and evaluation of scaffolds 
prepared from chitosan fibers for potential use in cartilage tissue engineering. Biomedical 
sciences instrumentation. 2004;40:117-22. 
186. Bhattarai N, Edmondson D, Veiseh O, Matsen FA, Zhang M. Electrospun chitosan-
based nanofibers and their cellular compatibility. Biomaterials. 2005;26(31):6176-84. 
187. Li L, Hsieh Y-L. Chitosan bicomponent nanofibers and nanoporous fibers. 
Carbohydrate Research. 2006;341(3):374-81. 
188. Chen Z, Mo X, Qing F. Electrospinning of collagen-chitosan complex. Materials 
Letters. 2007;61(16):3490-4. 
189. Yang X, Chen X, Wang H. Acceleration of Osteogenic Differentiation of 
Preosteoblastic Cells by Chitosan Containing Nanofibrous Scaffolds. Biomacromolecules. 
2009;10(10):2772-8. 
190. Jiang T, Abdel-Fattah WI, Laurencin CT. In vitro evaluation of chitosan/poly(lactic 
acid-glycolic acid) sintered microsphere scaffolds for bone tissue engineering. Biomaterials. 
2006;27(28):4894. 
191. Geng L, Feng W, Hutmacher D, Wong Y, Loh H, Fuh J. Direct writing of chitosan 
scaffolds using a robotic system Rapid Prototyping Journal 2005;11(2):90-7. 
192. Zhang Y, Zhang M. Synthesis and characterization of macroporous chitosan/calcium 
phosphate composite scaffolds for tissue engineering. J Biomed Mater Res. 2001;55(3):304-
12. 
193. Huang Y, Onyeri S, Siewe M, Moshfeghian A, Madihally SV. In vitro characterization 
of chitosan-gelatin scaffolds for tissue engineering. Biomaterials. 2005;26(36):7616-27. 
194. Xu HH, Simon CG, Jr. Fast setting calcium phosphate-chitosan scaffold: mechanical 
properties and biocompatibility. Biomaterials. 2005;26(12):1337-48. 
195. Abdel-Fattah WI, Jiang T, El-Bassyouni GE-T, Laurencin CT. Synthesis, 
characterization of chitosans and fabrication of sintered chitosan microsphere matrices for 
bone tissue engineering. acta biomaterialia. 2007;3(4):503-14. 
196. Oliveira JT, Santos TC, Martins L, Silva MA, Marques AP, Castro AG, et al. 
Performance of new gellan gum hydrogels combined with human articular chondrocytes for 
cartilage regeneration when subcutaneously implanted in nude mice. Joirnal of Tissue 
Engineering and Regenerative Medicine 2009;3(7):493-500. 
197. Martins A, Pereira R, Leonor I, Azevedo H, RL R. Chitosan scaffolds incorporating 
lysozyme into CaP coatings produced by a biomimetic route: A novel concept for tissue 
CHAPTER I. Introduction  
 36 
engineering combining a self-regulated degradation system with in situ pore formation. Acta 
Biomaterialia. 2009;5:3328–3336 
198. Kon E, Muraglia A, Corsi A, Bianco P, Marcacci M, Martin I, et al. Autologous bone 
marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in 
critical-size defects of sheep long bones. Journal of Biomedical Materials Research. 
2000;49(3):328-37. 
199. Kruyt M, Dhert W, Yuan H, Wilson C, van Blitterswijk C, Verbout A, et al. Bone tissue 
engineering in a critical size defect compared to ectopic implantations in the goat. J Orthop 
Res. 2004;22(3):544-51. 
200. Lucarelli E, Donati D, Cenacchi A, Fornasari PM. Bone reconstruction of large defects 
using bone marrow derived autologous stem cells. Transfusion and Apheresis Science. 
2004;30:169-74. 
201. Willers C, Chen J, Wood D, Xu J, Zheng MH. Autologous Chondrocyte Implantation 
with Collagen Bioscaffold for the Treatment of Osteochondral Defects in Rabbits. Tissue 
Engineering. 2005;11(7-8):1065-76. 
202. Giannoni P, Mastrogiacomo M, Alini M, Pearce SG, Corsi A, Santolini F, et al. 
Regeneration of large bone defects in sheep using bone marrow stromal cells. J Tissue Eng 
Regen Med. 2008;2(5):253-62. 
203. Heath CA. Cells for tissue engineering. Trends in Biotechnology. 2000;18(1):17-9. 
204. Evans M, Kaufman M. Establishment in culture of pluripotential cells from mouse 
embryos. Nature. 1981;292:154-6. 
205. Huss R, Lange C, Weissinger E, Kolb H-J, Thalmeier K. Evidence of Peripheral 
Blood-Derived, Plastic-Adherent CD34–/low Hematopoietic Stem Cell Clones with 
Mesenchymal Stem Cell Characteristics. Stem cells. 2000;18:252-60. 
206. Gimble JM, Guilak F. Adipose-derived adult stem cells: isolation, characterization, 
and differentiation potential. Cytotherapy. 2003;5(5):362-9. 
207. Sarugaser R, Lickorish D, Baksh D, Hosseini M, Davies J. Human Umbilical Cord 
Perivascular (HUCPV) Cells: A Source of Mesenchymal Progenitors. Stem cells. 
2005;23:220-9. 
208. De Coppi P, Bartsch G, Siddiqui M, Xu T, Santos C, Perin L, et al. Isolation of 
amniotic stem cell lines with potential for therapy. Nature. 2007;25:100-6. 
209. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T, Tsuji K. Human Placenta-
Derived Cells Have Mesenchymal Stem/Progenitor Cell Potential. Stem cells. 
2004;22(5):649-58. 
210. Pittenger M, Mackay AM, Beck S, Jaiswal R, Douglas R, Mosca JD, et al. Multilineage 
Potential of Adult Human Mesenchymal Stem Cells. Science. 1999;284:143-7. 
211. Jiang Y, Jahagirdar B, Reinhardt R, Schwartz R, Keene C, Ortiz-Gonzalez X, et al. 
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 
2002;418(6893):41-9. 
212. Jaiswal N, Haynesworth SE, Caplan AI, Bruder SP. Osteogenic differentiation of 
purified, culture-expanded human mesenchymal stem cells in vitro. Journal of Cellular 
Biochemistry. 1997;64(2):295-312. 
213. Takamizawa S, Maehata Y, Imai K, Senoo H, Sato S, Hata R-I. Effects of ascorbic 
acid and ascorbic acid 2-phosphate, a long-acting vitamin C derivative, on the proliferation 
and differentiation of human osteoblast-like cells. Cell Biology International. 2004;28(4):255-
65. 
214. Bellows CG, Heersche JNM, Aubin JE. Inorganic phosphate added exogenously or 
released from [beta]-glycerophosphate initiates mineralization of osteoid nodules in vitro. 
Bone and Mineral. 1992;17(1):15-29. 
215. Gerstenfeld LC, Chipman SD, Glowacki J, Lian JB. Expression of differentiated 
function by mineralizing cultures of chicken osteoblasts. Developmental Biology. 
1987;122(1):49-60. 
 CHAPTER I. Introduction 
 37 
216. Koshihara Y, Kawamura M, Oda H, Higaki S. calcification in human osteoblastic cell 
line derived from periosteum. Biochemical and Biophysical Research Communications. 
1987;145(2):651-7. 
217. Subramaniam M, Colvard D, Keeting PE, Rasmussen K, Riggs BL, Spelsberg TC. 
Glucocorticoid regulation of alkaline phosphatase, osteocalcin, and proto-oncogenes in 
normal human osteoblast-like cells. Journal of Cellular Biochemistry. 1992;50(4):411-24. 
218. Maniatopoulos C, Sodek J, Melcher A. Bone formation in vitro by stromal cells 
obtained from bone marrow of young adult rats. cell Tissue Res. 1988;254(2):317-30. 
219. Canalis E, Agnusdei D. Insulin-like growth factors and their role in osteoporosis. 
Calcified Tissue International. 1996;58(3):133-4. 
220. Mendes SC, Van den Brink I, De Bruijn JD, Van Blitterswijk CA. In vivo bone 
formation by human bone marrow cells: effect of osteogenic culture supplements and cell 
densities. J Mater Sci-Mater Med. 1999;9(12):855-8. 
221. Lee YM, Park YJ, Lee SJ, Ku Y, Han SB, Klokkevold PR, et al. The bone regenerative 
effect of platelet-derived growth factor-BB delivered with a chitosan/tricalcium phosphate 
sponge carrier. Journal of periodontology. 2000;71(3):418-24. 
222. Boyan B, Bonewald L, Paschalis E, Lohmann C, Rosser J, Cochran D, et al. 
Osteoblast-mediated mineral deposition in culture is dependent on surface microtopography. 
Calcif Tissue Int. 2002;71(6):519-29. 
223. Govinden R, Bhoola KD. Genealogy, expression, and cellular function of transforming 
growth factor-[beta]. Pharmacology & Therapeutics. 2003;98(2):257-65. 
224. Dean D. Effect of Transforming Growth Factor  2 on Marrow-Infused Foam 
Poly(Propylene Fumarate) Tissue-Engineered Constructs for the Repair of Critical-Size 
Cranial Defects in Rabbits. Tissue Engineering. 2005;11(5-6): 923-939 
225. Gomez G, Korkiakoski S, Gonzalez M-M, Lansman S, Ella V, Salo T, et al. Effect of 
FGF and Polylactide Scaffolds on Calvarial Bone Healing With Growth Factor on 
Biodegradable Polymer Scaffolds. The Journal of Craniofacial Surgery 2006;17(5):935-42. 
226. Osathanon T, Linnes ML, Rajachar RM, Ratner BD, Somerman MJ, Giachelli CM. 
Microporous nanofibrous fibrin-based scaffolds for bone tissue engineering. Biomaterials. 
2008;29(30):4091-9. 
227. Lian JB, Stein GS. Concepts of Osteoblast Growth and Differentiation: Basis for 
Modulation of Bone Cell Development and Tissue Formation. Critical Reviews in Oral Biology 
& Medicine. 1992;3(3):269-305. 
228. Owen TA, Aronow M, Shalhoub V, Barone LM, Wilming L, Tassinari MS, et al. 
Progressive development of the rat osteoblast phenotype in vitro: Reciprocal relationships in 
expression of genes associated with osteoblast proliferation and differentiation during 
formation of the bone extracellular matrix. Journal of Cellular Physiology. 1990;143(3):420-
30. 
229. Sabokbar A, Millett P, Myer B, Rushton N. A rapid, quantitative assay for measuring 
alkaline phosphatase activity in osteoblastic cells in vitro. 1994;27:57-67. 
230. Toquet J, Rohanizadeh R, Guicheux J, Couillaud S, Passuti N, Daculsi G, et al. 
Osteogenic potential in vitro of human bone marrow cells cultured on macroporous biphasic 
calcium phosphate ceramic. Journal of Biomedical Materials Research. 1999;44(1):98-108. 
231. Weiner S. Biomineralization: A structural perspective. Journal of Structural Biology. 
2008;163(3):229-34. 
232. Werb Z. Ecm and cell surface proteolysis: Regulating cellular ecology. Cell 
1997;91(4):439-42. 
233. Klokkevold PR. Osteogenesis enhanced by chitosan (poly-N-acetyl 
glucosaminoglycan) in vitro. J Periodontol 1996;67(11):1170-5. 
234. Cai K, Yao K, Cui Y, Lin S, Yang Z, Li X, et al. Surface modification of poly (D,L-lactic 
acid) with chitosan and its effects on the culture of osteoblasts in vitro. J Biomed Mater Res. 
2002 Jun 5;60(3):398-404. 
CHAPTER I. Introduction  
 38 
235. Cai K, Hu Y, Jandt K, Wang Y. Surface modification of titanium thin film with chitosan 
via electrostatic self-assembly technique and its influence on osteoblast growth behavior. 
Journal of Materials Science: Materials in Medicine. 2008;19(2):499-506. 
236. Bumgardner JD, Chesnutt BM, Yuan Y, Yang Y, Appleford M, Oh S, et al. The 
Integration of Chitosan-Coated Titanium in Bone: An In vivo Study in Rabbits. Implant 
Dentistry. 2007;16(1):66-79  
237. Coutinho D, Pashkuleva I, Alves C, Marques A, Neves N, Reis R. The Effect of 
Chitosan on the In vitro Biological Performance of Chitosan-Poly(butylene succinate) Blends. 
Biomacromolecules. 2008;9(4):1139-45. 
238. Mohammadi Y, Soleimani M, Fallahi-Sichani M, Gazme A, Haddadi-Asl V, Arefian E, 
et al. Nanofibrous poly(epsilon-caprolactone)/poly(vinyl alcohol)/chitosan hybrid scaffolds for 
bone tissue engineering using mesenchymal stem cells. Int J Artif Organs. 2007;30(3):204-
11. 
239. Holtorf H, Jansen J, Mikos A. Ectopic bone formation in rat marrow stromal 
cell/titanium fiber mesh scaffold constructs:Effect of initial cell phenotype. Biomaterials. 
2005;26:6208-16. 
240. Kasten P, Vogel J, Luginbu R, Niemeyer P, Tonak M, Lorenz H, et al. Ectopic bone 
formation associated with mesenchymal stem cells in a resorbable calcium deficient 
hydroxyapatite carrier. Biomaterials. 2005;26:5879-89. 
241. Trojani T, Boukhechba F, Scimeca J-C, Vandenbos F, Michiels J-F, Daculsi G, et al. 
Ectopic bone formation using an injectable biphasic calcium phosphate/Si-HPMC hydrogel 
composite loaded with undifferentiated bone marrow stromal cells. Biomaterials. 
2006;27:3256–64. 
242. Rentsch C, Rentsch B, Breier A, Hofmann A, Manthey S, Scharnweber D, et al. 
Evaluation of the osteogenic potential and vascularization of 3D poly(3)hydroxybutyrate 
scaffolds subcutaneously implanted in nude rats. Journal of Biomedical Materials Research 
Part A. 2010;92A(1):185-95. 
243. Schantz JT, Hutmacher DW, Chim H, Ng KW, Lim TC, Teoh SH. Induction of ectopic 
bone formation by using human periosteal cells in combination with a novel scaffold 
technology. Cell Transplant. 2002;11(2):125-38. 
244. Cai XX, Lin YF, Ou GM, Luo E, Man Y, Yuan QA, et al. Ectopic osteogenesis and 
chondrogenesis of bone marrow stromal stem cells in alginate system. Cell Biology 
International. 2007;31(8):776-83. 
245. Claase MB, de Bruijn JD, Grijpma DW, Feijen J. Ectopic bone formation in cell-
seeded poly(ethylene oxide)/poly(butylene terephthalate) copolymer scaffolds of varying 
porosity. J Mater Sci-Mater Med. 2007;18(7):1299-307. 
246. Lindsey RW, Gugala Z, Milne E, Sun M, Gannon FH, Latta LL. The efficacy of 
cylindrical titanium mesh cage for the reconstruction of a critical-size canine segmental 
femoral diaphyseal defect. Journal of Orthopaedic Research. 2006;24(7):1438-53. 
247. Pearce A, Richards R, Milz S, Schneider E, Pearce S. Animal models for implant 
biomaterial research in bone: a review. Eur Cell Mater. 2007;2(13):1-10. 
248. Fuji T, Anada T, Honda Y, Shiwaku Y, Koike H, Kamakura S, et al. Octacalcium 
phosphate-precipitated alginate scaffold for bone regeneration. Tissue Eng Part A. 
2009;15(11):3525-35. 
249. Zhang Z-Y, Teoh S-H, Chong MSK, Lee ESM, Tan L-G, Mattar CN, et al. Neo-
vascularization and bone formation mediated by fetal mesenchymal stem cell tissue-
engineered bone grafts in critical-size femoral defects. Biomaterials. 2010;31(4):608-20. 
250. Fialkov JA, Holy CE, Shoichet MS, Davies JE. In vivo bone engineering in a rabbit 
femur. Journal of Craniofacial Surgery. 2003;14(3):324-32. 
251. Nasser NJ, Friedman A, Friedman M, Moor E, Mosheiff R. Guided bone regeneration 
in the treatment of segmental diaphyseal defects: a comparison between resorbable and 
non-resorbable membranes. Injury. 2005;36(12):1460-6. 
 CHAPTER I. Introduction 
 39 
252. Mastrogiacomo M, Corsi A, E F, Di Comite M, Monetti F, Scaglione FA, et al. 
Reconstruction of Extensive Long Bone Defects in Sheep Using Resorbable Bioceramics 
Based on Silicon Stabilized Tricalcium Phosphate. Tissue Engineering. 2006;12(5):1261-73. 
253. Zhu L, Liu W, Cui L, Cao YL. Tissue-engineered bone repair of goat femur defects 
with osteogenically induced bone marrow stromal cells. Tissue Engineering. 2006 
Mar;12(3):423-33. 
254. Takahashi Y, Yamamoto M, Yamada K, Kawakami O, Tabata Y. Skull Bone 
Regeneration in Nonhuman Primates by Controlled Release of Bone Morphogenetic Protein-
2 from a Biodegradable Hydrogel. Tissue Engineering. 2007;13(2):293-300. 
255. Umeda H, Kanemaru Si, Yamashita M, Kishimoto M, Tamura Y, Nakamura T, et al. 
Bone Regeneration of Canine Skull Using Bone Marrow-Derived Stromal Cells and β-
Tricalcium Phosphate. The Laryngoscope. 2007;117(6):997-1003. 
256. Yuehuei H, Freidman R. Animal Models in Orthopaedic Research. 1st ed. Boca 
Raton: CRC press; 1999. 
257. Montjovent MO, Mathieu L, Schmoekel H, Mark S, Bourban PE, Zambelli PY, et al. 
Repair of critical size defects in the rat cranium using ceramic-reinforced PLA scaffolds 
obtained by supercritical gas foaming. Journal of Biomedical Materials Research Part A. 
2007;83A(1):41-51. 
258. Whang K, Healy KE, Elenz DR, Nam EK, Tsai DC, Thomas CH, et al. Engineering 
bone regeneration with bioabsorbable scaffolds with novel microarchitecture. Tissue 
Engineering. 1999;5(1):35-51. 
259. Stephan SJ, Tholpady SS, Gross B, Petrie-Aronin CE, Botchway EA, Nair LS, et al. 
Injectable tissue-engineered bone repair of a rat calvarial defect. The Laryngoscope. 
2010;120(5):895-901. 
260. Kim HW, Shin SY, Kim HE, Lee YM, Chung CP, Lee HH, et al. Bone formation on the 
apatite-coated zirconia porous scaffolds within a rabbit calvarial defect. J Biomater Appl. 
2008;22(6):485-504. 
261. Kim SJ, Lim JW, Ryu JJ, Ahn JS, Han IH, Shin SW. Effects of 4 Different Alloplastic 
Materials on Bone Regeneration in Rabbit Calvarial Defects. Tissue Eng Regen Med. 
2009;6(1-3):63-8. 
262. Yeo A, Wong WJ, Teoh SH. Surface modification of PCL-TCP scaffolds in rabbit 
calvaria defects: Evaluation of scaffold degradation profile, biomechanical properties and 
bone healing patterns. Journal of Biomedical Materials Research Part A. 2010;93A(4):1358-
67. 
263. Holmbom J, Sodergard A, Ekholm E, Martson M, Kuusilehto A, Saukko P, et al. Long-
term evaluation of porous poly(epsilon-caprolactone-co-L-lactide) as a bone-filling material. 
Journal of Biomedical Materials Research Part A. 2005;75A(2):308-15. 
264. Yokoyama A, Gelinsky M, Kawasaki T, Kohgo T, Konig U, Pompe W, et al. 
Biomimetic porous scaffolds with high elasticity made from mineralized collagen - An animal 
study. J Biomed Mater Res Part B. 2005;75B(2):464-72. 
265. Chu TMG, Warden SJ, Turner CH, Stewart RL. Segmental bone regeneration using a 
load-bearing biodegradable carrier of bone morphogenetic protein-2. Biomaterials. 
2007;28(3):459-67. 
266. van der Donk S, Buma P, Aspenberg P, Schreurs B. Similarity of bone ingrowth in 
rats and goats: a bone chamber study. Comp Med. 2001;51(4):336-40. 
267. Hidaka Y, Ito M, Mori K, Yagasaki H, Kafrawy AH. Histopathological and 
immunohistochemical studies of membranes of deacetylated chitin derivatives implanted 
over rat calvaria. Journal of Biomedical Materials Research. 1999;46(3):418-23. 
268. Lee JY, Nam SH, Im SY, Park YJ, Lee YM, Seol YJ, et al. Enhanced bone formation 
by controlled growth factor delivery from chitosan-based biomaterials. J Control Release. 
2002;78(1-3):187-97. 
CHAPTER I. Introduction  
 40 
269. Malafaya PB, Santos TC, van Griensven M, Reis RL. Morphology, mechanical 
characterization and in vivo neo-vascularization of chitosan particle aggregated scaffolds 
architectures. Biomaterials. 2008;29(29):3914-26. 
270. Spin-Neto R, Freitas RMd, Pavone C, Cardoso MrB, Campana-Filho SP, Marcantonio 
RAC, et al. Histological evaluation of chitosan-based biomaterials used for the correction of 
critical size defects in rats calvaria. Journal of Biomedical Materials Research Part A. 
2009;93A(1):107-14. 
271. Jiang T, Nukavarapu SP, Deng M, Jabbarzadeh E, Kofron MD, Doty SB, et al. 
Chitosan-poly(lactide-co-glycolide) microsphere-based scaffolds for bone tissue engineering: 
In vitro degradation and in vivo bone regeneration studies. Acta Biomaterialia. 2010;9: 3457-
3470 
272. Chang S-N, Chuang H, Chen Y, Chen J, Chung Y, Lu Y-L, et al. Gene expression 
profiling reveals PDGF recepor alpha as a target of cell contact dependent gene regulation in 
an endothelial cell-osteoblast co-culture model. Tissue Engineering. 2003;12(10):2889-903. 
 
 
 
 
 
 
 
 
 
 
SECTION 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
 
MATERIALS AND METHODS 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II. Materials and methods 
 45 
Chapter II 
MATERIALS AND METHODS 
 The main aim of this chapter is to describe in more detail the experimental work and 
protocols related to the experiments performed and the obtained results. Together with 
chapter I, it will establish the rationale of the research reported in this thesis, which was the 
biological evaluation of chitosan based scaffolds, in vitro and in vivo, envisioning bone tissue 
engineering applications. For that, it will be briefly described the materials used and the 
scaffolds processing methodologies. It will be explained in more detail the in vitro biological 
characterization techniques and the in vivo animal models used and respective 
characterization methodologies. 
 
1. Materials 
1.1. Chitosan 
 Chitosan (Ch) is a linear polysaccharide, obtained from the alkaline deacetylation of 
chitin, composed of glucosamine and N-acetyl glucosamine linked in a β (1-4) link (1). 
Important parameters affecting the characteristics of chitosan are its molecular weight (Mw) 
and its degree of deacetylation (DD) (2). The degree of deacetylation of chitosan refers to the 
ratio between the deacetylated and acetylated units. The solubility of chitosan depends on 
the free amino and N-acetyl groups being soluble in acidic pH (3). Chitosan is a semi-
crystalline polymer and the degree of crystallinity depends on the degree of deacetylation. 
Chitosan is a biodegradable polymer being degraded by lysozyme (4). The degradation rate 
of chitosan is inversely related to the degree of deacetylation (5). 
 Chitosan presents a wide range of biological properties, which makes it one of the 
most promising materials for tissue engineering applications. Important characteristics to be 
highlighted are its biodegradability, biocompatibility, antibacterial activity, wound healing 
properties and easy accessibility (low cost). Moreover, the chemical structure of chitosan 
(Figure 1) resembles the structure of glycosaminoglycans (GAGs) and these molecules play 
an important role in the modulation of various cell functions, morphology and differentiation 
(6). 
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Figure 1. Chemical structure of chitosan 
 
The chitosan herein used was purchased from France Chitine (Orange, France). 
Firstly, chitin was isolated from shrimp shells and squid bones by deproteinization and/or 
demineralization, respectively. The chitosan was further obtained by the removal of enough 
acetyl groups (CH3-CO) from the chitin molecule (deacetylation process), releasing the amine 
groups (NH) and giving to chitosan a cationic characteristic. 
 
1.2. Aliphatic polyesters 
 Synthetic polymers have been extensively studied in tissue engineering field, such as 
poly(lactic acid), poly(glycolic acid), poly(ε-caprolactone) (PCL) and their copolymers. These 
polymers are biodegradable, because the ester bonds present in its structure are hydrolyzed 
into non-toxic natural metabolites and are eliminated from the body via respiration. In the 
present thesis the synthetic materials used were PCL, poly(butylene succinate) (PBS) and 
poly(butylene terephthalate adipate) (PBTA). More detail and special emphasis will be given 
to PBS, since it was the material used in the majority of the studies due to its biological 
performance. 
 
1.2.1. Poly(butylene succinate) 
Poly(butylene succinate) (PBS) is an aliphatic polyester (Figure 2), commercially 
available under the trademark Bionolle®. It was obtained from Showa Highpolymer Co. Ltd. 
(Tokyo, Japan), with the reference 1050, a polybutylene succinate copolymer. Bionolle® has 
been shown to be biodegradable in a variety of natural environments, decomposing into 
water and carbon dioxide. It has been processed into films, sheets, filaments, nonwoven 
fabrics, laminates, molded foams and injection-molded products for diverse applications, 
namely in agriculture, fishery, forestry, civil engineering and for common household goods. 
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Figure 2. Chemical 
structure of poly(butylene succinate). 
 
Pure PBS presents a hydrophobic behavior with low water uptake (~ 1.5%) and after 
60 days of immersion in the isotonic saline solution it displays a decrease in the mechanical 
properties without any appreciable weight loss (~ 0.5%). This polymer presents a melting 
temperature (Tm) of 104.3ºC.  
 
2. Processing methods 
 The materials used in this thesis were, always composed by chitosan and a synthetic 
polymer. The compositions were prepared by extrusion prior to be processed into a three 
dimensional (3D) structure. For the scaffolds production two different methodologies were 
used: compression molding followed by salt leaching and fiber bonding. Chitosan and 
polyester blends used for the production of the scaffolds are described in chapters III, IV, V, 
VI and VII. Those materials were compounded in a twin-screw extruder. Blends of chitosan 
with poly(butylene succinate) (Ch-PBS) were mixed at two different ratios - 25/75 wt% and 
50/50wt%, blends of chitosan with poly(caprolactone) (Ch-PCL) and poly(butylene 
terephthalate adipate) (Ch-PBTA) were mixed at 50/50 wt%. In chapter IV, it was used 
poly(butylene succinate) to produce scaffolds to be used as controls in an experiment 
designed to test the relevance of chitosan in biological terms. 
 
2.1. Compression molding/particulate leaching  
 The scaffolds described in chapters III, IV and VII were prepared after grinding the 
compounded blends by solid mixing with NaCl particles, loaded into a mold that was further 
heated, and molded into large discs by compression. The salt content was 60% by weight 
and the size range of NaCl particles was 250–500 µm for all the blends. These compression-
molded discs were further sliced to obtain different types of geometrical structures used in 
different chapters, because of the size required to in vivo models employed. In chapter III, 
cubes of 5 mm3 were used, in chapter IV were used discs of 8 mm of diameter and 1 mm 
thick and in chapter VII were used small discs with 5 mm of diameter and 1mm thick were 
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used (Figure 3). These structures were then immersed in distilled water to leach out the 
porogen particles. The cubes were dried to constant weight and used for further tests. 
 
 
Figure 3. Scheme of the scaffolds produced by compression molding followed by salt 
leaching used in different chapters. 
 
2.2. Fiber Bonding 
 The chitosan/polyester blends used to process the scaffolds presented in chapters V 
and VI were compounded as previously described. The mixture of chitosan with 
poly(butylene succinate) (Ch-PBS) (50-50% wt) was extruded into fibers, by using a single 
screw micro-extruder. The obtained fibers were cut into 1 cm long and loaded into a Teflon 
mold. This mold was heated at 150ºC during a previously optimized time period. After that, 
pressure was applied to allow fibers to weld at the junctions, forming a stable fiber mesh 
structure. The porous mesh was further cut into discs with diameter of 6.5 mm and 1.5 mm 
thick. 
 
3. Scaffolds Characterization 
 When new polymeric scaffolds are developed, it is imperative to characterize these 
novel structures. Physical and chemical characterization is performed to determine the 
surface topography, morphological properties, 3D architecture, porosity and pore size, 
interconnectivity and mechanical properties. The following techniques were used to 
characterize the developed scaffolds used in this work. 
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3.1. Scanning Electron Microscopy 
All the developed chitosan based scaffolds were evaluated by scanning electron 
microscopy (SEM). This methodology is extremely important to study the morphology of 
polymeric materials and structures. This technique allows to analyze the morphology of the 
specimen, at large magnifications and also the details of the structure up to the sub-micron 
level. Polymeric structures are non-conductive, being generally coated with conductive 
materials, such as gold or carbon. This fact is due to the fact that the intensity of the electron 
beam can damage the thin polymeric samples, which can lead to the deformation and even 
melting of the polymer. Furthermore, the accumulation of electrons at the surface of the 
specimen causes the loss of image formed at the detector. 
The developed scaffolds were sputter-coated with gold (Fisons Instruments, model SC502; 
England) for 2 minutes at 15 mA. The samples were further analyzed by scanning electron 
microscopy (Leica Cambridge, model S360; England). Micrographs were recorded at 15 kV 
with magnifications ranging from 100 to 5000 times. 
 
3.2. Micro computed tomography 
 Micro computed tomography (µCT) technique was used to recreate 3D images of the 
scaffolds. This methodology is based on the use of a X-ray source to create shadow 
images/projections of a 3D object that later can be used with an appropriate software to 
recreate a virtual model. It is named micro because pixel sizes of the cross-sections are in 
the micrometer range. The X-ray source and detector are typically stationary during the scan, 
while the sample rotates, to allow obtaining the slices of the object morphology.  
 The scaffolds used in chapter III, V and VI were evaluated by µ-CT, carried out by 
scanning in high-resolution mode of 8.7 µm x/y/z and an exposure time of 1792 ms. The 
energy parameters defined in the scanner were 63 keV with a current of 157 µA. Data were 
obtained by the system and reconstructed in 2D images. These slice images were further 
compiled and analyzed to render 3D images and obtain quantitative architecture parameters. 
A μCT analyzer and a μCT Volume Realistic 3D Visualization, both from SkyScan, were used 
as image processing tools for both μCT reconstruction and to create/visualize the 3D 
representation. Regions of interest (square of 4.5x4.5 mm2) were selected in each slice 
image and thresholded to eliminate background noise. This threshold (to distinguish polymer 
material from pore voids) was selected and maintained constant for all the scanned 
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specimens and samples. The threshold was also inverted to obtain pore volume and to 
analyze both the pore morphology and its interconnectivity. 
 Chitosan-based fiber mesh scaffolds, exploited in chapter IV and VII, were scanned in 
high resolution mode using a pixel size of 8.24 μm and integration time of 2.0 ms. The X-ray 
source was set at 80 keV of energy and 124 μA of current. For all the scanned specimens 
representative data sets of 150 slices were transformed into binary using a dynamic 
threshold of 60-255 (grey values) to distinguish polymer material from pore voids. This data 
was used for morphometric analysis (CT Analyzer v1.5.1.5, SkyScan). 3D virtual models of 
representative regions in the bulk of the scaffolds were also created, visualized and 
registered using both image processing softwares (ANT 3D creator v2.4, SkyScan). Five 
scaffolds were examined for each type of scaffolds. 
 
3.3. Mechanical properties 
 The mechanical testing of the scaffolds was performed under compression loading 
using a crosshead speed of 2 mm/min and the results presented are the average of at least 
five specimens. Samples were conditioned at room temperature for at least 48 h before 
testing. The values reported are the average of at least five specimens per condition. The 
compressive modulus was determined in the most linear region of the stress–strain graph 
using the secant method. In the cases that the yield stress was not clearly defined, it was 
calculated as the stress at the intersection of a line drawn parallel to the linear region and 
intercepting the x-axis at 1% strain. 
 
3.4. In vitro degradation studies 
 The biomaterials used in this PhD thesis were biodegradable polymers. These 
materials degrade over time in a way that the neo-tissue can develop, without long-term 
presence of foreign components and finally cleared from the organism. Biodegradation of 
polymeric biomaterials requires cleavage of hydrolytically or enzymatically sensitive bonds in 
the polymer, leading to polymer erosion (7). Degradation products should be non-toxic and 
non-immunogenic, therefore not inducing strong inflammatory reaction. These products 
should be small enough to dissolve in the body fluids and, after transportation via lymphatic 
system into kidneys, these should be able to excrete them from the body (8). Polymers that 
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are known to degrade in the body, either by hydrolysis and/or enzymatic degradation can be 
modeled in vitro, in order to predict their behavior when implanted in vivo. 
 The degradation studies described in chapter VII were performed by incubating the 
scaffolds in phosphate buffered saline solution (pH 7.4) (control), with lipase from Aspergillus 
oryzal (Fluka) and/or lysozyme from chicken egg white (Sigma, St. Louis), at concentrations 
similar to the ones found in human blood serum (110 U/L for lipase and 13 mg/L for 
lysozyme), at 37ºC in dynamic conditions (60 rpm) for 1, 3, 6 and 12 weeks. In one 
experiment the solutions were changed every 7 days, while in the other the solutions were 
not changed throughout the experiment. At the end of each degradation period, the samples 
were removed, gently blotted to eliminate the water excess and immediately weighed for 
determination of water uptake and dried for later calculation of weight loss.  
 
3.4.1. Water uptake and weight loss measurements 
At the end of each degradation period, the samples were removed and immediately 
weighed for determination of water uptake (Equation 1) (Chapter V), washed thoroughly with 
distilled water and dried for later calculation of weight loss (Equation 2) (Chapters III, V, VI, 
and VII): 
 
Water uptake (%) = [(ww – wi)/ wi] x 100  (Equation 1) 
 
Weight loss (%) = [wi – wf)/ wi] x 100  (Equation 2) 
 
where wi is the initial weight, ww is the wet weight and wf  is the final weight of the sample. 
 
4. In vitro biological characterization  
 All the scaffolds used in the next sections of this thesis were sterilized by ethylene 
oxide. The routine followed in biological assessment of the developed scaffolds included 
cytotoxicity evaluation, direct contact tests with cell lines and in a later stage with human 
primary cells. 
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4.1. Cytotoxicity assessment 
 After the development of the scaffolds, the next step is the assessment of the 
eventual cytotoxicity. This initial screening is based on the use of the scaffold leachables, i.e., 
substances that leach out of the biomaterials. These leachables are placed in contact with a 
cell line, for a determined period of time. After that time, cell viability and morphology are 
evaluated, to determine the eventual toxicity to the cells. In this first stage it is recommended 
the use of cell lines, because these cells are reproducible, well characterized in the literature 
and large amounts of cells can be obtained with cell expansion. 
 In the work developed in this thesis it was used a rat lung fibroblast cell line -L929, 
acquired from the European Collection of Cell Cultures, to perform the initial cytotoxicity 
evaluation of the developed scaffolds. Cells were grown as monolayers in Dulbeccoʼs 
modified eagleʼs medium (DMEM) (Sigma, St. Louis, MO) supplemented with 1% fetal bovine 
serum (FBS) (Biochrom, Berlin, Germany) and 1% of antibiotic/antimycotic mixture (10,000 
U/mL penicillin G sodium; 10,000 U/mL streptomycin sulphate; 25 µg/mL amphotericin B) 
(Gibco, Invitrogen, USA). Trypsin/EDTA (0.25% w/v trypsin/0.02% EDTA, Sigma) was used 
to detach the cells from the culture flasks before the experiments were conducted. 
 Cells were seeded in 96-well plates (n=6) at a density of 1.8 x 104 cells/well and 
incubated for 24 h at 37ºC, in a humidified atmosphere with 5% CO2. The ratio of material 
weight to extract fluid was constant and equal to 0.25 g/mL. Latex rubber was used as a 
positive control of cell death, because it has a strong cytotoxic effect leading to extensive cell 
death. The ratio of latex material outer surface to extraction fluid was 2.5 cm2/mL. Culture 
medium was used as negative control of cytotoxicity, considered to be the ideal condition for 
cell growth. Test scaffolds (n=6) and positive control were extracted for 24 h at 37ºC, using 
complete culture medium as the extraction fluid. Before the tests, culture medium was 
removed from wells with cells adhered, and an identical volume (200 µL) of extraction fluid 
was added. The cells were left to proliferate in the extract fluid for 72 h. After this period, the 
extraction fluid was removed, and the metabolic activity and, consequently, cell viability was 
determined by a colorimetric assay named CellTiter 96® AQueous One Solution Cell 
Proliferation Assay (Promega, USA). Briefly, this assay is based on the bioreduction of a 
tetrazolium compound (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfofenyl)-2H tetrazolium, inner salt (MTS)) into a brown formazan product that is soluble in 
culture medium. This conversion is accomplished by the production of nicotinamide adenine 
dinucleotide phosphate (NADPH) or nicotinamide adenine dinucleotide (NADH) by the 
dehydrogenase enzymes existing in the metabolically active cells. The quantity of formazan 
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product bioreduced is directly proportional to the number of living cells in culture, as 
measured by the amount of 490 nm absorbance in a microplate reader (Bio-Tek, model 
Synergie HT, USA), after 3 h of incubation at 37ºC. Triplicates were made for each sample 
and per culture time. 
 
4.2. Direct cell contact tests 
4.2.1. Mouse bone marrow mesenchymal stem cell line - BMC9 
 If the scaffolds show no signs of cell cytotoxicity or morphological changes, the next 
step will be to proceed for direct contact assays with an appropriate cell source to develop a 
valid 3D construct for bone tissue engineering applications. 
 The developed scaffolds were composed of several aliphatic polyesters and chitosan. 
First all of these scaffolds were evaluated in terms of cell adhesion, proliferation and 
osteogenic potential. For this initial screening, described in chapter III, it was used a mouse 
mesenchymal stem cell line – BMC9. These cells were previously shown to be able to 
differentiate into several phenotypes, including the osteogenic lineage (9).  
 Cells were grown in DMEM, supplemented with 10% of FBS and 1% of antibiotic–
antimycotic mixture. When the adequate number of cells was obtained, they were detached 
with trypsin, and seeded at a density of 5x105 cells per scaffold. The seeding methodology 
consisted in dropping an aliquot of 10 µL on top of the scaffolds. After 2 h, 1 mL of 
osteogenic inducing culture medium was added to each well. The cell-seeded scaffolds were 
maintained at 37ºC, and 5% CO2. The osteogenic medium consisted in the same medium 
described before, but supplemented with osteogenic agents, dexamethasone 10-8 M, 
ascorbic acid 50 µg/mL and β-glycerophosphate 10 mM. These supplements are required for 
a successful osteogenic differentiation of stem cells. Dexamethasone is a glucocorticoid that 
increases the expression of several different genes associated with osteogenic differentiation 
(10). Ascorbic acid is essential for collagen synthesis and alkaline phosphatase activity (11). 
Culture of osteogenic cells depends on supplementation of their growth medium with a 
source of inorganic phosphate (12) - β-glycerophosphate, a non-physiological organic 
substrate of alkaline phosphatase, allowing to produce mineralized ECM. To simplify the 
nomenclature of the cell seeded and cultured scaffolds in vitro, these will be identified as 
“constructs” in the next chapters. 
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4.2.2. Primary cultures of human bone marrow mesenchymal stem cells 
 The subsequent work developed after the screening of the best scaffold formulation 
for bone tissue engineering, was performed with primary cultures of human bone marrow 
mesenchymal stem cells (hBMSCs). These cells were isolated from human bone marrow 
aspirates obtained during routine surgical procedures involving knee arthroplasties. The 
collection of samples was approved by the ethical committee of the São Marcos hospital in 
Braga, under the cooperation agreement established between the 3B´s research group-UM 
and that hospital. A detailed informed consent was signed by each donor. The isolation 
procedure relies on the principle that from the several cell populations existent in bone 
marrow, only the adherent fraction will be isolated, being considered marrow stromal cells 
(13). Briefly, the bone marrow aspirate was centrifuged and all the fat tissue fraction, as well 
as cartilage and bone remnants were discarded. The cell suspension was incubated with 
eritrocytes lysis buffer to lyse these cells. The resultant cell suspension was plated and 
cultured. The cell population characterized by flow cytometry for stemness markers (clusters 
of differentiation-CD) CD29, 44, 73, 90, 105 and 106 and as well for the hematopoietic 
exclusion markers CD34 and 45. These adherent cells showed spindle-shape morphology 
and colony-forming unit (CFU) capacity. The isolated cells were also characterized for its 
multipotential ability, being differentiated for osteogenic, chondrogenic and adipogenic 
lineages. 
 
4.3. hBMSCs culture, seeding into the scaffolds and differentiation into the osteogenic 
lineage 
 High numbers of hBMSCs are required to perform cell seeding into the developed 
scaffolds, for all quantitative and qualitative analysis. The isolated cells were expanded in 
basal medium consisting of alfa Eagleʼs medium (α-MEM; Sigma-Aldrich, Germany) 
supplemented with 10% FBS and 1 % antibiotic/antimyotic solution. Cells were cultured at 
37°C in an atmosphere of 5% CO2. 
 When cells reached confluency, at passages 4-5 they were harvested for static 
seeding onto the scaffolds, at a density of 2.5x105 cells/scaffold. The constructs were 
cultured under static conditions, in standard osteogenic differentiation medium, described in 
subsection 4.2.1. The constructs were collected at different culture times: 7, 14 and 21 days, 
because it is expected that by the end of the experiment, the cells already show a definied 
osteogenic phenotype (14).  
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4.3.1. Evaluation of cell morphology and distribution 
 SEM was used to analyze the level of cell attachment and its morphology, as well as 
distribution on the surface of the scaffolds. To achieve those goals it is required the use of 
methods of fixation or stabilization of the cells on the scaffolds to obtain biological samples in 
their natural state. Coating of the mples with gold was performed as described in subsection 
3.1. Additionally, due to the non-electric conductivity of those samples it is also needed to 
coat the samples with a conductive material such as gold or carbon. The constructs were 
fixed with 2.5% glutaraldehyde (Sigma, USA) in phosphate buffered saline (Sigma, USA) 
solution, during 15 min at RT. Then, they were dehydrated through graded series of ethanol 
and let to dry overnight. Finally, they were gold or carbon sputter coated (Fisons Instruments, 
model SC502; England) during 2 min at 15 mA, and analyzed by SEM (Leica Cambridge, 
model S360; England) equipped with an energy dispersive spectrometer (EDS; link-eXL-II). 
 The constructs were also analyzed by confocal laser scanning microscopy 
(FluoView1000, Olympus, Germany) in chapters III and IV. Cells were stained with calcein 
AM (Molecular Probes, Invitrogen, USA). This molecule is hydrolyzed by endogenous 
esterases into the highly negatively charged calcein, which is retained inside the cells. In this 
way, it is possible to observe the distribution of viable cells throughout the scaffold structure. 
 Histological analysis of the scaffolds was reported in chapter III. Hematoxylin-Eosin 
(H&E) staining was performed to observe the cell morphology and its distribution into the 
developed scaffolds. Basically, constructs were stained with Harris hematoxylin (Merck, 
Germany) during 1 to 3 minutes, until reaching the desired staining intensity. They were 
further washed in running tap water and afterwards a blue stain enhancement was performed 
by an immersion in 0.5% ammonia (Aldrich, Germany) for 5–10 seconds. The constructs 
were washed again in running tap water, followed by an immersion in alcohol 96 %, and 
stained in Shandon Eosin-Y (Thermo Scientific, UK) for 30 seconds. The samples were again 
washed in alcohol 96% and dehydrated through two immersions in alcohol 100 %. Before 
permanent mounting in Histomount™ (National Diagnostics, UK), the stained constructs were 
immersed in xylene for 1-2 min. Stained sections were observed under an optical microscope 
(BX61, Olympus Corporation, Germany) and images captured with a digital camera (DP70, 
Olympus Corporation, Germany). 
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4.3.2. Cell viability assay 
 Cell viability was assessed by indirect measurements based on its metabolic activity, 
at each time period by CellTiter 96® AQueous One Solution Cell Proliferation Assay 
(Promega; USA), as described in subsection 4.1. 
 
4.3.3. Cell proliferation assay – DNA quantification 
 Measurements of DNA synthesis are frequently taken to be representative of the 
amount of cell proliferation (15). Cell proliferation rate determination is often used to 
determine the response of cells to a particular stimulus, i.e., physical (e.g. topography of a 
substrate) or chemical (toxin or growth/differentiation factor).  
 In the present work, cell proliferation was quantified by the total amount of double-
stranded DNA (dsDNA) using an ultrasensitive fluorescent nucleic acid stain. Quant-iT™ 
PicoGreen® dsDNA reagent was selected since it enables to quantify as little as 25 pg/mL of 
dsDNA (50 pg dsDNA in a 2 mL assay volume) with a standard spectrofluorometer and 
specific fluorescein excitation and emission wavelengths. Additionally, dsDNA can be 
quantified in the presence of equimolar concentrations of ssDNA and RNA with minimal 
effect on the quantitative results obtained. The Quant-iT™ PicoGreen dsDNA Assay Kit 
(Invitrogen™, Molecular Probes™; Oregon, USA) was used according to the manufacturerʼs 
instructions. Briefly, cells in the construct were lysed by osmotic and thermal shock and the 
supernatant used for the DNA quantification assay. A fluorescent dye, PicoGreen, was used 
because of its high sensitivity and specificity to double-stranded DNA. The fluorescence of 
the dye was measured at an excitation wavelength of 485/20 nm and at an emission 
wavelength of 528/20 nm, in a microplate reader (Synergie HT, Bio-Tek, USA). The DNA 
concentration for each sample was calculated using a standard curve (DNA concentration 
ranging from 0.0 to 1.5 μg/ml) relating quantity of DNA and fluorescence intensity. Triplicates 
were made for each sample and per culturing time 
 
4.3.4. Alkaline phosphatase (ALP) quantification 
 A detailed analysis of the mineralization and of the progression of differentiation can 
be obtained by biochemical assays. Routine assessments involve the quantification of total 
calcium content and the activity of alkaline phosphatase (ALP), a cell surface protein bound 
CHAPTER II. Materials and methods 
 57 
to the plasma membrane though phosphatidylinositol phospholipid complexes (16). High ALP 
activity is associated with the active formation of mineralized matrix and highest levels are 
found in the mineralization front of the bone healing process. 
 The concentration of ALP was determined for all time culture periods, using the same 
samples used for DNA quantification. Briefly, the activity of ALP was assessed using the p-
nitrophenol assay. Nitrophenyl phosphate disodium salt (pnPP; Fluka BioChemika, Austria) is 
colourless, is hydrolyzed by alkaline phosphatase, produced by cells, at pH 10.5 and 
temperature of 37ºC, to form free p-nitrophenol, which is yellow. The reaction was stopped by 
the addition of 2 M NaOH (Panreac Quimica, Spain) and the absorbance read at 405 nm in a 
microplate reader (Bio-Tek, Synergie HT; USA). Standards were prepared with 10 μmol/ml p-
nytrophenol (pNP; Sigma, USA) solution, to obtain a standard curve ranging from 0 to 0.25 
μmol/ml). Triplicates of each sample and standard were made, and the ALP concentrations 
read off directly from the standard curve. 
 
4.3.5. Extracellular matrix mineralization content by energy dispersive spectroscopy 
(EDS) 
 Energy dispersive spectroscopy (EDS) methodology was used to detect the presence 
of calcium (Ca) and phosphorous (P) elements by analyzing the surface of the constructs. 
These two chemical elements are constituents of the mineral phase (hydroxyapatite) of bone 
ECM. Their presence positively indicates the formation of mineralized ECM at the surface of 
the constructs. As controls, it was analyzed the surface of unseeded scaffolds immersed in 
osteogenic medium for the same time periods, showing that the presence of P and Ca were 
the result of cellular activity. 
 The constructs were processed as described previously for SEM in subsection 3.1. 
The samples were sputter coated with carbon (JEOL JFC-1100) with the purpose of 
analyzing the presence of Ca and P elements at the surface by EDS with a Leica Cambridge 
S360 scanning electron microscope. Sputter coating with carbon avoids overlapping of 
signals of the coating with the elements being analyzed. 
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4.3.6. Extracellular matrix mineralization crystallinity by fourier transform infra-red 
spectroscopy (FTIR) 
 Fourier transform infrared spectroscopy (FTIR) method is used to study the chemical 
structure of a polymer, but it can also be used to analyze the chemical composition of the 
surface of a scaffold. In the present thesis it was used to confirm the results obtained from 
EDS analyses, indicating the presence of phosphate and carbonate groups, which are typical 
for carbonated apatite (17). Briefly, constructs were washed in phosphate buffered saline and 
fixed in 2.5% glutaraldehyde. The samples were pressed into pellets with potassium bromide 
(KBr; Riedel-de Haen, Germany) and further analysed by FTIR. The infrared spectrum was 
measured using a FTIR Spectrometer (model IRPrestige-21, Shimadzu; Germany) in the 
wavelength range of 4000–400 cm−1. The same controls (acellular scaffolds) used for the 
EDS analysis were used in tests. 
 
4.3.7. Gene expression analysis of specific osteogenic genes 
 The constructs cultured in vitro in osteogenic inducing medium were evaluated by 
analyzing the expression of genes encoding specific proteins during osteogenic 
differentiation of hBMSCs. This process is characterized by three sequential periods: 
proliferation, ECM maturation and mineralization (18). The osteogenic phenotype is 
recognized by cell maturation coordinated with the secretion of specific proteins, in a process 
that is asynchronously acquired as the progenitor cells successfully differentiate and the 
matrix matures and mineralizes (19). To evaluate the transient state of the stem cells during 
the differentiation process polymerase chain reaction (PCR) was performed, by amplifying 
specific sequences of a target osteogenic specific gene. 
 
 4.3.7.1. RNA isolation  
  Total ribonucleic acid (RNA) from the constructs was extracted using the Trizol® 
(Invitrogen, Life Technologies Inc., UK) method according to the manufacturerʼs protocol. At 
each time point, the constructs were washed with phospate buffered saline, immersed in 
Trizol and stored at -80ºC until further use. Proteins were removed with chloroform extraction 
and the RNA pellets were washed once with isopropyl alcohol and once with 70 % ethanol. 
The total RNA pellets were reconstituted in RNAase free water (Gibco, Invitrogen, UK). 
Determination of the RNA concentration for each scaffold replica (triplicates of each scaffold 
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per time point) was performed by spectrophotometry (NanoDrop ND-1000, USA). The 
integrity of the RNA samples was checked using agarose 1.2% gel electrophoresis.  
 
4.3.7.2. Reverse-transcriptase and real-time quantitative polymerase chain reaction 
 In chapter V, it was used non-quantitative reverse-transcriptase polymerase chain 
reaction (PCR). Briefly, aliquots of the total RNA (100 ng/μl) were used to synthesize 
complementary deoxyribonucleic acid (cDNA) and amplified by PCR, in one step RT-PCR 
beads (Amersham Biosciences, USA). The cDNA synthesis was executed by incubating the 
reaction mixture 5 min at 25ºC, followed by 30 min at 42ºC and terminated by an incubation 
at 85ºC for 5 min, using a termocycler (MyCycler™, Thermal Cycler, Biorad). 
Specific osteogenic gene sequences (primers) were used in PCR reaction. Human 
specific primers used were: for runt related transcription factor 2 (Runx2), osteocalcin, type I 
collagen, bone sialoprotein (BSP) and for the house keeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Each cDNA sample was run in triplicate for every PCR. 
Amplification was performed using a termocycler (MyCycler™, Thermal Cycler, Biorad). The 
first reverse transcription step at 42ºC for 30 min was followed by a step of denaturation at 
95ºC during 5 min. After this, 35 cycles of PCR were performed, each consisting of a 
denaturation stage at 95ºC for 1 min, annealing at a given temperature accordingly with the 
specific primer used and then an extension stage at 72ºC for 2 min. In all cases, a final 
extension at 72ºC for 5 min was performed before storing the samples at 4ºC.  
 PCR products were separated by 1% agarose (Biorad, USA) at least twice. The 
separated DNA fragments were visualized by ethidium bromide staining (Sigma, St Louis, 
MO) and observed with Eagleye software (Alpha Innotech, USA) using excitation at 514 nm 
and emission at 610 nm.  
In chapter IV, it was used quantitative real-time PCR. This technology presents 
several advantages over traditional PCR (reverse-transcriptase PCR). The measurement of 
the amount of amplified product is carried out with a quantitative laser-based method, and 
data collection is performed in the early exponential phase of the reaction, when none of the 
reagents is rate-limiting. The genes analyzed were Runx2, osterix (OSX), osteocalcin, type I 
collagen, BSP, osteopontin (OPN) and for the house keeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Real time PCR was performed accordingly to the 
protocol from iScript™ cDNA synthesis kit (BioRad, Hercules, CA, USA). Succinctly, a 
reaction mixture consisting of 1X iScript Reaction Mix, 1 µl iScript Reverse Transcriptase, 
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RNA template (1 µg total RNA) and nuclease-free water was prepared, in 40 µl of total 
volume. The single-strand cDNA synthesis occurred as described for conventional PCR.  
Amplification of the target cDNA for real-time PCR quantification was performed 
according to manufacturer protocol, using 2 µl RT cDNA products, 1 μM each primer, 1X iQ 
SYBR Green Supermix (BioRad, Hercules, CA, USA) and nuclease-free water, in a final 
volume of 25 μL. Forty-four cycles of denaturation (95ºC, 10 s), annealing (temperature 
dependent on the gene, 30 s) and extension (72ºC, 30 s) were carried out in the gradient 
thermocycler MiniOpticon real-time PCR detection system (BioRad, Hercules, CA, USA) for 
all genes. The transcripts expression data were normalized to the housekeeping gene 
glyceraldehyde-3-phosphate-dehygrogenase (GAPDH) for each time point and relative 
quantification calculated by the ∆CT method. 
 
5. In vivo studies 
 In vitro experimentation is limited in recreating the complex in vivo environment, being 
most of the times incapable of predicting in vivo performance in many settings, particularly in 
tissue engineering and regeneration of functional tissues.  
 All procedures were conducted in accordance with European regulations for animal 
testing (European Union Directive 86/609/EEC).  
 
5.1. In vivo tissue response in different locations 
 This work was developed in chapter IV. Twelve Wistar rats were used. This study was 
conducted after receiving approval from the Animal Ethical Committee of the Kırıkkale 
University, Ankara, Turkey. The scaffolds (8 mm in diameter and 1 mm thick) were sterilized 
by ethylene oxide. Animals were anaesthetized by intraperitoneal (IP) injection with a mixture 
of ketamine HCl (Parke Davis, 50 mg/ml, Taiwan) and Rompun (2%, Bayer, Germany). The 
scaffolds were implanted in 3 different regions per animal:  
 (i) single critical size defect with 8 mm diameter in crania;  
 (ii) pocket incision between perichondrium and ear cartilage, the scaffold being 
placed on the 1/3 proximal cartilage of the pocket;  
 (iii) incision of 10 mm close to iliac bone, the scaffolds being placed between 
periosteum and iliac bone (onlay model) (21).  
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 A total of 3 scaffolds per animal were implanted (one in each location).  In all cases, 
the incisions were closed using 5.0 silk sutures. After one month of implantation, the animals 
were sacrificed and implants were collected with the surrounding tissue and processed for 
histological processing. 
 
5.2. In vivo degradation studies and evaluation of the host response 
 In vivo implantation of developed scaffolds was performed in parallel with in vitro 
degradation studies. Biocompatibility is directly related with degradation process of the 
scaffolds. This is due to the fact that degradation of a biomaterial implanted in a host is 
influenced by the presence and recruitment of inflammatory cells and consequently by the 
production of inflammatory mediators. One of the most important requisites for clinical 
application of a biomaterial is its biocompatibility, that is defined as the ability of a material to 
perform with an appropriate host response in a specific application (22). The local reaction of 
an implant is studied histologically after a 3 months implantation period, as described in ISO 
standard 10993-6 (23). 
 For this study, described in chapter VII, Wistar rats were used. Scaffolds were 
implanted subcutaneously and at 1, 3, 6 and 12 weeks, samples were retrieved for further 
analysis. Animals were anesthetized by an IP injection of a solution of 75//0.5 mg/kg body 
weight ketamine:metedomidine (Imalgene®:Dorbenvet®). Subcutaneous (SC) pockets were 
created and 4 scaffolds were placed in each animal, away from the sutures site (incision) to 
avoid inflammation of the wound. The anaesthesia was then reverted with a SC injection of 
0.25 mg/kg Atipamezol (Antisedan®). After recovering from anaesthesia, animals were 
placed in their home cages and water and food were supplied ad libitum. Each animal 
received an SC injection of 1mg/kg analgesic Butorphanol (Torbugesic®) administered 
immediately after surgery and 24 h later, to avoid post-operative pain. At each time point, 3 
animals were euthanized by intraperitoneal injection of sodium penthobarbital, at a lethal 
dose and the respective implants were retrieved.  
 
5.3. In vivo cranial defect in nude mice 
 The in vivo approach should mimic the future clinical application envisaged and the 
bone defect must not heal spontaneously, i.e., a critical size defect (CSD) should be created 
(20). The work developed was described in detail in chapter VII. 
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 Athymic nude mice were used to examine the healing of cranial critical size bone 
defects filled with transplants of pre-cultured constructs. All procedures involving the use of 
animals were conducted in accordance with the guidelines of the Institutional Animal Care 
and Use Committee of the Technion, Haifa in Israel. In brief, the in vitro constructs (with 
1x106 cells) were cultured in osteogenic inducing medium for 2 weeks prior to implantation. 
The surgery consisted on drilling 2 bilateral critical size circular defects (5 mm diameter and 
1mm thick) in the parietal bones of the skull on either side of the sagittal suture line, with a 
hand drill and trephine bit. Extremely care was taken to not damage the sagittal suture or to 
interrupt the dura matter beneath the bone. During procedure, sterile saline was dripped over 
the drilling site, in order to avoid extensive heating and to protect brain tissue. Surgeries were 
performed under general anesthesia (xylazine: ketamine 1:1 solution in saline) by IP 
injection. Scaffolds (scaffolds seeded and cultured for 2 weeks with 1x106 hBMSC and 
scaffold without cells) were implanted into the defects. A total of 6 nude mice were used and 
12 cranial defects were created. Animals were kept under aseptic conditions. After 8 weeks 
post-surgery, animals were euthanized and crania were removed, cleaned and fixed 
immediately in formalin to be further analyzed by micro computed tomography analysis. 
 
5.4. In vivo results analysis 
5.4.1. Histological evaluation 
 Histological sections show the tissue inside of implant as well as the tissue 
surrounding it. To further identify the resident cells of those tissues, sections must be stained 
with specific staining. Retrieved samples at each time point were fixed in 10% neutral 
buffered formalin. The fixed samples were dehydrated and further embedded in paraffin, as 
described in subsection 4.3.1. The specimens were sectioned to obtain 3 µm thick 
longitudinal and transverse sections. 
 
5.4.1.1. Haematoxylin and Eosin (H&E) staining 
 H&E staining is a standard protocol to identify microscopically the morphology of the 
cells in tissues. Haematoxylin stains the nucleus with a dark blue color. Eosin stains the 
cytoplasm of the cell with a pink colour. Thus, the main cell structures are easily indentified. 
A standard protocol for H&E staining was used. Stained sections were observed by light 
microscopy. 
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5.4.1.2. Masson´s trichrome staining 
 Masson´s trichrome stain was performed to analyze the amount and distribution of 
mature collagen, differentiating the collagen fibers from smooth muscle and elastin fibers. 
Sections were stained with Weigertʼs haematoxilin at RT, for 5 min and washed with water. 
After that, slides were stained with ponceau-fucsin solution and washed. Then, slides were 
immersed in phosphomolibdic acid to remove the previous stain. Finally, sections were 
stained with light green, washed and immediately placed in ethanol 95% and then in xylene. 
Finally, they were mounted with Histofluid (Marienfeld GmbH & Co. KG, Germany) and 
observed by light microscopy (BX61, Olympus Corporation, Germany) and images captured 
with a digital camera (DP70, Olympus Corporation, Germany). 
 
5.4.1.3. Immunohistochemistry 
 Immunohistochemistry principle is based on a highly specific reaction antigen-
antibody, which implies that a determined antibody only reacts with a specific antigen. For 
formalin fixed and paraffin embedded sections, the most used protocol involves the use of an 
enzyme conjugated with a secondary antibody with specificity to the primary antibody used. 
This enzyme reacts with a specific protein (avidin or streptavidin), which will be revealed by a 
dye, such as horseradish peroxidase (HRP). Immunolocalization of a specific antibody is 
detected by a brown staining visible at light microscopy. 
 Immunostaining for alpha-smooth muscle actin (α-SMA) antibody was performed to 
evaluate the new vascularization (24). In order to perform immunohistochemistry, paraffin 
was removed. The antigen retrieval was heat induced in a water bath at 96ºC for 20 min, with 
incubation of the slides in citrate buffer (pH=6). The slides were washed with phosphate 
buffer saline and endogenous peroxidase was blocked with 0.6% hydrogen peroxide (H2O2) 
in methanol, at room temperature (RT) for 30 min. R.T.U. Vectastain® Universal Elite ABC 
Kit (Vector, VCPK-7200, USA) was used for antibody incubation, according to the 
instructions of the manufacturer. Briefly, sections were incubated with α-SMA primary 
antibody (Abcam, ab5694, UK) overnight at 4ºC, in a humidified atmosphere. After washing 
with phosphate buffered saline, antibody detection was revealed by using the Peroxidase 
Substrate Kit DAB (Vector, VCSK-4100). Slides were washed in water for 5 minutes and then 
counterstained with Harrisʼ haematoxylin for nuclear contrast, at RT for 2 min. After this, 
samples were washed with water, dehydrated in graded ethanol (50, 70, 95 and 100%), 
cleared with xylene, and mounted with Histofluid (Marienfeld GmbH & Co. KG, Germany). 
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Slides were observed by light microscopy (BX61, Olympus Corporation, Germany) and 
images captured with a digital camera (DP70, Olympus Corporation, Germany). 
 
5.4.2. Bone regeneration analysis by micro computed tomography  
 Entire crania were analyzed using a high-resolution μCT 1072 scanner (Skyscan, 
Kontich, Belgium). Specimens were scanned in high-resolution mode using a pixel size of 
19.13 μm and integration time of 1.7 ms. The X-ray source was set at 91 keV of energy and 
110 μA of current. For all the scanned specimens representative data sets of 1023 slices 
were transformed into binary using a dynamic threshold of 255-120, to distinguish bone from 
polymeric material. This data was used for morphometric analysis (CT Analyzer v1.5.1.5, 
SkyScan). 3D virtual models of the mice crania were created, visualized and registered using 
image processing software (ANT 3D creator v2.4, SkyScan).  
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CHAPTER III 
Adhesion, proliferation and osteogenic differentiation of a mouse mesenchymal stem 
cell line (BMC9) seeded on novel melt based chitosan/polyester 3D porous scaffolds 
 
ABSTRACT 
 The aim of the present work is to study the biological behavior of a mouse 
mesenchymal stem cell line when seeded and cultured under osteogenic conditions onto 
novel processed melt based chitosan scaffolds.  
 Scaffolds were produced by compression molding, followed by salt leaching. 
Scanning electron microscopy (SEM) observations and µCT analysis showed the pore sizes 
ranging between 250 to 500 µm and the interconnectivity of the porous structure. The 
chitosan-PBS scaffolds presented the high mechanical properties, similar to the ones of 
trabecular bone (E1% ~ 87.4MPa). Cytotoxicity assays were carried out using standard tests 
(accordingly to ISO/EN 10993 part 5 guidelines), namely MTS test with a 24 h extraction 
period, revealing that L929 cells had similar metabolic activities to that obtained for the 
negative control.  
 Cell culture studies were conducted using a mouse mesenchymal stem cell line 
(BMC9). Cells were seeded onto the scaffold and allowed to proliferate for 3 weeks, under 
osteogenic conditions. SEM observations demonstrated that cells were able to proliferate 
and massively colonize the scaffolds structure. The cell viability assay MTS demonstrated 
that BMC9 cells were viable after 3 weeks in culture. The cells clearly evidenced a positive 
differentiation towards the osteogenic lineage, as confirmed by the high ALP activity levels. 
Moreover, energy dispersive spectroscopy (EDS) analysis revealed the presence of Ca and 
P in the elaborated extracellular matrix (ECM). 
 These combined results indicate that the novel melt based chitosan/polyester 
scaffolds support the adhesion, proliferation and osteogenic differentiation of the mouse 
MSCs and shows adequate physicochemical and biological properties for being used as 
scaffolds in bone tissue engineering related strategies. 
 
 
 
CHAPTER III. Adhesion, proliferation and osteogenic differentiation of a mouse mesenchymal stem cell line (BMC9) seeded on 
novel melt based chitosan/polyester 3D porous scaffolds 
72 
1. INTRODUCTION 
 The last 15 years have witnessed the emergence of a novel multidisciplinary field of 
science called Tissue Engineering that has been in the forefront of a new wave of 
therapeutic/regenerative approaches for a variety of tissues, including bone. Its main 
purposes are the production of tissues and organs substitutes/equivalents that can replace or 
restore the natural features and physiological functions of natural tissues in vivo (1, 2).   
 The most common approach used in the bone tissue engineering field is based on the 
seeding of cells with osteogenic potential, commonly mesenchymal stem cells, on three 
dimensional (3D) scaffolds followed either by direct implantation on the injury site or by an in 
vitro culturing period upon which the construct is implanted (3). Ultimately, these so-called 
bone tissue engineering constructs should have two main functions when implanted in vivo 
(4-6): 1) provide structural support until the neotissue can assure it by itself and 2) promote 
osteoinduction, meaning in a simplistic way, the promotion of migration and differentiation of 
mesenchymal stem and osteoprogenitor cells, which later will lead to new bone formation. 
From the lines above it can be clearly concluded that 3D scaffolds play a major role within 
any bone tissue engineering concept. Ideally these temporary scaffolds should be porous in 
order to accommodate cell growth and facilitate both tissue regeneration and vascularization 
(1, 2, 7). Furthermore, they should also be biocompatible, mechanically stable under loads 
and have a physiologic biodegradation rate similar to the cell/tissue growth rates (1, 2, 7, 8). 
 Up to now, several materials, such as titanium alloys (9-11), ceramics (12-14) and 
biodegradable polymers (15-18) have been used to obtain these 3D structures. Among those 
materials, and due to their intrinsic characteristics, biodegradable polymers are those that 
have been used more frequently. The most widely used are poly(α-hydroxy acids), such as 
poly(lactic acid), poly(glycolic acid), and their copolymers because they have been already 
accepted by regulatory agencies. In spite of the fact that these materials have been 
thoroughly studied and extensively used in the clinical practice, it is also true that upon 
degradation they release acidic by-products, which may trigger inflammatory responses and 
compromise the needed integration by the host tissue (19, 20). 
 Therefore, there is an urgent need for the development of new biomaterials with 
scaffolding potential for bone tissue engineering. It is in this context that natural based 
polymers have been put forward in the last few years. Within this group, the polysaccharides, 
like starch (19, 21, 22) and chitosan (23-29) have been highlighted as the most promising, as 
they may act as analogs of polyssacharides present in vivo and adopt their roles (24). An 
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example of such affinity is the structural similarity observed between chitosan and 
glycosaminoglycans (GAGs) (29). Several reports about chitosan (23-29), the alkaline 
deacetylated product of chitin, have shown that this polymer might have a range of 
interesting properties, from biodegradability to biocompatibility, considered to be suitable for 
bone tissue engineering scaffolding. Nevertheless, chitosan still presents a challenge when 
compared to other materials, that is, the inability of being processed by means other than by 
solvent based technology, which frequently leads to the development of scaffolds with poor 
mechanical properties and insufficient control of its morphology.  
 Since 2005, we have developed a new concept based on the development of 
thermoplastic chitosan polymers (30-33). This was achieved by melt-blending chitosan with 
different aliphatic polyesters, poly(caprolactone) (PCL), poly(butylene succinate) (PBS), 
poly(butylene terephthalate adipate) (PBTA), and poly(butylene succinate adipate) (PBSA). 
By doing this, we conjugated the favourable biological properties of chitosan with the 
predictable degradative behavior of the aliphatic polyesters. Further information on the 
physical and chemical properties of these materials can be found in the reports of Correlo et 
al. (30-33).  
 The present study reports on the morphology, mechanical properties, 
cytocompatibility, cell proliferation and osteogenic differentiation of a mesenchymal stem cell 
line - BMC9 - on novel compression molding/salt leaching scaffolds based on blends of 
chitosan with PCL, PBS, PBTA and PBSA. Results have showed that the developed 
scaffolds had the adequate mechanical properties. Furthermore, they disclosed a non-
cytotoxic behavior and simultaneously supported the growth and osteogenic differentiation of 
mouse mesenchymal stem cells within its structure. 
 
2. MATERIALS AND METHODS 
2.1. Scaffolds production and processing 
 Chitosan was melt blended with several biodegradable polyesters for the first time by 
our group (31) a twin screw extruder with the purpose of producing scaffolds for tissue 
engineering applications. For the development of this work, the polyesters compounded with 
chitosan (ch) were PBS, PCL and PBTA. In all of these blends there was a rate of 50% (wt%) 
chitosan with 50% (wt%) polyester.  
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 The methodology used for the scaffolds production was melt based compression 
molding followed by salt leaching. The details of the processing conditions are described 
elsewhere (32). Briefly, the developed blends were grained and the powder mixed with salt 
particles with sizes between 250 and 500 µm. The chitosan based blends mixed with salt 
were loaded into a mold that was further heated and compression molded into discs. The salt 
content was 60% by weight. The discs were cut into 5x5x5 mm3 cubes. These cubes were 
then immersed in distilled water to leach out the salt, dried, sterilized by ethylene oxide and 
used for cell culture studies.  
 
2.2. Scaffolds characterization 
 The cross-section of all the developed scaffolds was analyzed using a Leica-
Cambridge S-360 Scanning Electron Microscope (SEM) for preliminary assessment on the 
scaffolds morphology. All the samples were sputter-coated with gold prior to SEM 
observations. 
 To investigate the internal 3D structure of the scaffolds, Micro-Computed Tomography 
equipment (SkyScan, Belgium) was used as a non-destructive technique. Four scaffolds of 
each condition were scanned in high resolution mode of 8.7 µm x/y/z and an exposure time 
of 1792 ms. The energy of the scanner used was 63 keV with 157 µA current. µCT scans 
followed by 3D reconstruction of serial image sections allowed to analyze 3D 
microarchitecture of the scaffolds, pore morphology as well as the determination of the 
porosity. 
 Uniaxial compression tests were performed on a square cross-section specimen of 
scaffolds using a Universal tensile testing machine (Instron 4505 Universal Machine). A 
crosshead speed of 2 mm/min was used. The values reported were the average of at least 
five specimens. The compressive modulus was determined by selecting the linear region of 
the stress-strain graph. 
 
2.3. Cell culture 
 A fibroblast cell line of rat lung - L929 -, acquired from the european collection of cell 
cultures (ECACC), was used for cytotoxicity tests. The cells were grown as monolayers in 
Dulbeccoʼs modified Eagleʼs medium (DMEM; Sigma, St. Louis, MO) supplemented with 10% 
foetal bovine serum (FBS; Biochrom, Berlin, Germany) and 1% of antibiotic-antimycotic 
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mixture (10000 U/ml penicillin G sodium; 10000 U/ml streptomycin sulphate; 25 μg/ml 
amphotericin B) (Gibco, Invitrogen, USA). Trypsin/EDTA (0.25% w/v trypsin/0.02% EDTA, 
Sigma) was used to detach the cells from the culture flasks before the experiments were 
conducted. 
 
2.3.1. Cell viability assay - MTS test  
           The ratio of material weight to extract fluid was constant and equal to 0.25 g/ml. Latex 
rubber and standard culture medium were used as positive and negative controls, 
respectively. Latex rubber is known to have a strong cytotoxic effect leading to extensive cell 
death. For the positive control the ratio of material outer surface to extraction fluid was 2.5 
cm2/ml. Test material (n=6) and positive control were extracted for 24 h at 37ºC, using 
complete culture medium as extraction fluid. Before the tests, culture medium was removed 
and an identical volume (200 μl) of extraction fluid was added to each well. 
 Cells were seeded in 96 well plates (n=6) at a density of 1.8x104 cells/well and 
incubated for 24 h at 37ºC, in a humidified atmosphere with 5% CO2. A kit (CellTiter 96 One 
solution Cell Proliferation Assay kit - Promega, Madison, WI) was used and it is based on the 
reduction of the substrate, 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2(4-
sulfofenyl)-2H-tetrazolium (MTS), into a brown formazan product by dehydrogenase enzymes 
active in the viable cells. After 72 h, the extraction fluid was removed and 200 μl of a serum-
free culture medium without phenol red and MTS, in a proportion of 5:1, was added to each 
well. Cells were then incubated for 3 h at 37ºC in a humidified atmosphere containing 5% 
CO2. After this time, optical density (O.D.) was measured with a plate reader (Bio-tek, model 
Synergy HTi, USA) at 490 nm. The O.D. values obtained were standardized taking into 
account the values for the negative control. 
 
2.4. Cell culture studies 
2.4.1. Cell seeding and culture 
 A mouse mesenchymal stem cell line (BMC9) was used. This conditionally 
immortalized clone was shown to exhibit four mesenchymal cell phenotypes: chondrocyte, 
adipocyte, stromal (support osteoclast formation), and osteoblast (34). The cells were grown 
as monolayer cultures in a culture medium consisting of DMEM medium, 10% FBS and 1% 
antibiotic/antimycotic mixture. When the adequate cell number was obtained, cells at 
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passage 10 were trypsinized, centrifuged and ressuspended in cell culture medium. Cells 
were seeded at a density of 5x105cells/scaffold under static conditions, using for this purpose 
aliquots of 10 μL loaded on the top of scaffolds. Two hours after seeding, 1 ml of culture 
medium was added to each well. The cell-seeded scaffolds were maintained in a humidified 
atmosphere at 37ºC, containing 5% CO2, under osteogenic differentiation inducing medium, 
during 21 days. The culture medium consisted of DMEM without phenol red, dexamethasone 
10-8 M (Sigma), ascorbic acid 50 μg/ml (Sigma) and ß-glycerophosphate 10 mM (Sigma), and 
was changed every 3 to 4 days until the end of the experiment. 
 
2.4.2. Cellular viability assay - MTS test 
 Cell viability was assessed after 3 h, 7, 14 and 21 days, by using the MTS test. The 
cell-seeded scaffolds (n=6) were rinsed in 0.15M phosphate buffered saline (Sigma) and 
immersed in a mixture consisting of serum-free cell culture medium and MTS reagent at 5:1 
ratio and incubated for 3 h at 37ºC in a humidified atmosphere containing 5% CO2. After this, 
200 Μl (n=6) were transferred to 96 well plates and the optical density (O.D.) determined at 
490 nm.  
 
2.4.3. Cell adhesion and morphology by SEM 
 Cell adhesion, morphology and average distribution were observed by SEM. The cell-
seeded scaffolds were washed in 0.15 M phosphate buffered saline and fixed in 2.5% 
glutaraldehyde in phosphate buffered saline.  
 After rinsing 3 times in phosphate buffered saline, the constructs were dehydrated 
using a series of graded ethyl alcohols (30, 50, 70, 90, 100% ethanol) for 15 minutes each, 
twice. Then, the samples were subjected to 2 changes for 15 minutes each with 100% 
hexamethyldisilazane (HDMS; Electron Microscopy Sciences, Washington, USA). Finally 
HDMS was removed and let to air dry for 2h. Afterwards, the constructs were sputter coated 
with gold (JEOL JFC-1100) and analyzed with a Leica Cambridge S360 scanning electron 
microscope. 
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2.4.4. Cell adhesion and cell viability by calcein AM staining through confocal laser 
microscopy  
 Cells were incubated with calcein AM (Molecular Probes, Oregan, USA). Once inside 
the cells, this compound is hydrolyzed by endogenous esterase into the highly negatively 
charged green fluorescent calcein, which is retained in the cytoplasm. The cell-seeded 
scaffolds were sectioned and cell adhesion and viability was observed in the inner regions of 
the scaffolds using an Olympus FluoView FV1000 confocal laser microscope. 
 
2.4.5. Histology 
 Eight-micron-thick sections from the 3 weeks culture of the constructs were cut with a 
cryomicrotome (CM 1900; Leica, Bensheim, Germany) and mounted on poly-L-lysine 
(Sigma) coated slides. Slides were stained with H&E and observed under optical microscope. 
 
2.4.6. Alkaline phosphatase quantification 
 A description of the assay can be found elsewhere (35). Briefly, the level of alkaline 
phosphatase (ALP) activity from the constructs (n=3) was quantified by the specific 
conversion of p-nitrophenyl phosphate (pNPP) (Sigma) into p-nitrophenol (pNP). The cell-
seeded scaffolds were allowed to thaw at room temperature and then were sonicated for 
roughly 15 min. The enzyme reaction was set up by mixing 100 ml of the sample with 300 ml 
of substrate buffer containing 1 M diethanolamine HCl (pH 9.8) and 2 mg/ml of pNPP. The 
solution was incubated at 37ºC for 1 h and the reaction was then stopped by a solution 
containing 2 M NaOH and 0.2 mM EDTA in distilled water. The optical density was 
determined at 405 nm. A standard curve was made using pNP values ranging from 0 to 20 
μmol/ml. The results are expressed in μmol of pNP produced/ml/h. 
 
2.4.7. Mineralization content by EDS 
 The constructs were processed as described previously for SEM. The samples were 
sputter coated with carbon (JEOL JFC-1100), in order to verify the presence of calcium and 
phosphate elements with a Leica Cambridge S360 electronic microscope.  
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2.5. Statistical analysis 
 Statistical evaluation was performed using 2 tailed paired t-student tests, to assess 
the statistical differences between each two groups of different time points. Statistical 
significance was defined as p<0.05 for a 95% confidence interval. 
 
3. RESULTS  
3.1. Scaffolds characterization 
 The mechanical properties (compressive modulus) of the developed scaffolds are 
presented in table I. The compressive modulus of the thermally produced scaffolds is in the 
range of the trabecular bone modulus (36).  
 
Table I. Compressive modulus and porosity of the 50% (wt) chitosan based scaffolds 
produced by melt based compression molding with salt leaching (60% salt and granulometry 
of 250-500 μm). 
Composition Compressive Modulus (MPa) Porosity (%) 
50Ch-50PBS 87.4±21.6 59.9 ± 6.5 
50Ch-50PCL 53.1±23.7 63.9 ± 0.7 
50C/50PBTA 21.8±7.8 59.4 ± 3.8 
 
 Scaffolds with higher and lower compressive modulus are the ones obtained using 
the blends Ch-PBS and Ch-PBTA, respectively. These results are in accordance with 
previous results obtained with compact injection molded samples (31).  
 
 Representative μCT images of the entire scaffolds (300 slices) are shown in figure 1. 
Three dimensional reconstructions of the bulk of the scaffolds were also performed. No 
considerable differences in terms of morphology were observed between the more interior 
parts (bulk) of the scaffolds and the most exterior ones. Two dimensional X-ray μCT images, 
with a region of interest of 4.5x4.5 mm, were also analyzed (figure not shown). 
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Figure 1. Representative 3D μCT image of the scaffolds obtained using chitosan based 
blends and NaCl particles with size 250-500 μm. 
 
 No significant morphological differences were observed between scaffolds produced 
using different chitosan based blends. Pores resulting from the leaching of the NaCl particles 
mimic the cubic shape of the porogen used. The scaffolds have a very narrow distribution of 
pores dimensions coincident with the NaCl particles size. Two dimensional binary images 
were analyzed for total porosity calculations. The porosity values presented in table I are the 
average of the individual porosity of 300 slices per scaffold. For each processing condition, 4 
scaffolds were analyzed. As expected, porosity depended on the amount of porogen used. In 
all the cases the porosity was very similar to the amount of salt used.  
 
3.2. Mechanical properties 
 The nominal stress – nominal strain curves for the developed chitosan-polyester 
scaffolds are shown in figure 2. The compressive modulus was calculated as the slope of the 
linear most region of the stress-strain curve prior to the yield point and their value is shown in 
table I. As expected, the shape of the stress-strain curve, and consequently the modulus, 
varies with the type of polyester. Scaffolds with higher and lower compressive modulus are 
the ones obtained using the blends Ch-PBS and Ch-PBTA, respectively. These results are in 
accordance with previous results obtained with compact injection molded samples (31). 
Nevertheless, the compressive modulus of the thermally produced scaffolds is in the range of 
the trabecular bone modulus (36). 
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Figure 2. Stress-strain plot of the chitosan-polyester scaffolds. 
 
3.3. In vitro cytotoxicity tests 
 In the MTS test (Figure 3), L929 cells produced large amounts of the brown formazan 
product after incubation with the tested extract. This fact shows that cells had similar 
metabolic activities (about 80%) to those obtained by the negative control and were able to 
incorporate and metabolize MTS and hence, showed their viability. Therefore, the leachables 
released from the tested scaffolds could be considered as non-cytotoxic. 
 
 
Figure 3. Cytotoxicity results of the 72 h extracts of the Ch-PBS, Ch-PCL and Ch-PBTA 
scaffolds. Results are based on optical density measurements, at O.D. of 490 nm and 
normalized for the negative control (n=6; ±sd; p<0.05). 
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3.4. Cell adhesion and morphology by SEM 
 Regarding the present experiment, SEM observations allowed to determine that 
mouse MSCs were able to adhere to the surface of the chitosan-polyester based scaffolds, 
where a monolayer of cells could be observed after 1 week in culture (Figures 4a, 4b, 4c). 
Furthermore it should be highlighted that there was no pore occlusion by the cells (Figure 
4d), which demonstrated the adequacy of the pore size range within the scaffolds (250-500 
μm).  
 
Figure 4. SEM micrographs of BMC9 cells adhesion and proliferation, under osteogenic 
stimulation, on the 50% wt Ch-PBS scaffolds after a) 1 b) 2 and c) 3 weeks of culture; on the 
50% wt Ch-PCL scaffolds after d) 1 e) 2 and f) 3 weeks of culture and on the 50% wt Ch-PCL 
scaffolds after g) 1 h) 2 and i) 3 weeks of culture.  
 
 By week 2 it was possible to observe a higher degree of colonization, denoting a 
multilayer of cells and the onset of elaboration of extracellular matrix (ECM), at the surface of 
all the scaffolds obtained from different chitosan based blends (Figures 4e, 4f). A closer 
observation demonstrated that in the blend composed by chitosan and PBS there was a 
higher degree of proliferation of the cells including the ones in the inner regions of the 
scaffolds (Figure 4g). Furthermore, by observing the inside scaffoldʼs inner regions (Figure 5) 
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it was shown that the cells were also capable of colonizing these areas, without occluding the 
pores of the scaffolds structure. 
 
Figure 5. Light micrograph illustrating a representative section of the colonization of the 
MSCs onto the chitosan-PBS scaffolds for 21 days, after H&E staining. Original magnification 
100X. 
 
 After 3 weeks, further development of the cell number and surface density were 
observed, indicating that the BMC9 cells massively adhered and proliferated within all the 
chitosan based scaffolds, also showing a calcified ECM elaboration (Figure 9).  
 The scaffolds composed by Ch-PBS showed cell adhesion and colonization of the 
surface and inner regions (Figure 5), and simultaneously evidencing the elaboration of a 
mineralized extracellular matrix, shown by the presence of Ca and P, by EDS analysis 
(Figure 9a).  
 
3.5. Cell viability by MTS assay/ calcein AM staining 
 Tracking the survival/activity of the cells seeded on the scaffolds from the time of 
seeding until implantation might be helpful for the optimization on the development of bone 
tissue engineered constructs (37).  
 Results showed that the tested MSCs were able to reduce MTS, showing increasing 
metabolic rates with increasing time of culture (Figure 6), and denoting a high viability and 
proliferation profile.  
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Figure 6. Viability of the BMC9 cells seeded and cultured onto the chitosan-PBS (Ch-PBS), 
chitosan-PCL (Ch-PCL) and chitosan-PBTA (Ch-PBTA) scaffolds following 3 hours after cell 
seeding, at 1, 2 and 3 weeks, by MTS assay (n=6; ±sd; p<0.05). 
 
 Cell viability assay with calcein AM staining (Figures 7a, 7b and 7c) confirmed the 
SEM results, where BMC9 cells were metabolically active in the scaffolds after 3 weeks in 
static culture. Moreover, with these results it can be established a time dependent cell 
proliferation, as it is notorious the presence of a higher number of cells for the latest time 
period.  
 
 
Figure 7. Confocal micrographs showing the cell adhesion and viability upon the scaffolds of 
50% wt Chitosan-PBS scaffolds a); 50% wt Chitosan-PCL scaffolds b) and 50% wt Chitosan-
PBTA scaffolds c), after 3 weeks of culture. 
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3.6. Alkaline phosphatase quantification 
 For all tested blends, ALP activity (Figure 8) increased until the second week, 
reflecting probably the early osteogenic differentiation stage of the MSCs. After this period, 
ALP activity decreased, presumably due to the onset of the mineralization process (36), 
denoting in this sense a positive indication of the transient character of the differentiation of 
the cells into the osteogenic lineage. Once more, the best results were evidenced by the 
scaffolds produced from the Ch-PBS blend, which showed the higher values of the ALP 
activity. 
 
Figure 8. Alkaline phosphatase activity assay: supernatants were weekly collected and 
frozen. After 3 weeks, supernatants were thawed. The results are shown in p-nitrophenol 
(μmol/ml/h) as a function of days. On day 7, cells were stimulated with 10 mM 
glycerophosphate (Sigma), 50 mM ascorbic acid (Sigma) and 10-8 M dexamethasone 
(Sigma). The ALP levels increased, reaching the highest values after 2 weeks in culture (n=6; 
±sd; p<0.05). 
 
3.7. Mineralization content by EDS analysis 
 The EDS analysis of the surface of the seeded and cultured scaffolds with mouse 
MSCs under osteogenic conditions for 21 days (Figure 9) detected the presence of Ca and P 
elements on the surface, being therefore, a clear indication of the formation of a mineralized 
ECM.  
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Figure 9. Energy dispersive spectra showed the presence of calcium and phosphorous at 
the surface of the seeded chitosan-PBS a), chitosan-PCL b) and chitosan-PBTA c) scaffolds, 
after 3 weeks under osteogenic culture conditions. 
 
4. DISCUSSION 
 In the last few years, natural based polymers have been presented as biomaterials for 
tissue engineered scaffolding. Among these, chitosan has emerged as one of the most 
promising, namely by its biodegradability, biocompatibility and its resemblance to GAGs (23). 
 In this study we report the biological performance, in terms of cell adhesion, 
proliferation and differentiation of mouse MSCs seeded and cultured onto the newly 
developed chitosan based scaffolds. 
 The melt based approach used to produce the scaffolds allowed us to obtain 3D 
porous structures without the use of organic solvents that could remain in the structure and 
damage the transplanted cells or the surrounding tissues (after transplantation). The 
mechanical properties, in terms of compressive modulus, were in the range of those for 
trabecular bone properties (36). 
 The developed scaffolds revealed to be non-cytotoxic to fibroblast cells, since the 
leachables released during the extraction period did not affect cell viability as well as did not 
inflict changes in cell morphology. 
 Cells were able to colonize the scaffolds structure up to periods of 3 weeks. The cell 
proliferation was gradual and continuously increasing over time of culture, being more 
evident on the ch-PBS scaffolds. The differences observed for the different blends are 
probably related with the different surface chemistry and mechanical properties of the 3D 
scaffolds with the best results being noticed for the scaffolds produced from ch-PBS blend.  
 It is known that if cells are undergoing osteogenic differentiation, ALP is considered to 
be one of the early markers (38). Although not being specific for the osteoblast lineage, ALP 
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is used typically to illustrate the early differentiation into a bone related phenotype, which is 
noticed by the increase of the enzyme activity until the second week.  
 The presence of Ca and P elements on the surface of the cell-seeded scaffolds 
revealed the presence of a mineralized ECM. This fact is in agreement with the data obtained 
for alkaline phosphatase experiments, showing that cells had undergone an osteogenic 
differentiation and were elaborating mineralized ECM. 
 
5. CONCLUSIONS 
 With the present study it was possible to show that the scaffolds based on 50:50 
(wt%) blends of chitosan and synthetic polyesters (PBS, PCL and PBTA) present a range of 
properties that are considered to be adequate for bone tissue engineering applications. 
 Scaffolds produced by compression molding followed by salt leaching were shown to 
be non-cytotoxic and clearly cytocompatible. The results of the direct contact assays under 
osteogenic conditions revealed that the three types of chitosan-based scaffolds selected for 
this study promoted the attachment and proliferation of mouse mesenchymal stem cells. 
Furthermore, they also presented high indexes of alkaline phosphatase activity and the 
production of a calcified ECM, which is due to the differentiation towards the osteogenic 
pathway. From the three tested blends, the chitosan-PBS blend showed the best results, 
namely in terms of cell adhesion and proliferation. Nevertheless the other blends also 
presented adequate properties for bone tissue engineering. 
 Due to the good combination of properties and excellent biological performance, it is 
strongly believed that the scaffolds herein proposed will be a valid alternative to the currently 
used materials when considering bone regeneration/tissue engineering applications. 
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CHAPTER IV 
Influence of chitosan content in the scaffold composition over the in vitro 
osteogenic differentiation of hBMSCs and in vivo tissue response 
 
ABSTRACT 
 Chitosan has been showing promising results for bone tissue engineering 
applications, namely for modulating cell behaviour in vitro and promoting bone regeneration 
in vivo. Previous results from our group evidenced that chitosan poly(butylene succinate) 
melt based scaffolds showed remarkable biological performance. This fact brought up the 
question of the role of chitosan in this specific blend. For this purpose scaffolds with 50% of 
chitosan (Ch) and 50% poly(butylene succinate) (PBS), 25% of Ch and 75% of PBS and 
100% PBS were produced by compression molding and salt leaching. These scaffolds were 
evaluated in vitro with human bone marrow mesenchymal stem cells (hBMSCs) and in vivo 
by implanting them in different anatomical regions (cranial defect model, iliac submuscular 
and auricular areas) in Wistar rats. Higher percentages of chitosan favoured better biological 
performance, when compared to PBS scaffolds alone. Cells showed enhanced viability over 
time, evidencing superior cell adhesion and proliferation. Moreover, alkaline phosphatase 
(ALP) activity and gene expression showed that cells were undergoing osteogenic 
differentiation in chitosan containing scaffolds. For all in vitro studies, PBS scaffolds 
presented inferior biological performance when compared to chitosan based scaffolds. 
 Scaffolds displayed a normal and mild inflammatory response after one month 
implantation and integrated well with the surrounding tissues. Connective tissue cells 
colonized the scaffolds structures. Tissue responses were milder in auricular and calvaria 
implantations when compared to the submuscular. Chitosan scaffolds evidenced better 
results, with enhanced cell penetration, without cell necrosis and large number of blood 
vessels in the proximity and inside the scaffolds.  
 The addition of chitosan positively influenced the osteogenic differentiation of 
hBMSCs, and also showed enhanced tissue biocompatibility, as compared to PBS alone. 
Considering the results herein reported it is reasonable to state that chitosan-PBS scaffolds 
demonstrate appropriate properties both in vitro and in vivo to be used in bone tissue 
engineering applications. 
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1. INTRODUCTION 
 A new field known as Tissue Engineering has recently emerged, having potential to 
overcome the increasing number of clinical needs for bone regeneration mainly due to the 
aging of population. This multidisciplinary approach involves the basic principles of 
engineering and life sciences, in order to develop biological substitutes aimed at restore, 
maintain or improve a tissue function or a whole organ (1). Firstly, a tissue construct is 
created, using cells and scaffolds. This scaffold is further matured in vitro, and then 
transplanted and integrated into the host defect site (2). Frequently, the cells are seeded and 
cultured onto a natural or synthetic biodegradable scaffold. The ideal scaffold must fulfill a 
number of requirements that include being biocompatible with specific biodegradability 
kinetics and should possess adequate porosity, pore size and mechanical properties 
compatible with the loads to which will be subjected (3).  
 Among the various natural polymers available, chitosan has emerged as a candidate 
biomaterial to produce biodegradable scaffolds for tissue engineering applications. The first 
report about the partially deacetylated form of chitin (chitosan) dates back from the 19th 
century (4). Chitosan presents biological properties that makes it appropriated to develop 
scaffolds for tissue engineering, including its biodegradability (5, 6), antibacterial activity (7, 
8), haemostatic and wound healing properties (9, 10), biocompatibility (11, 12) and easy 
accessibility. It is a linear polysaccharide composed of glucosamine and N-acetyl 
glucosamine with a β (1-4) link (13). Chitosan has a cationic character, which allows 
electrostatic interactions with anionic glycosaminoglycans (GAGs) and proteoglycans. 
Moreover, the chemical structure of chitosan has similarities with the structure of GAGs (14). 
These molecules play an important role in the modulation of cell function, morphology and 
differentiation.(13).  
 Interactions between cells and extracellular matrix (ECM) provide essential cues used 
by the cells to influence and adapt its intra and extracellular environment (15). Chitosan by 
itself or in combination with other biomaterials has been reported to have a positive effect 
over the cell behavior. Polystyrene coated with chitosan solution has shown cytocompatibility 
as a substrate for growth of human osteoblasts and chondrocytes (16). Poly-(L-lactide acid) 
(PLLA) films modified with chitosan evidenced improved cell adhesion, proliferation and 
biosynthetic activity, using articular chondrocytes (17). Commercially available chitosan 
supports the initial attachment and spreading of osteoblasts preferentially over fibroblasts 
(18). MC3T3-E1 osteoblastic-like cells proliferated and evidenced increased alkaline 
phosphatase activity, as well as up-regulation of osteogenic gene expression, in composite 
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chitosan/poly(lactic acid-glycolic acid) scaffolds as compared to poly(lactic acid-glycolic acid) 
scaffolds (19). In fact, in a recent study by Wu and co-workers, different proportions of 
poly(caprolactone)/chitosan scaffolds evidenced better results for the blends with higher 
chitosan content, using rat osteoblasts (20). Moreover, nanofibrous scaffolds containing 
chitosan revealed that stem cells adhere, proliferate and express phenotypic markers of 
osteogenic differentiation in a superior level than synthetic nanofibrous scaffolds without 
chitosan (21, 22). It has been described in the literature that combined chitosan–collagen 
matrices, with higher proportion of chitosan promoted osteoblastic differentiation of hBMSCs 
and improved the mechanical and physical properties of the sponges (23). Previous studies 
from our group, using chitosan particle aggregated scaffolds, evidenced good results favoring 
osteogenic and chondrogenic differentiation of adipose derived stem cells (24). Another work 
from our group reported that discs composed of chitosan-PBS and other biodegradable 
polyesters, obtained by injection molding, showed that chitosan had a positive effect over 
osteoblast-like cells activity in vitro (25). 
 Chitosan is difficult to be processed by methods that do not require the use of 
solvents. Accordingly, there is the need to combine it with other polymers to improve its 
processability. By this combination, the mechanical properties of the resulting biomaterial can 
also be improved to become adequate for load bearing tissues, such as bone (26). 
Previously, we proposed a methodology to process chitosan with aliphatic polyesters, 
facilitating its processing by melt and avoiding the need of solvents (27, 28). This processing 
route involves melt-based compression molding followed by particle leaching. Details about 
this technique were described elsewhere (28). Briefly, several aliphatic polyesters in different 
percentages were blended with chitosan. These various scaffold formulations were evaluated 
in vitro for osteogenic applications, using a mouse MSC cell line (BMC9). The composition 
having chitosan–PBS (50% wt) evidenced the strongest results, in terms of both cell 
adhesion and proliferation (29). These results raised the question of why this specific blend 
shows such enhanced cell behavior. We herein addressed this important question by 
studying different blends with two different concentrations of chitosan: chitosan-PBS (25-75% 
wt) and chitosan-PBS (50% wt), as well as, without chitosan, with only PBS (100% wt), with 
human MSCs seeded and cultured in osteogenic conditions. In vivo tissue response was 
evaluated by implanting scaffolds with the extreme compositions, chitosan-PBS (50% wt) and 
scaffolds without chitosan (PBS 100) in Wistar rats. The implantation locations were defined 
to evaluate the inflammatory response in regions with different degrees of vascularization. 
The regions were the cranial bone that is a region with relevance for the intended application, 
submuscular, a highly vascularized location and auricular area, which is a region with lower 
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vascularization. 
 
2. MATERIALS AND METHODS 
2.1. Scaffolds processing  
 The aim of this specific study required the production of scaffolds with different 
compositions of chitosan and PBS. Namely, we produced scaffolds having 100% of polyester 
(PBS 100); 25% of chitosan and 75% of PBS (Ch-PBS 25-75); and 50% of chitosan and 50% 
PBS (Ch-PBS 50-50). In both cases, the composition is in a weight basis.  
 Chitosan and PBS powder were melt blended by extrusion. The extrudate was 
subsequently grinded into powder. This powder was physically mixed with NaCl particles with 
controlled sizes (obtained by sieving) and processed by compression molding into large 
discs. These large discs were subsequently sectioned to obtain the required geometry for the 
final scaffolds. The sectioning was performed using a CNC equipment (3D Plotter MDX-20 – 
Roland), which allows cutting solid objects in a controlled and reproducible manner. In a first 
stage, the outer skin of the large disk produced initially by compression molding was 
removed. A plate with the final required thickness was obtained from where smaller discs 
were cut with the desired geometries to be used as scaffolds. A subsequent salt leaching 
process was performed by immersion in water during a sufficient period to allow all NaCl 
particles to be dissolved and leached out. In this way, porous scaffolds with controlled 
geometry are obtained. Specific details of the processing conditions are described elsewhere 
(28). Taking into account the final applications, we herein produced discs with diameters of 8 
mm and two different thicknesses, 1 mm and 3 mm. Finally, the discs intended to be used in 
further cell culture studies or for in vivo implantation were sterilized by ethylene oxide. 
 
2.1.1. Scaffolds characterization by micro computed tomography (µCT) 
 A micro computed tomography equipment µCT Skyscan 1072 scanner (Skyscan, 
Knotich, Belgium) was used to analyze the internal 3D structure of the scaffolds. Three 
scaffolds of each formulation were scanned in high-resolution, using a resolution pixel size of 
8.79 µm and exposure time of 1.792 ms. The energy of scanner was selected to use 63 keV 
and 157 µA current. Approximately 400 projections were acquired over a rotation range of 
180º with a rotation step of 0.45º. µCT scans were reconstructed using a cone-beam 
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reconstruction software (NRecon v1.4.3, also from SkyScan). Representative data sets of 
200 sections were segmented into binary images with a dynamic threshold of 150 to 255 
(grey values) and were used for morphometric analysis including porosity, pore 
interconnectivity and mean pore size (CT analyzer, v1.5.1.5, SkyScan) and to reconstruct 3D 
models (ANT 3D creator, v2.4, SkyScan). 
 
2.1.2. Mechanical tests  
 Compression tests were performed for determining the compressive modulus of the 
developed scaffolds using a Universal tensile testing machine (Instron 4505 Universal 
Machine, USA). Tests were performed using a crosshead speed of 2 mm/min until 60% of 
strain was reached. Tested scaffolds were cylinders of approximately 8 mm in diameter and 
3 mm in thickness. The results presented are the average of testing at least five specimens. 
The compressive modulus was determined by selecting the most linear region of the stress-
strain graph. 
 
2.2. Cell studies 
 The biological performance of the scaffolds was assessed by in vitro assessment of 
cell adhesion, viability and osteogenic differentiation. Biocompatibility was analyzed by 
implanting the scaffolds in different body regions of Wistar rats. The parameters and 
conditions used in those tests will be described in detail in the current section. 
 
2.2.1. Cell seeding and cell culture 
Human bone marrow mesenchymal stem cells (hBMSCs) cells were grown in a 
culture medium consisting of alpha medium (Sigma, St. Louis, MO), 10% fetal bovine serum 
(Biochrom AG, Germany), 5 mM L-glutamine (Sigma, St. Louis, MO), 1 ng/ml basic fibroblast 
growth factor (bFgF) (PeproTech, USA) and 1% of antibiotic-antimycotic mixture (Sigma, St. 
Louis, MO).  When an adequate cell number was obtained, cells at passage 2 were detached 
with trypsin/EDTA. Cells were seeded by means of a cell suspension at a density of 2.8x105 
cells/scaffold under dynamic conditions (orbital shaker), during 24 h. The constructs were 
placed in new 24-well plates and 1 ml of osteogenic medium was added to each well. The 
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osteogenic culture medium consisted of DMEM without phenol red, dexamethasone 10-8 M 
(Sigma, St. Louis, MO), ascorbic acid 50 μg/ml (Sigma, St. Louis, MO) and ß-
glycerophosphate 10 mM (Sigma, St. Louis, MO). The cell-constructs were cultured for 
periods of up to 7, 14 and 21 days in a humidified atmosphere at 37ºC, containing 5% CO2. 
The culture medium was changed every 2 to 3 days until the end of the experiment. 
 
2.2.2. Cell viability  
 Cell viability was assessed after 7, 14, and 21 days using the MTS test. The cell-
scaffold constructs (n=3) were rinsed 3 times in phosphate buffered saline solution (Sigma, 
USA), and immersed in a mixture consisting of serum-free cell culture medium and MTS 
reagent in a 5:1 ratio. After that, the samples were incubated during 3 hours at 37ºC in a 
humidified atmosphere containing 5% CO2. The optical density (O.D.) was measured on a 
microplate ELISA reader (BioTek, USA) using an absorbance of 490 nm.  
 
2.2.3. Cell adhesion and morphology - scanning electron microscopy (SEM) 
 The adhesion, morphology and spatial distribution of cells on the scaffolds were 
analyzed by SEM. The constructs were washed in phosphate buffered saline solution and 
fixed in 2.5% glutaraldehyde. After that, the constructs were dehydrated with increasing 
percentages of ethanol and let to air dry. Afterwards, the constructs were sputter coated with 
gold (JEOL JFC-1100) and analyzed using a SEM Leica Cambridge S360. 
 
2.2.4. Early osteogenic marker - alkaline phosphatase  
 Samples were collected as previously described. Alkaline phosphatase (ALP) activity 
of the constructs (n=3) was measured by the specific conversion of p-nitrophenyl phosphate 
(pNpp) (Sigma, USA) into p-nitrophenol (pNp). The constructs were thawed at room 
temperature and sonicated during 15 min. The enzymatic reaction was set up by mixing 100 
µl of the sample with 300 µl of substrate buffer containing 1 M diethanolamine HCl (pH 9.8) 
and 2 mg/ml of pNpp. The solution was further incubated at 37ºC during 1 hour and the 
reaction was stopped by the addition of a solution containing 2 M NaOH and 0.2 mM EDTA 
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in distilled water. The O.D. was determined at 405 nm. A standard curve was prepared using 
pNp values ranging from 0 to 20 μmol/ml.  
 
2.2.5. Osteogenic gene expression -– real time reverse transcriptase PCR (RT-PCR) 
 Samples were collected after 7, 14 and 21 days of culture and Trizol® (Invitrogen, Life 
Technologies Inc., UK) was added to the constructs and immediately placed at -80ºC. Total 
RNA was isolated from cells with Trizol according to the manufacturer protocol. A NanoDrop 
microspectrophotometer (NanoDrop ND-1000 Spectrophotometer, Alfagene, USA) was used 
to measure the total RNA concentration. The integrity of the RNA samples was checked 
using denaturing agarose 1.2% gel electrophoresis. 
 The real time PCR analysis used in this work consisted of a two-step fluorogenic 
assay using the SyberGreen system (BioRad, USA). All the reagents used in this procedure 
were obtained from Bio-Rad in accordance with the instructions of the manufacturer.  
 cDNA synthesis was performed using iScriptTMcDNA Synthesis Kit (BioRad, USA). 
Briefly, cDNA synthesis was carried out using a reaction mixture consisting of 1X iScript 
Reaction Mix, 1μL iScript Reverse Transcriptase, RNA template (1 μg of total RNA) and 
nuclease-free water was prepared to a final reaction volume of 40 μL. After that stage, the 
obtained cDNA was used as template for the amplification of the genes. Specific genes, 
primer sequences and annealing temperatures are listed in Table I.  
 
Table I. Amplified genes, specific primer pair sequences and annealing temperatures. 
Gene Primer sequence Tm (ºC) 
Runx 2 R- 5'-CAG CGT CAA CAC CAT CAT TC - 3' F- 5'-TTC CAG ACC AGC AGC ACT C - 3' 58.1 
Osterix R- 5'-CCCTTTACAAGCACTAATGG - 3' F- 5'-ACACTGGGCAGACAGTCAG - 3' 57.1 
Osteopontin R- 5'-GGG GAC AAC TGG AGT GAA AA - 3' F- 5'-CCC ACA GAC CCT TCC AAG TA - 3' 58.4 
Akaline Phosphatase R- 5'-AGA CTG CGC CTG GTA GTT G - 3' F- 5'-CTC CTC GGA AGA CAC TCT G - 3' 58.8 
Osteocalcin R- 5'-CTG GAG AGG AGC AGA ACT GG- 3' F- 5'-GGC AGC GAG GTA GTG AAG AG- 3' 61.4 
Bone sialoprotein R- 5'-CCT CGT ATT CAA CGG TGG TG - 3' F- 5'-CAA CAG CAC AGA GGC AGA AAA - 3' 59.8 
Type I collagen R- 5´-TCA AAA ACG AAG GGG AGA TG-3 F- 5´-CCA AAT CTG TCT CCC CAG AA-3 58.4 
GAPDH R- 5'-GAC AAG CTT CCC GTT CTC AG - 3' F- 5'-ACA GTC AGC CGC ATC TTC TT - 3' 58.4 
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 Each real time PCR run was carried out with an initial incubation at 95ºC for 10 min 
followed by forty cycles of denaturation (95ºC, 10 s), annealing (temperature accordingly with 
the specific primer used, 30 s) and extension (72ºC, 30 s) in the gradient thermocycler 
MiniOpticon real-time PCR detection system (BioRad, USA). At the end of each cycle, the 
fluorescent products were detected and quantified. 
 GAPDH was used as the housekeeping gene and the expression of all the target 
genes was normalized to the GAPDH of that sample in the respective time point. The 
obtained results were further analyzed with CFX Manager Software – version 1.5 (BioRad, 
USA).  
 
2.3. Animal model and surgical protocols 
 Twelve Wistar rats weighing between 250-300 g were used in the in vivo studies. All 
rats were fed ad libitum during the experiments. The animals were maintained in a 
temperature and humidity controlled environment at the animal research center of Hacettepe 
University. The study was conducted after receiving approval from the Animal Ethical 
Committee of the Kırıkkale University. A sterile surgical technique was applied 
throughout the surgical procedures. The scaffolds (8 mm in diameter and 1 mm thick) were 
previously sterilized by ethylene oxide. Animals were anesthetized by intraperitoneal injection 
with a mixture of ketamine HCl (Parke Davis, 50 mg/ml, Taiwan) and Rompun (2%, Bayer, 
Germany). The implantation site of the tested animals was shaved and disinfected with 
Baticon solution (Droksan, 10%, Turkey). The scaffolds were implanted in 3 different 
anatomical regions (Figure 1) to analyze the inflammation extent in zones with different 
degrees of vascularization:  
(i) Cranial critical size defect: the periosteum was pulled back from the cranial 
surface, the cranial bone was removed by using a circular driller and the scaffold 
was immediately placed in the defect (inlay model), covered by the periosteum; 
(ii)  Auricular – ear: a pocket was made between the perichondrium and the ear 
cartilage and the scaffold was placed on the 1/3 proximal cartilage in the pocket;  
(iii) Submuscular: an incision of 10 mm was made to reach the iliac bone. The 
scaffold was placed between the periosteum and the iliac bone (onlay model). A 
total of 3 scaffolds per animal were implanted.  In all cases, the incision was 
closed using 5.0 silk sutures.  
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Figure 1. Scheme of the dorsal view of a rat showing the implantation sites. 
 
2.4. Statistical analysis 
 Statistical analysis was performed using the SPSS statistic software (Release 15.0.0 
for Windows). A Shapiro-Wilk test was used to ascertain about the data normality and 
variance equality. The normality was strongly rejected and for the results obtained for cell 
viability and ALP assays, the non-parametric test Kruskal-Wallis followed by Tukeyʼs HSD 
test was applied to compare the three independent groups of samples for each variable. P 
values lower than 0.01 were considered statistically significant in the analysis of the results. 
In the case of gene expression results, the non-parametric Mann-Whitney U test was used. 
 
3. RESULTS AND DISCUSSION 
3.1. Scaffolds characterization by µCT 
 The morphological analysis of the scaffolds was performed by µCT, by reconstructing 
scaffoldsʼ tridimensional morphology (Figure 2).  
 
Figure 2. Tridimensional µCT reconstructions of the PBS 100 a), Ch-PBS 25-75 B), and Ch-
PBS 50-50 scaffolds. 
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 The qualitative analysis of scaffolds morphology showed the consistency of the 
porous morphology of the produced scaffolds. The material composition does not affect the 
morphology and structure of the scaffolds developed by compression molding followed by 
salt leaching.  
 Individual 2D analysis of the binary images obtained along the scaffold cross-section 
consisting of 300 slices was carried out for morphometric calculations (Table II).  
  
Table II. Porosity, pore size, interconnectivity and compressive modulus of the produced 
scaffolds obtained by µCT 
 
Porosity (%) Pore size (µm) Interconnectivity (%) 
Compressive 
Modulus (MPa) 
100PBS 64.4±4.0 134.7±9.7 86.8±1.9 16.2±8.9 
25Ch-75PBS 68.3±4.3 178.7±15.7 92.8±0.9 9.0±3.3 
50Ch-50PBS 69.6±7.1 184.4±11.9 90.8±1.5 22.8±9.9 
 
 
 The analysis showed that the produced scaffolds have a very high open porous 
network. The level of interconnectivity of the porosity ranges from 86.8±1.9% to 92.8±0.9%, 
which is adequate to allow the diffusion of cells into the inner regions of the scaffolds. The 
percentage of porosity was directly proportional to the quantity of the porogen used 
(approximately 60%), with a small but not statistically significant increase for higher 
percentages of chitosan. Pore sizes were in general lower than the size range of the salt 
particles used. This is maybe due to the fact that compression molding process tends to 
break down some salt particles, resulting in a pore size in the scaffolds slightly lower than the 
original size of the porogen particles (28). The pore range of 100-250 µm was already shown 
in literature to be suitable for bone regeneration (30). The values for the compressive 
modulus of the various scaffolds are also shown in Table II.  
 We observed that the formulation with lower chitosan content (25% wt) has the lowest 
compressive modulus of all produced scaffolds. The formulation with higher amount of 
chitosan (50% wt) shows the highest elastic modulus. However, it should be noted that the 
pore size and level of porosity, as well as the interconnectivity of the scaffolds produced with 
formulations including chitosan have consistently larger values. These differences in 
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morphology may be responsible for the lower level of reinforcement achieved with chitosan 
compounds in this study. The mechanical properties are within the levels required for its 
application, as scaffolds for bone regeneration, since its values are compatible with those of 
trabecular bone (31).  
 
3.2. Cell adhesion and morphology by SEM 
 The morphology of the cells and the extent of cell adhesion were analyzed by SEM 
(Figure 3). 
 
Figure 3. SEM micrographs showing the morphology of the seeded and cultured hBMSCs 
after 1, 2 and 3 weeks in PBS 100 scaffolds (a, b and c); Ch-PBS 25-75 (d, e and f); and Ch-
PBS 50-50 (g, h and i), respectively. 
 Cells adhered in larger numbers to the chitosan containing scaffolds (Figures 3d and 
3g) when compared to the PBS formulation (Figure 3a). Practically no cell colonization is 
visible in PBS 100 scaffolds (Figures 3a, 3b and 3c) for all time points. The formulation Ch-
101the cultured scaffolds (Figures 3e and 3f). The stronger results in terms of cell adhesion 
were obtained for the formulation with the highest percentage of chitosan, showing that the 
presence of chitosan promoted cell adhesion and proliferation over time. Those results 
confirm our previous data (29) and clearly indicate a positive influence of chitosan over the 
adhesion and proliferation of hBMSCs seeded on the scaffolds. A study with chitosan-
coralline scaffolds with a similar porosity evidenced a similar cell behavior (32). 
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3.3. Cell viability 
 Cell viability results (Figure 4) corroborate the SEM observation, showing that higher 
chitosan content has a positive influence on the viability of hMSCs. The absolute values 
obtained for chitosan based scaffolds were indeed high (Figure 4). At all time points, Ch-PBS 
25-75 and Ch-PBS 50-50 displayed significantly higher cell viability than PBS 100. After 7 
and 14 days of culture, Ch-PBS 50-50 scaffolds shown a significantly higher amount of cell 
viability than Ch-PBS 25-75. After 21 days of culture, no significant difference was obtained 
between Ch-PBS 25-75 and Ch-PBS 50-50. For PBS 100 scaffolds, the values of viability 
were quite low for all time points and even decreased with time, which correlates with the 
SEM images showing almost no cells at the surface of the scaffolds. The Ch-PBS 25-75 
formulation evidenced increasing cell viability with time, even though the highest value 
obtained after 21 days of culture is still lower than the one obtained for the first time point (7 
days) of the Ch-PBS 50-50 formulation. Ch-PBS 50-50 evidenced the highest values of cell 
viability, although there is a slight decrease of cell viability corresponding to the longer time 
point. This may be explained by the surface of the scaffold being already fully covered by the 
cells at this longer time point.  
 
 
Figure 4. Cell viability (Abs 490 nm) in PBS 100, Ch-PBS 25-75 and Ch-PBS 50-50 after 7, 
14 and 21 days of culture. Data were analyzed by nonparametric way of a Kruskal-Wallis test 
followed by Tukeyʼs HSD test. (*) denotes significant differences compared to PBS 100. 
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3.4. Early osteogenic marker- ALP 
 ALP activity has been used as an indicator of osteogenic cell differentiation (33, 34). 
This membrane bound enzyme, which is expressed at relatively high levels in the 
osteoblasts, has long been recognized as a marker of osteoblastic differentiation, since it has 
been implicated in the mineralization process (35). ALP is upregulated in the early stages of 
biomineralization in order to form a large pool of inorganic phosphate, from which the ECM 
can be mineralized (36). An increasing ALP activity was observed over time for all scaffolds 
formulations. Similar trends were also observed for hMSCs cultured onto collagen-HA (37), 
silk (38) and chitosan (21, 23) 3D scaffolds. As expected from the SEM analysis and by data 
obtained from the viability tests, the seeded PBS 100 scaffolds presented the lowest values 
of ALP (Figure 5), corroborating the low cell adhesion detected in those scaffolds (Figures 
3a, 3b and 3c). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. ALP activity of PBS 100, Ch-PBS 25-75 and Ch-PBS 50-50 after 7, 14, and 21 
days of culture. Data were analyzed by nonparametric analysis using the Kruskal-Wallis test 
followed by Tukeyʼs HSD test. (*) denotes significant differences compared to PBS 100, (#) 
denotes significant differences compared to Ch-PBS 25-75. 
 
 Formulations containing chitosan showed similar trends of ALP activity, increasing 
with time, as well as a high level of activity. Furthermore, the formulation with the largest 
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chitosan content showed also the highest values of the expression of ALP for the longest 
time point. 
 
3.5. Osteogenic differentiation - gene expression 
 Bone cell differentiation is characterized by three different periods: proliferation, ECM 
maturation and mineralization (39). The osteogenic phenotype is recognized by cell 
maturation coordinated with the secretion of specific proteins, in a process that is 
asynchronously acquired and/or lost as the progenitor cells differentiate and the matrix 
matures and mineralizes (40). A preferred method to evaluate the transient state of the stem 
cells during differentiation is by analyzing gene expression profile during its culture in 
osteogenic differentiating conditions, as shown in Figure 6. 
 
 
Figure 6. Relative gene expression of osteogenic related genes (Runx2, Oste0rix, 
Osteocalcin, Osteopontin, Alkaline phosphatase and Bone Sialoprotein) in hBMSCs cultures 
onto Ch-PBS 50-50, Ch-PBS 25-75 scaffolds in osteogenic conditions. The expression of 
these genes was normalized against the housekeeping gene GAPDH and calculated by ΔCT 
method. Data were analyzed by nonparametric Mann-Whitney U test. 
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 We performed a real time quantitative PCR study to evaluate the level of the relative 
expression of osteogenic related genes. Gene expression for the formulation PBS 100 was 
not analyzed, due to the fact that these scaffolds did not support cell adhesion in sufficient 
amounts to obtain the quantity of mRNA to synthesize the minimum cDNA. The genes 
analyzed included Runx-2, Osterix, Alkaline phosphatase, Osteopontin, Bone Sialoprotein 
and Osteocalcin. The relative quantification of each gene was normalized against the 
expression of the housekeeping gene (GAPDH) for each time point. A constitutive expression 
of all mRNA transcripts was detected during the 21 days of the experiment. Runx-2 is 
expressed in an early multipotential mesenchymal cell population that can give rise to 
chondrogenic, osteogenic, and dentinogenic tissues as well as other lineages (41). Both 
chitosan scaffolds formulations presented a similar Runx-2 expression trend, with minor 
variation over time. Osterix is a transcription factor that is expressed in osteoblasts of all 
endochondral and membranous bones (42), acting during the stage of commitment of the 
osteoprogenitor cell into a pre-osteoblast (43). This gene was expressed in comparable 
levels for both Ch-PBS 25-75 and Ch-PBS 50-50 scaffolds. Osteocalcin gene is considered 
an important marker of the mineralization phase, reaching its maximum level before or during 
this process (39). In the present work this gene reached its maximum at 14 days of culture 
for both types of scaffolds. Osteopontin is one of the most abundant non-collagenous 
proteins in bone, binding to various extracellular molecules, including type I collagen, 
fibronectin or osteocalcin and contributes to the physical strength of the extracellular matrices 
(44). Osteopontin mRNA peak was at 14 days of hBMSCs culture, determining the end of the 
matrix deposition and the initiation of the mineralization stage. Higher values were obtained 
for Ch-PBS 50-50 formulation. Both osteocalcin and osteopontin mRNA maximum transcripts 
determine the presence of mature ostoblasts and the beginning of the mineralization. 
Alkaline phosphatase is localized in the plasma membrane of osteoblasts and although its 
precise function is not clearly understood, there are studies suggesting its involvement in 
mineralization process (33). It is an enzyme expressed by osteoblasts and it is considered a 
marker of osteogenic differentiation (45). Alkaline phosphatase has been shown to be 
responsible for the cleavage of pyrophosphate, a molecule that binds to hydroxyapatite 
crystals preventing further incorporation of phosphate into the crystals (46). This mRNA 
transcript evidenced opposed trends for the different scaffolds formulations, i.e., for Ch-PBS 
25-75, ALP expression decreased with time, whereas for Ch-PBS 50-50 increased with time, 
also presenting higher absolute values for the latest culture periods. Bone sialoprotein is an 
adhesive bone ECM protein exclusively associated with mature osteoblasts and suggested to 
be also involved in the mineralization phase of bone formation (47). This mRNA transcript 
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showed a similar profile for both types of scaffolds, increasing from 7 to 14 days and with a 
slight decrease at 21 days. This decrease can be considered relative, given the standard 
deviation associated. This is in accordance of what was expected, since this protein is 
expressed by mature osteoblasts (43). The whole set of genes consistently upregulated, 
strongly evidences a successful osteogenic differentiation of hBMSCs at the surface of 
chitosan containing scaffolds. 
  
3.6. Host tissue response to the implanted scaffolds 
  The implantation of a biomaterial scaffold in a tissue is performed to verify the local 
effects on host tissues. The biocompatibility of a device in a tissue is assessed in terms of 
acute and chronic inflammatory responses, granulation tissue development, foreign body 
host reaction and potential of integration of the implanted scaffold with host tissue (49). The 
evaluation of the local pathological effects was carried out at both tissue level (macroscopic) 
and at microscopic level. The histological evaluation is used to characterize various important 
biological response parameters (50).  
 The tissue biocompatibility was evaluated in vivo by implanting Ch-PBS 50-50 and 
PBS 100 scaffolds in relevant tissue locations, including hard tissue in the cranial defect 
(Figure 7) and soft tissues in auricular (Figure 8) and submuscular (Figure 9) regions. The 
Ch-PBS 25-75 condition was excluded based on the in vitro results, since this condition 
evidenced a similar performance to Ch-PBS 50-50 and to minimize the number of animals 
used. All surgical incisions healed without evidence of infection or other complications. 
Retrieved implants showed no signs of serious inflammation.  
 Tissue reaction to an implanted biomaterial is often characterized by an initial acute 
inflammatory response, with the presence of polymorphonuclear cells (PMNs or neutrophils) 
that migrate from blood to the tissue (51). Acute inflammation is the immediate response to 
injury and most of the times destroy the foreign material. However, the implant may act as a 
persistent stimulus to inflammation, and the host response will evolve into a chronic 
inflammation response. The chronic inflammation is associated to angiogenesis, fibrosis or 
eventually, tissue necrosis (52). The leukocyte infiltration is composed by lymphocytes, 
macrophages and plasma cells, that in combination with angiogenesis and fibroplasia 
constitutes the granulation tissue (53). This chronic reaction has also another particularity, 
the possibility of recruiting giant cells (G), formed by macrophage fusion, mostly associated 
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to the failure of phagocytosis of large particles released from the device (54). This reaction is 
denominated by foreign body reaction (FBR).  
 After one month of implantation, an invasion of host cells throughout the implanted 
porous structures was visible for all tissue locations (Figures 7, 8 and 9). The implanted 
scaffolds caused mild inflammation, characterized by infiltration of mononuclear phagocytic 
cells, macrophages, lymphocytes, fibroblasts and some polymorphonuclear leukocytes in 
hard and soft tissues at the implantation site. For each implantation location:  
 
i) Cranial defect  
 Both types of scaffolds were placed in close contact with the cortical bone of the 
calvaria. It is visible a significant ingrowth of connective tissue cells into the scaffolds porous 
structure (Figures 7a and 7d). Furthermore, new blood vessels were present (Figures 7b and 
7e) and collagen is present in both type of scaffold (Figures 7c and 7f) formulations but in a 
higher amount for chitosan based scaffolds (Figures 7c). Foreign body giant cells were 
observed, being more pronounced for chitosan based scaffolds (Figure 7b) and it was 
already reported that chitosan may induce the formation of granulation tissue in vivo (55).  
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Figure 7. H&E histological sections of Ch-PBS 50-50 (a and b) and PBS 100 (d and e) 
implants in cranial defects. Masson trichrome stained sections of Ch-PBS 50-50 (c) and PBS 
100 (f) implants in the same region, showing collagen in green. CB-Compact bone; CT- 
Connective tissue; TN- Tissue necrosis; Ch-Chitosan; PBS-Poly(butylene succinate). 
 
ii) Auricular implantation 
 In this region scaffolds show, as in the cranial defect, a mild inflammatory response 
(Figure 8). This lower tissue response may be in part related to the fact that ear tissue is not 
intensely vascularized. PBS scaffolds evidenced lower cell colonization (Figures 8d and 8e), 
than Ch-PBS scaffolds. At high magnifications it was possible to observe cell necrosis inside 
the pores of PBS implants (Figure 8e). On the other hand, it was visible a massive 
colonization of inflammatory giant cells in chitosan implants (Figure 8b). Previous results 
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using chitosan and ovine MSCs with TGFβ-3 implanted into partial thickness lesions created 
in sheep legs, evidenced a hyaline-like cartilaginous matrix, well integrated into the host 
cartilage what provides further confidence for the potential of the present chitosan-based 
material also for cartilage regeneration (56). 
 
 
Figure 8. H&E histological sections of Ch-PBS 50-50 (a and b) and PBS 100 (d and e) 
implants in auricular area. Masson trichrome stained sections of Ch-PBS 50-50 (c) and PBS 
100 (f) implants in the same region, showing collagen in green. Ep-Epidermis; De-Dermis; 
Ca-Cartilage; G-Giant cell; TN- Tissue necrosis; Ch-Chitosan; PBS-Poly(butylene succinate). 
 
iii) Iliac submuscular implantation 
 In the submuscular region the scaffold was connected with bone at the bottom, and 
with periosteum-muscle at the top surface. In general, this implantation site showed more 
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inflammatory cells, namely neutrophils (Figure 9). This result may be due to the fact that this 
particular region has higher tissue vascularization, as well as higher tissue stresses caused 
by locomotion. Ch-PBS scaffolds evidenced robust infiltration by the host cells (Figures 9a 
and 9b), compared to PBS scaffolds that showed also in this implantation site some cell 
necrosis inside the implant (Figures 9d and 9f). Residual neutrophils were present in Ch-PBS 
scaffold implants (Figure 9b) caused by the presence of chitosan that is known to be 
attractive to neutrophils upon implantation (12, 57). It was also visible more collagen in 
chitosan based scaffolds (Figure 9c) in comparison with the PBS ones, where only residual 
collagen is observed (Figure 9f). 
 
Figure 9. H&E histological sections of Ch-PBS 50-50 (a and b) and PBS 100 (d and e) 
implants in submuscular zone. Masson trichrome stained sections of Ch-PBS 50-50 (c) and 
PBS 100 (f) implants in the same location, showing collagen in green. G-Giant cell; TN- 
Tissue necrosis; Ch-Chitosan; PBS-Poly(butylene succinate). 
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4. CONCLUSIONS 
 Different chitosan and poly(butylene succinate) formulations were used to produce 
scaffolds by compression molding followed by salt leaching. The aim was to study the 
influence of chitosan over the viability, adhesion and osteogenic differentiation of hMSCs and 
in vivo tissue biocompatibility. Chitosan based scaffolds evidenced superior results in terms 
of in vitro cell performance, with PBS 100 scaffolds showing consistently inferior results. 
 Overall, a higher content of chitosan induce a stronger cellular performance in terms 
of cell adhesion, proliferation and differentiation, when using the produced scaffolds for the 
strategy presented in this work. 
 For all types of scaffolds tested in vivo, the tissue response was lower in calvaria and 
in auricular implantations when compared to the submuscular region. Chitosan based 
scaffolds evidenced more cell penetration, without any signs of cell necrosis. Furthermore, 
many blood vessels were observed in the immediacy of the scaffolds. A chronic inflammatory 
response without fibrosis was developed. Therefore, it is concluded that chitosan exerts a 
strongly positive effect over the cell performance in vitro as well as in vivo. Thus, the 
developed chitosan based scaffolds are strong candidates to be used in the bone tissue 
engineering field. 
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CHAPTER V 
Osteogenic Differentiation of Human Bone Marrow Mesenchymal Stem Cells Seeded 
on Melt based Chitosan scaffolds for Bone Tissue Engineering Applications 
 
ABSTRACT 
 The purpose of this study was to evaluate the growth patterns and osteogenic 
differentiation of human bone marrow mesenchymal stem cells (hBMSCs) when seeded onto 
new biodegradable chitosan/polyester scaffolds. 
 Scaffolds were obtained by melt blending chitosan with poly(butylene succinate) in a 
proportion of 50% (wt) each, and further used to produce a fiber mesh scaffold. hBMSCs 
were seeded on those structures and cultured for 3 weeks under osteogenic conditions. Cells 
were able to reduce MTS and demonstrated increasing metabolic rates over time. SEM 
observations showed cell colonization at the surface as well as within the scaffolds. The 
presence of mineralized extracellular matrix (ECM) was successfully demonstrated by peaks 
corresponding to calcium and phosphorous elements detected in the EDS analysis. A further 
confirmation was obtained when carbonate and phosphate group peaks were identified in 
Fourier Transformed Infrared (FTIR) spectra. Moreover, by Reverse transcriptase (RT)-PCR 
analysis it was observed the expression of osteogenic gene markers, namely Runt related 
transcription factor 2 (Runx2), type 1 collagen, bone sialoprotein (BSP) and osteocalcin. 
 Chitosan-PBS (Ch-PBS) biodegradable scaffolds support the proliferation and 
osteogenic differentiation of hBMSCs cultured at their surface in vitro, enabling future in vivo 
testing for the development of bone tissue engineering therapies.  
 
1.INTRODUCTION 
Mesenchymal Stem Cells (MSCs) isolated from bone marrow stroma have the 
capacity to differentiate into cells of connective tissues, namely into osteoblasts, 
chondrocytes and adipocytes (1-4). However, recent studies (5), indicate that they may have 
a much broader differentiation potential. Accordingly, the multipotential capacity of MSCs, 
their accessible origin, high ex vivo expansive potential, and ethical acceptance, make these 
cells attractive tools for tissue engineering and cell-based therapies.  
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Annually, more than 2.2 million bone grafting procedures (autologous bone graft and 
banked bone) are performed worldwide to ensure adequate bone healing in many skeletal 
problems, such as nonunion fractures, cervical and lumbar spine fusion, joint arthrodesis, 
revision arthroplasty (6). Unfortunately, the gold standard of bone grafting (autologous bone) 
requires an extra surgery to retrieve it from the patient. This leads to an increase in surgical 
and recovery times. Potential complications, such as chronic pain at the donor site, 
infections, and eventual disability (7) can occur. Tissue engineering offers a strategy to 
circumvent those problems. The concept involves the use of a porous and biodegradable 
scaffold, allowing cells to adhere and proliferate, creating conditions for the formation of 
ECM-like structures (8-10). Previous studies have shown that natural based polymers such 
as starch (11-18) or chitosan (19-28) have great potential for bone tissue engineering 
applications. The main advantages of these materials include low immunogenic potential, 
bioactive behavior, good interaction with host tissues, chemical versatility and high 
availability in nature (7).  
Chitosan has already shown a range of properties, including its non-antigenicity (24) 
and cytocompatibility (21, 29), that suggest having adequate properties for  bone tissue 
engineering applications. However the material offers limited versatility in its processability. 
To overcome this problem, we propose a novel methodology to process chitosan by 
compounding this material with biodegradable aliphatic polyesters (26). The blend combines 
the favorable biological properties of chitosan with the good mechanical properties and 
processability of polyesters (26, 28, 30-33), leading to a chitosan based material with 
adjustable properties for tissue engineering applications (30-32).  
The purpose of the present work is to evaluate the performance of the developed 
microfiber mesh scaffolds. For that, we assess the cell adhesion, proliferation and osteogenic 
differentiation of human MSCs isolated from bone marrow and seeded onto novel 
chitosan/polyester micro fiber mesh scaffolds aimed to be used in bone tissue engineering 
field. 
 
2. MATERIALS AND METHODS 
2.1. Scaffold processing 
New chitosan based scaffolds were, developed by a fiber bonding technique. The 
processing methodology is entirely melt based, thus avoiding the limitations of solvent-based 
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processing, and it is described in detail elsewhere (26). Briefly, chitosan was melt blended 
with polybutylene succinate (PBS) (50/50 wt%) in a twin-screw extruder. The extrudate was 
grinded into powder and further processed into microfibers, using a microextruder. The 
diameter of the fibers was controlled by the diameter of the die. After that, Ch-PBS fibers 
were cut and submitted to hot compression. This last step (15) consisted in applying 
temperature and pressure to obtain a fiber mesh scaffold with inherent porosity and 
interconnectivity. The scaffolds were sterilized by ethylene oxide and used for cell culture 
studies.  
 
2.2. Scaffolds characterization 
Chitosan-based fiber mesh scaffolds were analysed using a high-resolution micro-
computed tomography Skyscan 1072 scanner (Skyscan, Kontich, Belgium). Five scaffolds 
were scanned in high resolution mode using a pixel size of 8.24 μm and integration time of 
2.0 ms. The X-ray source was set at 80 keV of energy and 124 μA of current. For all the 
scanned specimens representative data sets of 150 slices were transformed into binary 
using a dynamic threshold of 60-255 (grey values) to distinguish polymer material from pore 
voids. This data was used for morphometric analysis (CT Analyser v1.5.1.5, SkyScan). The 
morphometric analysis included porosity, scaffolds interconnectivity and mean pore size 
quantification. Three dimensional (3D) virtual models of representative regions in the bulk of 
the scaffolds were also created, visualized and registered using the image processing 
software (ANT 3D creator v2.4, SkyScan).  
The mechanical properties of the scaffolds were tested on compression tests carried 
out in a universal tensile testing machine (Instron 4505, Universal Machine). A crosshead 
speed of 5 mm/min was used and the compression modulus was determined from the most 
linear region of the stress-strain curve and averaged from the results obtained with five 
specimens.  
 
2.3. Cell culture studies 
2.3.1. In vitro cytotoxicity tests 
 A rat lung fibroblast cell line (L929), acquired from the european collection of cell 
cultures (ECACC), was used for the initial standard cytotoxicity assays. Tests were carried 
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out following the international standard ISO 10993. The procedure and methods are 
described elsewhere (27).  
 
2.3.2. hBMSCs seeding and culture onto the scaffolds 
Primary cultures of hBMSCs were used. The cells were characterized by flow 
cytometry for MSCs markers (CD31, CD34, CD45-negative and CD13, CD29, CD73, CD90, 
CD105, CD166-positive cells) and differentiation studies into osteogenic, chondrogenic and 
adipogenic lineage (34). The cells were grown in a culture medium consisting of alpha 
medium (Sigma, St. Louis, MO), 10% fetal bovine serum (Biochrom AG, Germany), 5 mM L-
glutamine (Sigma, St. Louis, MO), 1 ng/ml basic fibroblast growth factor (bFgF) (PeproTech, 
USA) and 1% of antibiotic-antimycotic mixture (Sigma, St. Louis, MO).  When an adequate 
cell number was obtained, cells at passage 2 were detached with trypsin/EDTA. Cells were 
seeded at a density of 2.5x105 cells/scaffold under static conditions, by means of a cell 
suspension. After 24 hours of attachment, constructs were placed in new 24-well plates and 
1 ml of osteogenic medium was added to each well. The osteogenic culture medium 
consisted of DMEM without phenol red, dexamethasone 10-8 M (Sigma, St. Louis, MO), 
ascorbic acid 50 μg/ml (Sigma, St. Louis, MO) and ß-glycerophosphate 10 mM (Sigma, St. 
Louis, MO). The constructs were cultured for periods of up to 7, 14 and 21 days in a 
humidified atmosphere at 37ºC, containing 5% CO2. The culture medium was changed every 
2 to 3 days until the end of the experiment. 
 
2.3.3. Cellular viability assay - MTS test 
Cell viability was assessed after 3 hours, 7, 14 and 21 days, using the MTS test. The 
constructs (n=3) were rinsed 3 times in phosphate buffered saline (Sigma, St. Louis, MO), 
and immersed in a mixture consisting of serum-free cell culture medium and MTS reagent in 
a 5:1 ratio and incubated for 3 hours at 37ºC in a humidified atmosphere containing 5% CO2. 
After this, 200 µl (n=3) were transferred to 96 well plates and the optical density (O.D.) was 
measured on a microplate ELISA reader (BioTek, USA) using an absorbance of 490 nm.  
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2.3.4. Cell adhesion and cell viability stained with calcein-AM using confocal laser 
microscopy  
Cells were incubated with calcein AM (Molecular Probes, Invitrogen, USA). Inside the 
cells, calcein-AM is hydrolyzed by endogenous esterases into the highly negatively charged 
green fluorescent calcein, which is retained inside the cytoplasm. The constructs were 
sectioned and cell adhesion, proliferation and viability were observed in the inner regions of 
the scaffolds using an Olympus FluoView FV1000 confocal laser scanning microscope. 
 
2.3.5. Cell adhesion and morphology by scanning electron microscopy (SEM) 
Cell adhesion, morphology, and spatial distribution were observed by SEM. The 
constructs were washed in 0.15 M phosphate buffered saline and fixed in 2.5% 
glutaraldehyde. After that, the constructs were dehydrated using a graded series of ethanol 
(30, 50, 70, 90, 100%) for 15 minutes, twice. Then, the samples were immersed in 
hexamethyldisilazane (35) (HDMS; Electron Microscopy Sciences, Washington, USA), and 
let to air dry for 2 h. Afterwards, the constructs were sputter coated with gold (JEOL JFC-
1100) and analyzed using a Leica Cambridge S360 scanning electron microscope. 
 
2.3.6. Cell proliferation by DNA quantification 
hBMSCs proliferation on the Ch-PBS scaffolds was determined using a fluorimetric 
dsDNA quantification kit (PicoGreen, Molecular Probes, Invitrogen, USA). Samples collected 
at days 7, 14 and 21, were washed twice with a sterile phosphate buffered saline solution 
and transferred into 1.5 ml microtubes containing 1ml of ultra-pure water. Constructs were 
cryopreserved at -80ºC for further analysis. Prior to DNA quantification, samples were 
thawed and sonicated for 15 min. Standards were prepared with concentrations ranging 
between 0 and 2 mg/ml. Per each well of an opaque 96-well plate were added 28.7 µl of 
sample (n=3) or standard, 71.3 µl of PicoGreen solution, and 100 µl of Tris–EDTA buffer. The 
plate was incubated for 10 minutes in the dark and fluorescence was measured using an 
excitation wavelength of 480 nm and an emission wavelength of 528 nm. 
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2.3.7. Alkaline phosphatase quantification 
 Samples were collected as previously described. Alkaline phosphatase (ALP) activity 
of the scaffolds/cells constructs (n=3) was measured by the specific conversion of p-
nitrophenyl phosphate (pNpp) (Sigma, St. Louis, MO, USA) into p-nitrophenol (pNp). The 
constructs were thawed at room temperature and sonicated for 15 min. The enzymatic 
reaction was set up by mixing 100 ml of the sample with 300 ml of substrate buffer containing 
1 M diethanolamine HCl (pH 9.8) and 2 mg/ml of pNpp. The solution was further incubated at 
37ºC for 1 hour and the reaction was stopped by the addition of a solution containing 2 M 
NaOH and 0.2 mM EDTA in distilled water. The O.D. was determined at 405 nm. A standard 
curve was made using pNp values ranging from 0 to 20 μmol/ml. The results were 
normalized by DNA values and expressed in μmol of pNp produced/μg ds DNA. A detailed 
description of the assay can be found elsewhere (36). 
 
2.3.8. Mineralization content by energy dispersive spectroscopy (EDS) 
 The constructs were processed as described previously for SEM. The samples (n=3) 
were sputter coated with carbon (JEOL JFC-1100) with the purpose of analyzing the 
presence of Ca and P elements at the surface by EDS with a Leica Cambridge S360 
scanning electron microscope. Sputter coating with carbon avoids overlapping of signals of 
the coating with the elements being analyzed. 
 
2.3.9. Mineralization crystallinity by fourier transform infra-red spectroscopy (FTIR) 
 The constructs were washed in phosphate buffered saline and fixed in 2.5% 
glutaraldehyde. The samples were pressed into pellets with potassium bromide (KBr; Riedel-
de Haen, Germany). The IR spectrum was measured using a FTIR Spectrometer (model 
IRPrestige-21, Shimadzu; Germany) in the wavelength range of 4000–400 cm−1. 
 
2.3.10. Osteogenic differentiation by reverse transcriptase PCR 
 Total RNA was isolated from cells with Trizol (Sigma, St Louis, USA), according to the 
manufacturer protocol. A NanoDrop Microspectrophotometer (NanoDrop ND-1000 
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Spectrophotometer, Alfagene, USA) was used to measure the total RNA amounts (ng/µl). 
Aliquots of the total RNA (100 ng/μl) were transcripted into cDNA and amplified in each PCR 
in one step RT-PCR beads (Amersham Biosciences) and gene specific primers were added. 
Each cDNA sample was run in triplicate for every PCR. Amplification was performed using a 
Mastercycler gradient (MyCycler™, Thermal Cycler, Biorad). The first reverse transcription 
step at 42ºC for 30 min was followed by a step of denaturation at 95ºC during 5 min. After 
this, 35 cycles of PCR were performed, each consisting of a denaturation stage at 95ºC for 1 
min, annealing at a given temperature accordingly with the specific primer used, and then an 
extension stage at 72ºC for 2 min. In all cases, a final extension at 72ºC for 5 min was 
performed before storing the samples at 4ºC. Specific primers used were: for human Runx2, 
osteocalcin, type 1 collagen, BSP and for the house keeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH).  PCR products were separated by 1% agarose (Biorad, 
USA) at least twice. The separated DNA fragments were visualized by ethidium bromide 
(Sigma, St Louis, MO) staining and observed with an Eagleye software (Alpha Innotech, 
USA) using excitation at 514 nm and emission at 610 nm.  
 
2.3.11. Statistical analysis 
 Results of MTS and ALP are expressed as mean ± standard deviation with n=3 for 
each group. Statistical significance of differences was determined using Studentʼs t-test 
multiple comparison procedure at a confidence interval of 95% (p < 0.05). 
 
3. RESULTS  
3.1. Scaffolds characterization 
Porous chitosan based fiber mesh scaffolds used in this study were produced with a 
blend of 50% chitosan and 50% of poly(butylene succinate). The scaffolds were prepared 
using melt extrusion, followed by hot compression (fiber bonding).  Scaffolds were cut into 
cylinders of approximately 6.5 mm diameter and thickness of 1.5 mm. Figure 1 shows the top 
surface of the novel chitosan based fiber mesh scaffold produced by the described melt 
based process. Scaffolds show a large porosity and inherent interconnectivity, as well as an 
irregular distribution of the fiber orientation as intended. 
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Figure 1. Three-dimensional (3D) images obtained by µ-CT reconstruction model (a) and 
SEM photomicrograph of Ch-PBS (50% wt) fiber mesh scaffold (b).  
 
The µCT technology allows obtaining series of X-ray slice images covering a 
representative volume region of the porous scaffold. The solid volume representation and the 
quantitative data is obtained following image processing using specific software and the X-
rays micrographs obtained in each slice. This technique was used to obtain 3D images of the 
novel chitosan fiber mesh scaffolds (Figure 1a) and to quantitatively determine the average 
porosity (44.8% ± 2.1) and the interconnectivity of 89.6% ± 1.9. Compression mechanical 
tests have shown that scaffolds have a compression modulus of 32.6 ± 12.8 MPa, which is 
within the range of interest for bone applications (37).  
The fibers used to produce these scaffolds have an average diameter of 450 µm and 
as can be seen in Figure 1b, evidence an interesting surface roughness that may contribute 
to enhance the cell adhesion by increasing the surface area. Moreover, detailed observations 
using µCT equipment show that microfibers in addition to the surface roughness also 
possess some microporosity at the surface that further enhances the surface area (Figure 
1a).  
 
3.2. In vitro cytotoxicity tests 
 In the MTS test (data not shown), L929 fibroblasts metabolized MTS into brown 
formazan product after incubation with the scaffoldʼs extract. This fact evidences that the 
cells have metabolic activities (around 80%) similar to those obtained by cells grown in 
DMEM (negative control). Moreover, they were able to incorporate and metabolize MTS, 
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showing very high viability. Therefore, the leachables released from the tested scaffolds can 
be considered as non-cytotoxic. 
 
3.3. Cell viability by MTS and Calcein-AM staining 
Results showed that the tested hBMSCs were also able to reduce MTS (Figure 2), 
demonstrate high metabolic rates as a function of time, and denote a high viability and 
proliferation profile. Moreover, a cell viability assay with calcein-AM staining (Figure 3) 
demonstrated that hBMSCs were metabolically active and well distributed throughout the 
scaffold surfaces after 3 weeks. 
 
 
Figure 2. MTS viability assay of constructs and cultured Ch-PBS scaffolds following 3 hours 
(0 days), 7, 14 and 21 days, after cell seeding. Results are expressed as means ± standard 
deviation with n=3 for each bar, (*) indicate a significant difference (p < 0.05) between testing 
conditions as a function of time.  
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Figure 3. Cell viability after three weeks of cell-culture in the scaffolds analyzed by calcein-
AM staining. Confocal micrograph showing cell adhesion and viability on the Ch-PBS fiber 
mesh scaffolds after 3 weeks in culture. 
 
3.4. Cell adhesion and morphology by SEM 
After 1 week, hBMSCs cultured under osteogenic conditions, were able to adhere to 
the fibrous surface and inner pores of the scaffolds and to proliferate during the subsequent 
periods in culture (Figures 4A, 4D and 4G). The production of ECM can be analyzed in more 
depth at higher magnifications (Figures 4C, 4F and 4I). Furthermore, it is observed that the 
cells were able to create “bridges” between neighboring fibers, but without occluding the 
pores (Figures 4B and 4E). Cells were also capable of colonizing the inner regions of the 
scaffolds, keeping the viability on those inner pores (Figures 4J, 4K and 4L).  
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Figure 4. SEM micrographs of the adhesion and proliferation of hBMSCs, under osteogenic 
induction, on the 50 % wt Ch-PBS fiber mesh scaffolds at the surface after 1 week (Figures 
A, B, C), 2 weeks (Figures D, E, F) and 3 weeks (Figures G, H, I). The micrographs J, K and 
L correspond to cross sections of the cell seeded scaffolds after 3 weeks, showing the bulk 
colonization by the cells. 
 
3.5. Alkaline phosphatase quantification 
The expression of ALP is typically used as an early marker of the osteogenic 
phenotype. The ALP expression shows the typical pattern of expression (Figure 5), 
increasing until the second week, where it reached its maximum. This observation reflects 
the early osteogenic differentiation stage of the MSCs. After this period, ALP activity 
decreased, probably due to the onset of the mineralization process (36). This observation is a 
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positive indication of the transient character of the differentiation of cells into the osteogenic 
lineage.  
 
Figure 5. Alkaline phosphatase activity of hBMSCs cultured on the scaffolds at time points, 
1, 2 and 3 weeks, under osteogenic induction. The results are normalized by µg of dsDNA, 
and presented in amount of p-nitrophenol (µmol/ml/h/µg dsDNA). Results are expressed as 
average ± standard deviation with n=3 for each bar, (*) indicates a significant difference 
(p<0.05) between conditions as a function of time.   
 
3.6. Mineralization content of ECM by EDS and FTIR analysis 
EDS analysis of the surface of constructs detected the presence of Ca and P 
elements (Figure 6 A). Acellular scaffolds (control) do not show any presence of those two 
elements during the same period of immersion in osteogenic inducing culture medium. These 
results clearly indicate the formation of mineralized ECM at the surface of cell seeded 
scaffolds. These results were further confirmed by FTIR analysis (Figure 6C), showing the 
presence of phosphate and carbonate groups, which are typical for carbonated apatite (38). 
 
Figure 6. EDS spectra of the acellular scaffolds (A), 3 weeks in culture of hBMSCs  on Ch-
PBS scaffolds (B), and FTIR spectra of the control and constructs (C) (*CO32- , + # PO43-). 
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3.7. Osteogenic differentiation of hMSCs upon chitosan based scaffolds 
To further analyze the differentiation towards the osteogenic phenotype, the RNA of 
the cell cultured in the scaffolds is analysed by reverse transcriptase PCR (Figure7).  
 
 
Figure 7. PCR analysis of the genes that encode for the transcription factor Runx2, the  bone 
ECM protein osteocalcin, type I collagen, bone sialoprotein (BSP) and the house keeping 
gene GAPDH on hBMSCs grown under osteogenic conditions on Ch-PBS fiber mesh 
scaffolds for 21 days. 
PCR analysis show the expression of specific genes related to the osteogenic 
lineage, namely the transcription factor Runx2, considered to be a crucial transcription gene 
within the osteogenic phenotype (39, 40). Its expression was detected at all time points, 
being more pronounced at the third week of culture. The gene expression patterns of the 
various extracellular proteins, including osteocalcin, type 1 collagen and BSP, was detected 
at all time points and in increased levels at the latest time point. This indicates a successful 
differentiation into the osteogenic phenotype. 
 
4. DISCUSSION 
The demand for new therapies for diseases affecting musculoskeletal tissues is 
continuously increasing, especially considering the high number of patients suffering from 
skeletal degenerative diseases. Bone tissue engineering has been proposing solutions to 
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address those clinical problems. The strategy could combine cells with a 3D scaffold and 
growth factors, seeking to achieve the regeneration of bone tissue. 
Natural-based polymers such as chitosan, a polymer produced by partial 
deacetylation of chitin, have been proposed as having potential for tissue engineering 
applications. Chitosan is characterized by its good biocompatibility, low immunogeneicity, 
non-cytotoxicity and wound healing capability. These properties make chitosan a strong 
candidate material for bone tissue engineering applications. Due to its limited mechanical 
properties and process ability, scaffolds produced only with chitosan are more difficult to 
optimize for hard tissue applications. An alternative methodology to overcome those 
limitations consists in blending chitosan with synthetic and biodegradable aliphatic polyesters 
(26, 33). Thermoplastic biodegradable polymers have already shown great potential in the 
clinic as implantable biomaterials due to their reported non-cytotoxicity and biodegradability. 
Their degradation products are also non-cytotoxic, although they lack the cell recognition 
affinity typically provided by natural polymers. Thus by blending chitosan with synthetic 
polyesters it is possible to obtain a good balance between biological affinity (30-32) and 
processability, not compromising the biodegradability. 
The developed fibrous scaffolds showed a significant interconnectivity (Figure 1), 
which is known to be a critical condition for successful cell colonization and viability. Extracts 
from the developed scaffolds are non-cytotoxic in contact with L929 cells (data not presented 
herein).  
Human MSCs showed high metabolic levels when adhered onto the scaffolds both by 
the reduction of the MTS substrate (Figure 2) and also by the calcein-am staining (Figure 3).  
SEM micrographs (Figure 4) show that hBMSCs adhered at the surface of the 
scaffolds and were able to “bridge” between fibers without occluding the pores (Figure 4C). 
The proliferation of hBMSCs and the production of ECM showed increased levels over time 
(Figures 4A, 4D and 4G). SEM observations and cell viability results can help to establish a 
time dependent cell proliferation patterns as showing the presence of higher number of cells 
at late time periods. It was also observed that cells proliferated and colonized the inner 
regions (Figures 4J, 4K and 4L) of the scaffolds, which demonstrate that porosity and 
interconnectivity exhibited by the scaffolds are adequate for cell infiltration and ingrowth. 
ALP activity measurements (Figure 5) showed a maximum at the second week of 
culture, reflecting the early osteogenic differentiation stage of hMSCs (36). After this period, 
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ALP activity decreased due to the onset of the mineralization process, which is a typical 
positive indication.  
hBMSCs were able to produce mineralized ECM confirmed by the presence of Ca 
and P elements (Figure 6a). Furthermore, the existence of characteristic peaks of carbonate 
and phosphate groups in FTIR spectra (Figure 6C) indicates the presence of carbonated 
apatite at the surface of constructs. 
The differentiation of the hBMSCs towards the osteogenic lineage was ultimately 
demonstrated by the expression of genes that are usually associated with the mineralization 
during osteogenesis, such as the transcription factor Runx2, and the matrix proteins 
osteocalcin, type 1 collagen and BSP (Figure 7). Runx2 is essential for the differentiation of 
MSCs into mature osteoblasts in the skeletal development of numerous mammalian 
organisms (39, 40). Osteocalcin, one of the few osteogenic specific genes, is a bone matrix 
protein and it is known to play an important role in the differentiation of osteoblast progenitor 
cells, with significant up-regulation observed both in matrix synthesis and in the 
mineralization process (39). BSP is secreted, bind cell surface integrin receptors, and 
regulate mineralization and type I collagen represents the majority of the organic part of bone 
matrix (41).  
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5. CONCLUSIONS 
 Chitosan–poly(butylene succinate) fiber mesh scaffolds were successfully produced 
by a melt based routine, avoiding the use of solvents. The scaffolds presented a high degree 
of interconnectivity (89,6% ± 1.9) and adequate mechanical properties (32.6 ± 12.8 MPa) for 
bone tissue engineering applications. 
 It was demonstrated that chitosan-PBS scaffolds are cytocompatible, both with L929 
cells and hBMSCs. The scaffolds support hBMSCs adhesion and proliferation under 
osteogenic inducing conditions. The cells presented high levels of viability, demonstrating 
that besides the remarkable colonization of the scaffold structure, the cells were 
metabolically active.  
 ALP expression a mineralized ECM is detected by the presence of Ca and P 
elements in EDS spectra, and also confirmed by FTIR. The expression of osteogenic related 
genes (Runx2, osteocalcin, type 1 collagen and bone sialoprotein) show successful 
differentiation of the cells in the scaffolds towards an osteogenic phenotype. 
 Due to the extremely well balanced combination of properties and excellent biological 
performance, it is strongly believed that the scaffolds herein proposed in combination with 
human adult mesenchymal stem cells will provide new therapies for the development of 
tissue engineering solutions for bone regeneration. 
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CHAPTER VI 
In vitro degradation and biocompatibility assessment of chitosan-
poly(butylene succinate) fiber mesh scaffolds 
 
ABSTRACT 
 In a tissue engineering approach it is important to determine the kinetics of the 
biodegradation of biomaterials in vitro, as well as in vivo. Furthermore, the evaluation of a 
host response to the implantation of the biomaterials must be performed to understand the 
extent of the inflammatory reaction. 
 Chitosan-poly(butylene succinate) fiber mesh scaffolds, in previous studies evidenced 
enhanced biological performance, not only in terms of cell adhesion and proliferation, but 
also as supporting the osteogenic differentiation of mouse and human MSCs. The following 
step consisted on the study of the degradation process in vitro using relevant enzymes, 
lipase and lysozyme, responsible for the degradation of the poly(butylene succinate) and 
chitosan, respectively. Moreover, subcutaneous implantation of the scaffolds was performed 
to assess the tissue response. Histology and immunoshistochemistry were used to visualize 
the type of inflammatory cells present in the surrounding tissue, as well as within the 
scaffold.. 
 In the presence of lipase, or with lysozyme, water uptake of the scaffolds increased. 
This phenomenon is probably due to the degradation of scaffolds by the enzymes. Weight 
loss results and scanning electron micsoscopy (SEM) analysis evidenced that lysozyme 
combined with lipase have a notable effect on the degradation of the scaffolds in vitro. 
 In vivo implantation showed a normal inflammatory response with the typical 
presence of neutrophils in a first stage and macrophages, lymphocytes and giant cells in a 
later stage. Vascularization was observed, increasing with time, by the presence of blood 
vessels in the surrounding tissue and within the implant. Moreover, collagen deposition, 
vizualized by Masson trichrome stain, increased over time inside of the implant. During the 
entire in vivo experiment the scaffolds maintained the structural integrity, although after 12 
weeks it was possible to observe cell colonization inside the fibrous structure. In vitro results 
showed a faster and greater degradation compared to those observed in vivo. 
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1. INTRODUCTION 
 Many biodegradable polymers have been proposed to produce scaffolds in Tissue 
Engineering field. These structures sustain the extracellular matrix (ECM) production by cells 
and at the same time, it is expected to degrade gradually to allow the surrounding tissue to 
replace the supporting function of the scaffold (1).  
 Biodegradable polymers are able to act as a a temporary substrate that will degrade 
over time, in a controlled way into products, which will be eliminated by regular metabolic 
pathways in the body (biodegradation) (2). Furthermore, the biological performance of some 
biomaterials depends on their degradation behavior, since this process influences cell 
performance and inflammatory response. Therefore, it is crucial to study the degradation 
properties of the scaffold for a long term success of the tissue engineered construct (3). 
 In the last years, natural biodegradable polymers have been used to produce 
scaffolds for tissue engineering. Due to their resemblance with the ECM, natural polymers 
may avoid the stimulation of chronic inflammation or toxicity, generally found out for synthetic 
polymers (4). Chitosan, the partially deacetylated product of chitin, has emerged as one of 
the favorites, mainly because of the similarity to glycosaminoglycans (GAGs), native 
components of ECM (5). Additionally, the cationic nature of chitosan allows electrostatic 
interactions with anionic GAGs and proteoglycans (6). 
 In our group, we have been working with chitosan based scaffolds (7-15). One of the 
most promising biomaterials is the chitosan-poly(butylene succinate) processed into 
scaffolds by melt based technology (16-18). These scaffolds combine the biological 
properties of chitosan and the mechanical properties of aliphatic polyesters (17, 18). In vitro 
studies performed with different cell types showed a remarkable cell colonization of these 
scaffolds (10, 13, 14, 19). Chitosan has been proposed as a biomaterial for biomedical 
applications mainly due to its biocompatibility (20). Furthermore, it has been described as a 
potent wound healing accelerator (21-26), as well as to modulate the immune system by 
activating macrophages (27) to produce cytokines (28) and to inhibit infection (29).  
 Poly(butylene succinate) is a biodegradable synthetic polymer with good 
processability when compared to poly(lactic acid) or poly(glycolic acid) (30). Moreover, it 
shows good mechanical properties for bone tissue engineering, comparable to those of poly-
caprolactone (31). The degradation profile of poly(butylene succinate) in the environment has 
been widely studied (32-34). Succinic acid is the main degradation product, which is an 
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intermediate of the tricarboxilic acid cycle, that ultimately degrades into carbon dioxide and 
water (32, 34).  
 Some biomaterials are degraded by hydrolysis, a non-enzymatic degradation, whose 
materials are mainly decomposed by contact with water or serum, being this process non 
specifically regulated (35). Biodegradation of polymeric biomaterials requires cleavage of 
hydrolytically and/or enzymatically sensitive bonds in the polymer, leading to polymer erosion 
(36). Degradation products should be non-toxic and free of immunogenicity. The resulting 
products should be small enough to dissolve in the body fluids and, after transportation via 
lymphatic system, the kidneys should be able to excrete them from the body (37). The 
degradation behavior of polymers can be tested previously in vitro, in order to predict their 
behavior when implanted in vivo. Usually, biomaterials are incubated in phosphate buffered 
solution, with or without enzymes, at 37ºC, under static and/or dynamic conditions to better 
simulate the in vivo conditions. It is common that degradation studies are performed in 
parallel with biocompatibility tests, both in vitro and in vivo. This close relation is due to the 
fact that the degradation of a biomaterial implanted in a host is influenced by the presence 
and recruitment of inflammatory cells and, consequently, by the production of inflammatory 
mediators.  
 In vivo, chitosan was shown to be degraded mainly by lysozyme (38-40). The 
degradation kinetics of chitosan is inversely related to the degree of deacetylation (39, 41), 
since this enzyme targets the acetylated residues of chitosan polymer (38, 40). Human 
lysozyme is found in several body fluids, including serum (42, 43), tears (42, 43), saliva (42, 
43) and other fluids, like those surrounding cartilage (44). It is also important to highlight the 
fact that during inflammation process, neutrophils and macrophages cells will release 
enzymes, namely lysozyme and reactive oxygen species (45). On the other hand, PBS is an 
aliphatic polyester and these polymers are known to be degraded by lipases (46). This 
enzyme is water soluble, hydrolyzing ester bonds of triglycerides, phospholipids and 
cholesteryl esters (47, 48). Human lipases include pre-duodenal lingual, gastric, extra-
duodenal pancreatic, hepatic, lipoprotein and endothelial lipases (49). Serum lipase is mainly 
derived from pancreatic cells, but tissues such as digestive track, adipose tissue, lungs and 
leucocytes also contain lipase (50, 51). 
 One of the most important requisites for clinical application of a biomaterial is its 
biocompatibility, that is defined as the ability of a material to perform, with an appropriate 
host response, in a specific application (52). The implantation of a biomaterial device sets off 
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a cascade of events that starts with an acute inflammatory response that may lead to a 
chronic inflammatory response. Polymorphonucleated cells (PMNs), macrophages and new 
blood vessels are present and granulation tissue can be developed, with subsequent foreign 
body reaction and fibrous capsule development (53). The inflammation process serves to 
contain, neutralize or dilute the injurious agent or process. Thus, the intensity and the 
duration of the inflammatory reaction may characterize the biocompatibility of a biomaterial 
(54). In the case of biodegradable polymers, the intensity of these responses may be 
modulated by the biodegradation process that can cause changes in shape, size, surface 
roughness, porosity and release of degradation products (54). Generally, the local reaction of 
an implant is studied after a 3 months implantation period, as described in the ISO standard 
10993-6 (55). This time frame usually reflects a steady state, where the local 
acceptance/rejection can be evaluated.  
 In this work we studied the biodegradation process, as well as the biocompatibility of 
chitosan-poly(butylene succinate) fiber mesh scaffolds. The tests in vitro involved enzymes 
responsible for the degradation of chitosan and PBS, lysozyme and/or lipase, respectively. 
The in vitro degradation studies were carried out using the enzymes in concentrations similar 
to those present in the human blood serum. In vivo studies were performed with the main 
aims of studying the biodegradation and the biocompatibility of these scaffolds, using a 
subcutaneous model in Wistar rats during 3 months of implantation. 
 
2. MATERIALS AND METHODS 
2.1. Scaffolds production 
 The processing methodology is described in previous works from our group (19). 
Briefly, chitosan was melt blended with polybutylene succinate by extrusion (50% wt). The 
resulting extrudate was grinded into powder and processed into microfibers also by 
extrusion. The fibers were cut and submitted to hot compression. In this study the scaffolds 
dimensions were 6.5 mm diameter and 1 mm. The scaffolds were sterilized by ethylene oxide 
to be further used in subsequent tests. 
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2.2. In vitro degradation studies 
 Degradation studies were performed in triplicate by incubating the scaffolds in 
phosphate-buffered saline solution (pH 7.4) (control), with lipase from aspergillus oryzal 
(Fluka) (110 U/L) and/or lysozyme chicken egg white (Sigma) (13 mg/L). The concentrations 
used were similar those found in human blood serum, at 37ºC in dynamic conditions (60 rpm) 
for 1, 3, 6 and 12 weeks. At the end of each degradation period, the samples were removed 
and immediately weighed to determine the water uptake and dried for later calculation of the 
weight loss.  
 
2.2.1. Water uptake and weight loss measurements 
 All samples were weighed before incubation in phosphate buffered saline or 
enzymatic solutions (initial weight). After 1, 3, 6 and 12 weeks, three samples of each 
condition were removed and immediately weighed for determination of water uptake 
(Equation 1), washed thoroughly with distilled water and dried for later calculation of weight 
loss (Equation 2),  
 
Water uptake (%) = [(ww – wi)/ wi] x 100  (Equation 1) 
 
Weight loss (%) = [wi – wf)/ wi] x 100  (Equation 2) 
 
where wi is the initial weight,  ww is the wet weight and wf  is the final weight of the sample. 
 
2.2.2. Analysis of sample morphology by scanning electron microscopy 
 The samples morphology, before and after degradation with the different solutions 
was analyzed by scanning electron microscopy (NanoSEM, FEI company, USA). 
 
2.3. In vivo degradation studies 
 One day before subcutaneous implantation surgery the implants were immersed in 
phosphate buffered saline solution under sterile conditions. Twelve adult male Wistar Han 
rats (41-44 days old at the beginning of the experiment), Specified Pathogen Free, were 
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purchased from Charles River Laboratories, France. The animals were kept one week in a 
quarantine room and transferred to a conventional maintenance room of the experimental 
unit of the animal facility, where they were housed for the all period of the experiment. 
 For the present study, 12 animals were used for subcutaneous implantation of 
acellular scaffolds. At 1, 3, 6 and 12 weeks, samples were retrieved for further analysis. 
Animals were anesthetized by an intraperitoneal injection of a solution of 75//0.5 mg/kg body 
weight ketamine/metedomidine (Imalgene®/Dorbenvet®). After confirming depth of 
anesthesia by pedal reflex, the dorsum of the animals was shaved and they were placed in 
ventral position. The incision site at the dorsal skin was disinfected with clorohexidine and 2 
medial longitudinal incisions were performed. Subcutaneous pockets were created and 4 
scaffolds were placed in each animal, away from the suture site (incision) to avoid 
inflammation of the wound. The incisions were closed with a 4.0 silk suture (Look, Harvard, 
USA), which was removed 10 days after surgery in the animals with longer implantation 
periods. The anesthesia was then reverted with a subcutaneous injection of 0.25 mg/kg 
Atipamezol (Antisedan®). Once animals become active, they were placed in their home 
cages and water and food were supplied ad libitum. Each animal received a subcutaneous 
injection of 1mg/kg analgesic Butorphanol (Torbugesic®) administered immediately after 
surgery and 24h later, to avoid post-operative pain. At each time point, animals were 
euthanized by intraperitoneal injection of sodium penthobarbital, at a lethal dose, and the 
respective implants retrieved.  
All procedures were conducted in accordance with European regulations for animal 
laboratory testing (European Union Directive 86/609/EEC).  
 
2.4. Histological evaluation 
2.4.1. Implants processing and H&E staining 
 The implants were collected with the surrounding tissues and processed for histology. 
The retrieved implants together with the surrounding tissue were fixed in 10% neutral 
buffered formalin. The specimens were cut to obtain 3 µm thickness longitudinal and 
transverse sections to analyse the kinetics of degradation of the scaffolds. Sections were 
stained with hematoxylin and eosin (H&E) to evaluate the in vivo degradation and cellular 
infiltration throughout the implants.  
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2.4.2. Massonʼs trichrome staining 
 Massonʼs trichrome stain was used to evaluate the amount and the distribution of 
mature collagen. This stain is useful to differentiate collagen fibers from other fibers, 
particularly smooth muscle and elastin. Masson trichrome stains collagen green, nuclei black 
and cytoplasm red.  
 
2.4.3. Immunohistochemistry 
 Immunostaining for α-smooth muscle actin (α-SMA) antibody was performed to 
assess the vascularization degree. Antigen retrieval was heat induced in a water bath at 
96ºC for 20 min, with incubation of the slides in citrate buffer (pH=6). The slides were washed 
with phosphate buffer saline and endogenous peroxidase was blocked with 0.6% hydrogen 
peroxide (H2O2) in methanol, at room temperature (RT) for 30 min. R.T.U. Vectastain® 
Universal Elite ABC Kit (Vector, VCPK-7200) was used for antibody incubation, according to 
the instructions of the manufacturer. Briefly, sections were incubated with primary antibody 
(Abcam, ab5694) overnight at 4ºC, in a humidified atmosphere. After washing with 
phosphate bufferes saline, antibody detection was revealed by using the Peroxidase 
Substrate Kit DAB (Vector, VCSK-4100). Slides were washed in water for 5 minutes and then 
counterstained with Harrisʼ haematoxylin for nuclear contrast. All images were obtained using 
an Olympus BX61 Motorized System Microscope and attached video camera (Olympus 
DP70).  
 
3. RESULTS AND DISCUSSION 
3.1. Weight loss and water uptake 
 In this study, scaffolds based on chitosan-poly(butylene succinate) were prepared by 
melt spinning and fiber bonding (18, 19). The main aim of the in vitro degradation studies 
was to simulate physiological conditions using enzymes present in human serum, which are 
responsible for the degradation of chitosan-poly(butylene succinate) fiber mesh scaffolds. 
 Degradation studies using lysozyme and/or lipase were performed using dynamic (60 
rpm). No differences were observed in the pH of the different degradation solutions after 
each incubation time.  
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 The ability of a material to absorb water and its water permeability are important 
parameters to be studied, since it will influence the absorption of body fluids and the transfer 
of cell nutrients and metabolites throughout the materials. The water uptake data (Figure 1) 
shows that scaffolds immersed in phosphate buffered saline solution (control) in dynamic 
conditions without changing the solutions, have a hydration degree of approximately 40%. 
Those scaffolds were blends of chitosan (50% wt), an extremely hydrophilic material and 
poly(butylene succinate), known to be more hydrophobic than chitosan. When only lysozyme 
was present, the degradation of the scaffolds was quite similar to the control (Figure 1). 
However, in the presence of lipase or lipase with lysozyme, the water uptake of the materials 
had a remarkable increase (Figure 1). This behaviour might be due to degradation of the 
scaffolds in the presence of these enzymes.  
 
 
 
Figure 1. Water uptake of the scaffolds as a function of immersion time in PBS with 
lysozyme (13 mg/L), lipase (110 U/L) and both lipase and lysozyme. PBS alone was used as 
a control (pH 7.4, T=37ºC), in dynamic conditions. 
 
 When analyzing the weight loss profile using lysozyme or lipase, few differences were 
observed (Figure 2). The degradation of chitosan in the human body has been reported to be 
mediated by lysozyme (39, 40). The scaffolds immersed in phosphate buffered saline 
supplemented with lysozyme presented the highest weight loss (5%) in the first week, as 
compared with the other conditions. The weight loss remained constant until the end of the 
experiment (Figure 2). It was clear that degradation of the scaffolds in the presence of 
lysozyme it was not pronounced. This result might be explained by the degree of 
deacetylation of chitosan used in this study. This chitosan has 85% deacetilation degree and 
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it is well documented in the literature that the degree of deacetylation is inversely related to 
the degradation rate (38, 41, 43). 
 
 
Figure 2. Weight loss of the scaffolds as a function of immersion time in PBS with lysozyme 
(13 mg/L), lipase (110 U/L), and both lipase and lysozyme. PBS alone was used as a control 
(pH 7.4, T=37ºC), in dynamic conditions. 
 
 Lipase is an enzyme responsible for the hydrolysis of ester bonds in polyesters (46, 
56). In the presence of lipase the values of weight loss were higher than those obtained in 
the presence of lysozyme, increasing as a function of immersion time (Figure 2). 
Nevertheless, immersion periods up to 12 weeks did not cause the scaffolds to loose their 
structural integrity in the presence of either lysozyme or lipase.  
 In order to investigate the effect of an enzyme cocktail containing lipase and 
lysozyme, the scaffolds were also incubated with both enzymes. The highest weight loss was 
observed in the presence of lipase and lysozyme together (Figure 2). These results are in 
agreement with previous studies using different enzymatic cocktails (57, 58). In contrast with 
the other conditions, lipase and lysozyme together induced the loss of structural integrity of 
the scaffolds after 3 weeks. At the 6th week, all scaffolds lost their structural integrity in the 
presence of both enzymes.  
 
3.2. Morphology of the scaffolds before and after in vitro degradation  
 The morphology of the scaffolds was studied before and after degradation with the 
different solutions by SEM (Figure 3). It is possible to observe the surface of the fibers before 
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degradation (Figures 3A and 3B). The surface of the fibers showed fractures as a result of 
degradation (Figures 3C, 3D, 3E, 3F, 3G, 3H, 3I and 3J). It is possible to observe that the 
samples incubated in phosphate buffered saline, evidence a rougher surface (Figures 3C 
and 3D). The scaffolds incubated with lysozyme solution (Figures 3E and 3F) presented 
cracks at the surface of the fiber, at the same level than in those incubated in phosphate 
buffered saline. This result may be explained by the fact that the chitosan used has a high 
level of deacetylation and it is well documented in the literature that for high degrees of 
deacetylation, lysozyme has a minimal effect on the polymer degradation (38). However for 
scaffolds incubated with lipase solution (Figures 3G and 3H) more cracks are visible at the 
surface of the fibers, which confirms that lipase, is attacking the polyester phase. The 
combination of both lysozyme and lipase (Figures 3I and 3J), as expected by the water 
uptake and weight loss results, evidenced larger cracks at the surface of the fibers. 
 
Figure 3. SEM micrographs showing the morphology of chitosan-poly(butylene succinate) 
scaffolds before degradation (A and B), after 12 weeks in PBS (C and D), plus lysozyme (E 
and F), lipase (G and H) and both lysozyme and lipase (I and J). 
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3.3. Biocompatibility assessment by histological analysis 
 No signs of infection were observed during the study or after surgery. Scaffolds were 
implanted subcutaneously and explants were retrieved after 1, 3, 6 and 12 weeks. Local 
tissue integration, inflammatory response and degradation behavior were assessed by 
histological stains (H&E and Masson´s thricrome). 
 The implantation of a biomaterial may result in injury to tissues or organs (53, 59). 
The tissue response to injury depends on various factors, including the extent of the injury, 
blood-material interactions, extent or degree of cellular necrosis, provisional matrix formation 
and the inflammatory response (54). Materials currently used in clinical applications 
considered non-immunogenic, non-toxic and chemically inert, elicit frequently acute and 
potential chronic inflammatory response (60).  
 Chitin and chitosan have been shown to accelerate wound healing and the attainment 
of a good healing surface. Histological findings suggest that these substances stimulate 
migration of polymorphonuclear and mononuclear cells and accelerate connective tissue 
regeneration and angiogenesis (61). It is also known that chitosan has the ability to attract 
neutrophils and activate macrophages (27, 62).  
 Histological sections of implanted scaffolds revealed that the porous morphology of 
the scaffolds is maintained after 7 days of implantation (Figure 4). 
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Figure 4. Representative H&E stained histological sections of tissues surrounding chitosan-
based implants after (A, B) 1 week and (C, D) 3 weeks of subcutaneous implantation in 
Wistar rats. B and D represent the magnified sections of selected areas (squares) of A and 
B, respectively. Black arrows point to blood vessels. Ch – chitosan, PBS – poly(butylene 
succinate). 
 
 A detailed observation of the sections evidenced that the inflammatory infiltrate is 
mainly constituted of neutrophils (Figure 4B). Those cells are characterized by multilobulated 
nuclei, recruited from blood circulation, reacting to the implantation of chitosan-poly(butylene 
succinate) scaffolds. These cells are characteristic of the acute inflammatory response, 
which is the initial process of inflammation process. Acute inflammation has short duration 
(hours to days) and is characterized by exudation of fluid and plasma proteins (edema) and 
the emigration of leukocytes, mainly neutrophils. The major role of these cells in acute 
inflammatory response is to phagocytose microorganisms and foreign materials. In the case 
of biomaterials, neutrophils are not able to phagocytose them because of the size disparity 
(Figure 4B).  
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 At 3 weeks of implantation, the presence of neutrophils was almost residual. It was 
clear the presence of blood vessels within the scaffold structure (Figures 5C and 5D). 
Furthermore, smooth muscle actin immunostaining is visible inside the fibers of the scaffold 
(Figure 5B), which indicates that connective tissue is growing and vascularization is 
increasing throughout the scaffold (11). At the same time, collagen is being deposited by 
fibroblasts (Figure 6B). The appearance of blood vessels and fibrosis is an indication of a 
chronic inflammatory response. This type of response emerges when a persistent stimulus is 
present (59). 
 
 
Figure 5. Representative α-SMA immunostained sections of tissues inside fibers of chitosan-
poly(butylene succinate) mesh scaffolds after (B) 3 week, (C) 6 weeks and (D) 12 weeks of 
implantation. (A) Negative control. Black arrows point to new blood vessels. Dashed arrow 
points to a phagocyted chitosan particle. Ch – chitosan, PBS – poly(butylene succinate). 
 
 After 6 weeks of implantation (Figures 7A and 7B), it was possible to observe the 
evolution of the acute inflammatory response into a chronic response, by the presence of 
granulatomous tissue and giant cells. Chronic inflammatory response is longer than acute 
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and it is characterized by the presence of mononuclear cells, which includes macrophages, 
lymphocytes and plasma cells (63). Implantation of foreign materials elicits the normal foreign 
body reaction (FBR), i.e., foreign body reaction composed of foreign body giant cells and 
granulation tissue development, constituted by macrophages, fibroblasts and capillaries (54). 
Biodegradable materials elicit a FBR that, with time will become chronic until final 
degradation. In the case of non-degradable materials, the reaction continues until a capsule 
is formed around the implant, isolating it and FBR from the local tissue environment (60). 
Foreign body giant cells are formed when material particles are too large to be phagocytosed 
by macrophages and these cells fuse. In figure 5C it could be observed the phagocytosis of a 
chitosan particle by giant cells (dashed arrow). A major organization of the tissue within the 
implant was observed, with marked presence of α-SMA (Figure 5C) and collagen deposition 
(Figure 6C). 
 
Figure 6. Masson´s thricrome stained sections of tissues of chitosan-poly(butylene 
succinate) mesh scaffolds after (A) 1 week, (B) 3 weeks, (C) 6 weeks and (D) 12 weeks of 
implantation. Green stain is collagen. Ch – chitosan, PBS – poly(butylene succinate). Bar 
correspond to 500 µm. 
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 Up to 3 months, implanted scaffolds did not show evident signs of significant 
degradation. Histological findings only presented the ingrowth of cells within each fiber of the 
scaffold (Figures 8C and 8D). Giant cells attempted to phagocytose the particles of the 
scaffold, with some evidence, as presented in figure 6C. 
 
 
Figure 7. Representative H&E stained histological sections of tissues surrounding chitosan-
based implants after (A, B) 6 week and (C, D) 12 weeks of subcutaneous implantation in 
Wistar rats. B and D represent the magnified sections of selected areas (square) of A and B, 
respectively. Black arrows point to new blood vessels. Ch – chitosan, PBS – poly(butylene 
succinate). 
 
 After 12 weeks of implantation (Figures 7C and 7D), all scaffolds maintained its shape 
and structure, in contrast with the in vitro results, which after 6 weeks incubated in lipase and 
lysozyme, the scaffolds lost their structural integrity (Figure 2). Thus, it is clear that in vitro 
degradation was much faster than in vivo degradation. One fact that must be highlighted is 
that the magnitude of tissue response to a biodegradable material depends upon the site of 
implantation (64). Another issue is the type of the enzymes used, that even at concentrations 
CHAPTER VI. In vitro degradation and biocompatibility assessment of chitosan-poly(butylene succinate) fiber 
mesh scaffolds 
 158 
similar to the ones found in human serum, are not from human origin and its action may be 
slightly different. Furthermore, in vitro tests provide a much more hydrated environment than 
the host environment in vivo. It is important to state as well that pH did not change during the 
entire in vitro experiment, being this a major factor contributing to medium acidification and 
accelerating the degradation effects (autocatalytic effect) (65). Since in vivo the degradation 
was slower it seems that pH also did not change, otherwise the scaffolds would evidence a 
higher degree of degradation.  
 
4. CONCLUSIONS 
 The degradation rate of the scaffolds must be tailored appropriately accordingly with 
the growth rate of the new tissue. It was shown that an enzymatic cocktail with lysozyme and 
lipase (in concentrations equivalent at the ones found in human body) had a strong positive 
effect on the scaffolds degradation in vitro. After 12 weeks of implantation, scaffolds did not 
lose their structural integrity. It should be noted the difference in kinetics of biodegradation in 
vitro and in vivo. A fast degradation in vivo is not desirable, since the degradation should be 
compatible with the rate of tissue formation and bone defects may require some months to 
heal. 
 The implanted scaffolds displayed a normal and mild tissue response, with the 
development of chronic inflammatory response and foreign body reaction.  
 It is therefore worthwhile continuing to investigate the functional performance 
potential of chitosan-poly(butylene succinate) fiber mesh scaffolds for bone tissue 
engineering and regenerative medicine. 
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CHAPTER VII 
Chitosan-poly(butylene succinate) scaffolds and human bone marrow stromal 
cells induce bone repair in a mouse calvaria model  
 
ABSTRACT 
 Tissue Engineering sustains the need of a tridimensional (3D) scaffold to promote the 
regeneration of tissues in volume. Usually, scaffolds are seeded with an adequate cell 
population allowing its growth and maturation upon implantation in vivo.  
 Previous studies obtained by our group evidenced significant growth patterns and 
osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) when 
seeded and cultured on melt based porous chitosan fiber mesh scaffolds. Therefore, it is 
crucial to test the in vivo performance of the in vitro 3D constructs.  
 In this study, chitosan based scaffolds were seeded and cultured in vitro with 
hBMSCs for 3 weeks under osteogenic stimulation conditions and analyzed for cell adhesion, 
proliferation and differentiation. Implantation of 2 weeks pre-cultured constructs in osteogenic 
culture conditions was performed into critical cranial sized defects in nude mice. The 
objective of this study was to verify the scaffold integration and new bone formation. At 8 
weeks of implantation, scaffolds were harvested and prepared for micro computed 
tomography analysis (µCT). Retrieved implants showed good integration with the 
surrounding tissue and significant bone formation, more evident for the scaffolds cultured and 
implanted with human cells. 
 Results of this work demonstrated that chitosan based scaffolds, besides supporting 
in vitro proliferation and osteogenic differentiation of hBMSCs, induced bone formation in 
vivo. Thus, it was validated its osteogenic potential in orthotopic location in immunodeficient 
mice, evidencing good prospects for its use in bone tissue engineering therapies.  
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1. INTRODUCTION 
 Tissue Engineering has emerged in the last 17 years as a new regenerative approach 
for the treatment of a variety of tissues, including bone. The concept is based on the 
development of strategies aimed at obtaining tissue and organ equivalents, that can replace 
or restore the natural features and physiological functions of natural tissues in vivo (1). One 
of the fundamental principles relies on the need of a specific cell population in combination 
with a 3D structure, in order to promote, in volume, tissue regeneration (2) 
 The ideal cell population is considered to be autologous undifferentiated stem cells 
that can be isolated from adult sources. Although embryonic stem cells display an enormous 
potential, they raise ethical and moral issues, mainly because of the removal and destruction 
of human embryos (3). In this context, adult stem cells present an alternative option, being 
isolated from several sources, such as bone marrow (4), brain, liver, skin, skeletal muscle, 
intestine, pancreas, peripheral blood, dental pulp (3), adipose tissue (5) or fetal tissues such 
as umbilical cord (6) or amniotic fluid. Stem cells are defined as cells that have clonogenic 
and self-renewing capabilities and that differentiate into multiple cell lineages (7). 
 Mesenchymal stem cells (MSCs) can be combined with appropriate carriers – 
scaffolds – where a cell population will be grown and further implanted in vivo. Scaffolds 
used for tissue engineering purposes mimic the extracellular matrix (ECM) of the 
regenerating bone environment. Selection of the material for scaffold production in bone 
related applications is a very important step towards the creation of a tissue-engineered 
construct (8). 
 In the last years, natural polymers emerged as an alternative to synthetic polymers, 
mainly due to their biocompatibility and biodegradability. Most of the synthetic biomaterials 
are effective in supporting bone regeneration, either alone or in conjunction with growth 
factors, although they display limitations. Ideally this structure should be biodegradable, 
allowing cells to adhere and proliferate, leading to the formation of ECM (9). Different natural 
based polymers have been proposed for this demanding application, such as starch (10, 11) 
and chitosan (12-15). Chitosan has shown an excellent combination of properties, including 
non-antigenicity and non-cytotoxicity, making this biomaterial quite attractive for bone tissue 
engineering applications (16, 17).  
 We have developed a set of biomaterials using the thermal based processing of 
thermoplastic polymers, by blending chitosan (Ch) with different aliphatic polyesters such as, 
poly-(ε-caprolactone) (PCL), poly(butylene succinate) (PBS), poly(butylene terephthalate 
adipate) (PBTA), and poly(butylene succinate adipate) (PBSA) (18, 19). After testing the 
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eventual cytotoxicity of the developed scaffolds, the next step consisted on the biological 
screening of the most suitable scaffold formulation for bone tissue engineering applications. 
For that, we tested several blends with a mouse mesenchymal stem cell line (BMC9), 
promoting the differentiation into the osteogenic lineage. Results evidenced that the 
chitosan–PBS blend formulation, 50% wt, and 60% porosity, showed the best performance in 
terms of cell behavior (13). Further studies were performed using human bone marrow 
mesenchymal stem cells (hBMSCs) in fiber mesh scaffold morphology, with excellent results, 
in terms of cell adhesion, proliferation and osteogenic differentiation (15). Also, osteogenic 
differentiation of these cells onto the scaffolds was consistently detected by the presence of 
mineralized ECM (20, 21). Therefore, the fibrous morphology enhanced conditions to 
promote cell infiltration into the inner regions of the scaffold. 
 Thus, the next step is to evaluate this tissue engineering strategy in vivo, using a 
feasible animal model. For that, we have selected the cranial defect in nude mice (22, 23) 
since it enables testing several aspects of this strategy. Calvaria is a flat bone, which allows 
the creation of a uniform circular defect with an adequate size for easier surgical procedure 
and specimen handling. Fixation is provided by the dura mater and the overlying skin. The 
model has been thoroughly used and studied and is well reproduced (22-24). The low 
vascularization in cranial area turns this model one of the toughest to evaluate the in vivo 
performance of tissue engineered constructs (25). The nude mouse model is required since 
human cells will be implanted, avoiding graft rejection responses from the host (20). The 
critical size defect (CSD) for this model is 4-5 mm. A CSD is defined as the intraosseous 
wound in a specifically bone and species of animal without spontaneous healing during the 
lifetime of the animal (21). 
 Herein, we have selected compression molded - salt leaching scaffolds. We 
considered this production method as the most appropriate for the development of scaffolds 
that meet the required dimensions to fit into the animal calvaria defect. In the present study, 
we have assessed the in vitro biological behavior of hBMSCs cultured on Ch-PBS scaffolds, 
and these 3D constructs were validated in an in vivo model of a critical cranial defect in nude 
mice.  
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2. MATERIALS AND METHODS 
2.1. Scaffolds production 
 The scaffolds used in this study were produced by melt based compression molding 
followed by salt leaching. Briefly, chitosan was melt blended with PBS (50% in weight) by 
extrusion and further grinded into a powder. This powder was subjected to a solid mixing with 
salt particles with size between 250 and 500 µm, and a salt content of 60%. Details on the 
processing methodology can be found elsewhere (19).  
 
2.2. Scaffolds characterization 
 Cross-sections of all the developed scaffolds were analyzed using a Leica-Cambridge 
S-360 Scanning Electron Microscope (SEM) for preliminary assessment on their morphology. 
All the samples were sputter-coated with gold prior to the SEM analysis. 
 To evaluate the internal 3D structure of the scaffolds, micro computed tomography 
equipment (SkyScan, Belgium) was used as a non-destructive characterization methodology. 
Three scaffolds were scanned in high resolution mode of 8.7 µm x/y/z and an exposure time 
of 1792 ms. The scanner energy was set to 63 keV with 157 µA current. µCT scans followed 
by 3-D reconstruction (µCT analyzer and a µCT Volume Realistic 3D Visualization, from 
SkyScan) of serial image sections allowed to reconstruct and analyze the 3D 
microarchitecture of the scaffolds, pore morphology, determination of porosity and 
interconnectivity. 
 
2.3. In vitro cell culture 
 Human bone marrow mesenchymal stem cells were isolated from bone marrow and 
characterized for the MSC phenotype (26). Cells were expanded in alpha minimum essential 
medium (α-MEM) (Sigma, St. Louis, MO) with 10% fetal bovine serum (Biochrom AG, 
Germany), 1 ng/ml basic fibroblast growth factor (bFGF) (PeproTech, USA) and 1% of 
antibiotic/antimycotic mixture (Sigma, St. Louis, MO).  When a sufficient cell number was 
obtained, cells at passage 2 were seeded onto scaffolds at a density of 2.5x105 cells/scaffold. 
After 24 hours of attachment, constructs were placed in new 24-well plates and 1 ml of 
osteogenic medium containing dexamethasone 10-8 M (Sigma, St. Louis, MO), ascorbic acid 
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50 μg/ml (Sigma, St. Louis, MO) and β-glycerophosphate 10 mM (Sigma, St. Louis, MO) was 
added to each well. The constructs were cultured for 7, 14, and 21 days in a humidified 
atmosphere at 37ºC, containing 5% CO2.  
 
2.3.1. Cell adhesion and morphology by scanning electron microscopy (SEM) 
 Cell adhesion, morphology and distribution throughout the scaffolds were analyzed by 
SEM. Constructs were fixed and dehydrated using a sequence of ethanol gradients and 
further sputter coated with gold (JEOL JFC-1100) to analyze using a Leica Cambridge S360 
scanning electron microscope. 
 
2.3.2. Cell viability assay - MTS test 
 Cell viability was assessed after 3 hours, 7, 14, and 21 days using the MTS test. 
Constructs (n=3) were washed in phosphate buffered saline (Sigma, St. Louis, MO), 
immersed in a mixture consisting of serum-free cell culture medium and MTS reagent in a 5:1 
ratio and incubated for 3 hours at 37 ºC in a humidified atmosphere containing 5% CO2. 
Scaffolds alone incubated for the same time in osteogenic medium were used as controls. 
After this, 200 µl (n=3) were transferred to 96 well plates and the optical density (O.D.) was 
measured on a microplate ELISA reader (BioTek, USA) using an absorbance of 490 nm. 
 
2.3.3. Alkaline phosphatase (ALP) quantification 
Samples were washed with phosphate buffered saline solution and transferred to 1.5 
ml microtubes containing 1ml of ultra-pure water. Constructs (n=3) were cryopreserved at -
80ºC for further analysis. Prior to ALP quantification, samples were thawed and sonicated for 
15 min. 
Alkaline phosphatase (ALP) activity was measured by the specific conversion of p-
nitrophenol phosphate (pNpp) (Sigma, St. Louis, MO, USA) into p-nitrophenol (pNp). The 
enzymatic reaction was set up by mixing 100 ml of the sample with 300 ml of substrate buffer 
containing 1 M diethanolamine HCl (pH 9.8) and 2 mg/ml of pNp. The solution was further 
incubated at 37ºC for 1 hour and the reaction was stopped by adding a solution containing 2 
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M NaOH and 0.2 mM EDTA. The O.D. was determined at 405 nm. A standard curve was 
made using pNp values ranging from 0 to 20 µmol/ml.  
 
2.4. In vivo cranial defect in nude mice 
 Athymic nude mice with 7 weeks old (Harlan, Jerusalem, Israel) were used to 
examine the healing of cranial critical size bone defects in response to transplants in the 
defects according to the method described previously (20). All procedures involving the use 
of animals were conducted in accordance with the guidelines of the Institutional Animal Care 
and Use Committee of the Technion, Israel.           
 The in vitro cell-scaffold constructs were cultured in osteogenic inducing medium for 2 
weeks prior implantation. Each scaffold was seeded with 1x106 cells. All surgeries were 
performed under a protocol approved by Animal Care and Use Committee of the Technion, 
Israel. 
 Two bilateral critical-size circular defects (5 mm diameter and 1 mm thick) were 
performed with a hand drill and trephine bit in the parietal bones of the skull on either side of 
the sagittal suture line (Figure 1). Care was taken not to damage the sagittal suture or to 
interrupt the dura mater beneath the bone. During the procedure, sterile saline was dripped 
over the drilling site in order to avoid extensive heating and to protect the brain. Figure 1 
illustrates the location of the defects in the mice crania. Surgeries were performed under 
general anesthesia (xylazine:ketamine, 1:1 solution in saline) by intra peritoneal injection.  
 
 
 
 
 
 
 
Figure 1. Low magnification image of cranial defects immediately after implantation.  
Cell/constructs (Sc+MSCs) and scaffolds without cells (Sc). 
 
 Scaffolds were randomly implanted into the defects and divided into 2 experimental 
groups that received the following implants: scaffolds seeded and cultured for 2 weeks with 
1x106 hBMSC and scaffold without cells A total of 6 nude mice were used and 12 cranial 
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defects were created. Animals were kept under aseptic conditions. After 8 weeks post-
surgery, animals were euthanized and crania were removed, cleaned, and fixed immediately 
in formalin for 24 h to be analyzed by µCT analysis. Briefly, the mice crania (with or without 
cells) were also analyzed using a high-resolution µCT Skyscan 1072 scanner (Skyscan, 
Kontich, Belgium). Six specimens were scanned in high resolution mode using a pixel size of 
19.13 μm and integration time of 1.7 ms. The X-ray source was set at 91 keV of energy and 
110 μA of current. For all the scanned specimens representative data sets of 1023 slices 
were transformed into binary using a dynamic threshold of 255-120, to distinguish bone from 
polymeric material. This data was used for morphometric analysis (CT Analyzer v1.5.1.5, 
SkyScan). 3D virtual models of the mice crania were created, visualized, and registered 
using image processing software (ANT 3D creator v2.4, SkyScan).  
 
2.5. Statistical analysis 
Results of MTS and ALP are expressed as mean ± standard deviation with n=3 for 
each group. Statistical significance of differences was determined using Studentʼs t-test 
multiple comparison procedure at a confidence interval of 95% (p<0.01). 
 
3. RESULTS AND DISCUSSION 
3.1. Scaffolds characterization 
 SEM micrographs of the porous scaffolds are presented in Figure 2. Figure 2a shows 
scaffolds morphology with 4 mm diameter and 1 mm thick. Previous studies (13, 27, 28) 
demonstrated that these scaffolds had adequate porosity to allow extensive cell proliferation 
(Figure 2b). 
 
Figure 2. SEM micrographs showing a general a) and magnified views b) of Ch-PBS (50% 
wt) salt leaching scaffold. 
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  For a detailed characterization of the scaffoldsʼ internal structure, µCT studies were 
conducted. Images of the region of interest were acquired and transformed into binary 
images (Figure not shown). For all scaffolds, a dynamic threshold ranging from 255–150 gray 
scale values was used to distinguish polymer material from pore voids. Individual 2D analysis 
of the binary images (with a circle of interest of 4.5 mm2) (Figure 2a) was obtained from the 
scaffold cross-sections (Figure 2a), consisting of 300 slices (Figure 2b) and used for 
morphometric analysis (Table I). 
 
 
Figure 3. Representative 2D µCT image (a) and 3D µCT image of the scaffold obtained from 
the sequence of 2D sections (b). 
 
Table I. Porosity, pore size and interconnectivity of the scaffolds produced from chitosan–
PBS blend and salt particle size ranging from 250 to 500 µm 
Porosity (%) Pore size (mm) Interconnectivity (%) 
59.0±11.4 144.9±33.4 60.9±25.7 
 
 The overall porosity of approximately 60% is consistent with the amount of leachable 
NaCl particles used in scaffoldsʼ preparation. The average pore size is lower than expected, 
since the selected range of NaCl particles used was between 250 and 500 micrometers. 
However, the mixing in the solid phase and the subsequent compression molding may cause 
significant reduction of the leachable particles, and consequently of the pore size. The level 
of interconnectivity indicates that most of the pores are open and probably allow cell 
infiltration into the scaffoldʼ inner pores.   
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3.2. In vitro cell culture studies 
3.2.1. Scanning electron microscopy (SEM) 
 SEM analysis showed that cells present a great affinity to the scaffolds surface, which 
is evident by the massive cell adhesion at the surface of the scaffolds (Figure 4).  
 
 
Figure 4. SEM micrographs of the seeded scaffolds cultured under osteogenic induction, 
after 1 week (a and b), 2 weeks (c and d) and 3 weeks (e and f).  
 
 Previous results also showed this cell behavior at the surface of similar scaffolds (15). 
After only 1 week of culture (Figures 4a and 4b) it was already visible a remarkable cell 
proliferation on the 3D structures. At the second week of culture, it was shown that a 
multilayer of cells is covering the surface of the 3D scaffold (Figures 4c and 4d). After 3 
weeks of culture, it was visible that cell proliferation further developed into a dense multilayer 
cell structure (Figure 4e). Furthermore, it was clear the presence of Ca-P deposits (Figure 
4f), corresponding to the produced mineralized ECM that was visible at higher 
magnifications. These results were confirmed by EDS analysis performed in samples 
cultured up to 21 days (Figure 5). Unseeded scaffolds (kept immersed in osteogenic medium 
for the same period of time) were used as control of EDS analysis. The presence of Ca and P 
peaks in the spectrum confirmed the presence of Ca and P elements at the surface of the 
cell seeded scaffolds, which indicated that cells are producing mineralized ECM and thus 
confirming the osteogenic differentiation after 21 days of culture.  
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Figure 5. Energy dispersive spectra (EDS) showing the presence of calcium (#) and 
phosphorous (*) at the surface of the seeded chitosan-PBS (a), and scaffolds without cells 
(control) (b), after 3 weeks under osteogenic culture conditions. 
 
3.2.2. Cell viability (MTS) 
 Cell viability assay (MTS) was used to assess the activity of the cells over time. 
Results demonstrated that hBMSCs seeded onto chitosan-PBS scaffolds were able to reduce 
MTS substrate and progressively increased its metabolic activity during the time of culture 
(Figure 6).  
 
Figure 6. MTS viability assay of constructs and cultured Ch-PBS scaffolds following 3 hours 
(0 days), 7, 14 and 21 days, after cell seeding. Results are expressed as mean ± standard 
deviation with n=3 for each bar, (*) indicate a significant difference (p < 0.01) between testing 
conditions as a function of time. 
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 Cell viability assay (MTS) was used to assess the activity of the cells over time. 
Results demonstrated that hBMSCs seeded onto chitosan-PBS scaffolds were able to reduce 
MTS substrate and progressively increased its metabolic activity during the time of culture 
(Figure 6). The obtained optical density values show a significant increase after 21 days of 
culture. These results were corroborated by SEM images (Figure 4), with the increase of cell 
colonization over time. Furthermore, the presence of such active cells just after seeding (time 
0), corresponded to a great seeding efficacy, which was due to the preference of the cells for 
these scaffolds, instead of the tissue culture plate. These results were in accordance with 
previous results using different cells cultured onto similar scaffold (13, 15, 27, 28). 
 
3.2.3 Alkaline phosphatase activity (ALP) 
 The ALP activity of human MSCs cultured onto the scaffolds did not follow the typical 
trend of this marker of osteogenic differentiation, as it is demonstrated after 21 days (Figure 
7). After this time point, a significant increase in ALP activity was observed (Figure 7). 
Usually, ALP reaches a peak at an earlier time point. However, the presence of visible 
deposits of mineralized matrix after 21 days (SEM images, cell viability and EDS results) 
suggests that cells were viable and continued to deposit matrix, thereby indicating the cellsʼ 
osteogenic differentiation. 
 
 
Figure 7. Alkaline phosphatase activity of hBMSCs cultured on the scaffolds after 1, 2 and 3 
weeks under osteogenic induction. Results are expressed as mean ± standard deviation with 
n=3 for each bar, (*) indicates a significant difference (p < 0.01) between conditions as a 
function of time. 
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3.3. In vivo cranial defect in nude mice  
 After in vitro studies, the following step involved the in vivo validation, using a suitable 
animal model. For that, constructs were tested using a critical size cranial defect. Briefly, we 
planned a study using the critical size calvaria bone defect in nude mice, using Ch-PBS 
scaffolds and human cells. In this way, we were able to test both the viability of the 3D cell-
construct in vivo, as well as the ability of those constructs to regenerate bone tissue. Cranial 
reconstruction represents a unique model to study bone regeneration, mainly because the 
calvaria is an anatomic area under limited mechanical stress, quite unlike the axial skeleton, 
which is subjected to long periods of compressive load (29). We used a 5 mm diameter 
defect, based in previous data found in the literature, showing that adult nude mice did not 
demonstrate significant calvaria bone healing in defects of 3, 4 and 5 mm in diameter (20).  
 Scaffoldsʼ diameter was optimized to enable some swelling before implantation. 
Previous studies showed that these scaffolds have approximately 21% of water uptake. 
Based on these findngs, we have implanted scaffolds with 4.5mm of diameter to match the 
size of the defect at the time of implantation. 
 Bone formation was evaluated by µCT. This methodology is a low radiation and a non 
invasive method for studying the structure of bone samples. This technique can generate 
high-resolution images and provide the accurate quantitative analysis of the bone structure 
parameters (30). 
 Bone possesses some self-healing capacity. However, there is a limit to the size of 
bone fractures and defects that can be self-repaired. This limit is designated “critical size 
defect” (21, 23) and will not heal completely during the lifetime of the patient. For large bone 
defects, medical intervention is often necessary to repair the bone. In this study we have 
used hBMSCs cultured onto chitosan based scaffolds, in order to assess the ability of these 
tissue engineered constructs to induce bone regeneration in nude mice cranial critical size 
defects. To our knowledge, there are few studies documenting the use of xenogeneic grafs 
(i.e., human cells and scaffolds) on the athymic nude mouse model (31-34). We have used 
nude mice in order to study the osteogenic potential of the hBMSCs seeded and cultured on 
Ch-PBS scaffolds, when implanted in a critical size defect. The µCT results suggested that 
after 8 weeks of implantation, constructs promoted bone regeneration of the calvaria critical 
size defect (Figure 8). 
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Figure 8. Micro computed tomography analysis of calvaria defects in nude mice. Images 
show the endpoint result after 8 weeks, of bone healing upon implantation of scaffolds in the 
cranial defect of nude mice. E – empty; Sc – scaffold alone; Sc+MSCs – scaffolds with 
hBMSCs pre-cultured in vitro in osteogenic medium.  
 
 Micro CT images also support that scaffolds cultured with MSCs presented enhanced 
bone ingrowth. Some of the images clearly show an almost complete healing of the defect 
(Figures 8b and 8c). These findings are in accordance with previous results where scaffolds 
seeded with pre-induced osteogenic MSCs enhanced bone regeneration in critical size defect 
when the same animal model was used (32). Scaffolds per se were able to induce some 
bone regeneration/ingrowth (Figure 8c). New bone formation could be due to invading 
reparative cells from the dura or from adjacent host tissues. The selected implantation time 
seemed to be adequate for assessing the complete bone healing at the site defect, as shown 
in figure 8c. Further studies need to be addressed using these scaffolds without cells, in 
immunocompetent animals, to confirm the tissue regeneration ability of Ch-PBS scaffolds. 
 
4. CONCLUSIONS 
 In the present study, chitosan-poly(butylene succinate) scaffolds were successfully 
produced by melt-based compression molding followed by salt leaching. The 
microarchitecture of the scaffolds was assessed by SEM and µCT, revealing a fully porous 
and interconnected 3D structure.  
 In vitro cell culture studies using hBMSCs have shown properties compatible with 
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bone engineering applications. Cells evidenced high levels of viability as a function of 
cultured time and well correlated with SEM images that showed extensive cell colonization of 
the scaffolds. The produced ECM showed the presence of Ca and P elements, detected in 
EDS spectra of cultured scaffoldsʼ surface, which confirmed the mineralization. Successful 
bone regeneration was achieved using the critical size defect in calvaria of nude mice, with 
prominent results for the in vitro cell construct compared to the scaffold without cells. 
 The combination of good biological performance of hBMSCs cultured onto chitosan 
based scaffolds and the ability to regenerate bone tissue in a critical size defect, significantly 
expands previous evidences that these materials can and will have a role to play in bone 
tissue engineering strategies.  
 This study evidenced very positive results that highlight the possibility of chitosan-
PBS-hBMSCs constructs to be used as implants for non load-bearing bone defects. 
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CHAPTER IX 
GENERAL CONCLUSIONS AND FINAL REMARKS 
 Bone is a complex and dynamic tissue composed of different cell types contributing to 
the maintenance of homeostasis throughout life. Fractures are one of the most common 
occurrences associated with the musculoskeletal system. They can result from trauma or 
they can be a side effect of bone related diseases, such as osteoporosis or bone cancer, 
which weakens the bone and compromises its integrity. One of the most promising therapies 
is bone tissue engineering. There are several strategies within this field such as delivery of 
isolated autologous cells, associate these autologous cells to an appropriate three-
dimensional (3D) support - scaffold, and/or by incorporating bioactive molecules into 
scaffolds in order to promote bone regeneration. 
 The bone tissue engineering strategy followed under the scope of this thesis was 
based on the use of a biodegradable scaffold that will act as a support for cells to adhere, 
proliferate and differentiate into an osteogenic phenotype, creating a bone extracellular 
matrix (ECM). These in vitro structures (constructs) were ultimately implanted in a relevant 
animal model, validating the tissue engineering strategy.  
  The scaffold has a major importance in this strategy and several properties are 
required in order to be functional. It must have adequate mechanical properties to support the 
tissue growth at the bone defect. A highly porous and interconnected structure is required for 
cell ingrowth. Furthermore, it should be biodegradable in the human body at a similar rate to 
neo-tissue formation. The material used for scaffold production should be non-toxic, non-
immunogenic and biocompatible. The natural occurring polymer chitosan has emerged as a 
suitable biomaterial to produce scaffolds for bone tissue engineering, since it presents the 
adequate characteristics.  
 In this thesis, the osteogenic potential of chitosan based scaffolds seeded and 
cultured with primary cultures of human bone marrow mesenchymal stem cells (hBMSCs) 
was evaluated. In chapter III, different scaffolds containing the same percentage of chitosan 
and different aliphatic polyesters poly(butylene succinate), poly(butylene terephtalate 
adipate) and poly(caprolactone) were studied, by means of cytotoxicity and direct contact 
tests using cell lines. It was demonstrated that all scaffolds produced by compression 
molding followed by salt leaching were cytocompatible and clearly non-toxic to the cells. The 
direct contact evaluation with a mesenchymal stem cell line, under osteogenic culture 
conditions, showed that chitosan-poly(butylene succinate) (Ch-PBS) formulation evidenced 
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superior results, when compared to all studied formulations. The previous results raised the 
following question: why Ch-PBS formulation promoted superior in vitro cellular response? In 
order to answer that question, the work described in chapter IV was designed to study the 
influence of different percentages of chitosan (0, 25 and 50%) and PBS (100, 75 and 50%) 
on cell behavior in vitro. The main aim of this study was to analyze the influence of chitosan 
content on cell viability and osteogenic differentiation of primary cultures of hBMSCs. 
Scaffolds containing a higher content of chitosan showed greater cell performance, by 
presenting major cell adhesion and enhanced cell viability. Furthermore, it evidenced higher 
levels of alkaline phosphatase (ALP) and upregulation of ostegenic genes. PBS scaffolds 
(100%) consistently showed the inferior results in terms of cell performance. Additionally, the 
in vivo tissue response was evaluated by implanting the higher chitosan containing 
formulation and PBS only, for one month, in different anatomic regions (cranial, auricular and 
submuscular) of rats. The selection of these regions was performed to verify about different 
inflammatory response, based on the degree of vascularization of each tissue. The resident 
inflammatory cells were macrophages, lymphocytes, plasma cells and foreign body giant 
cells. These types of cells are presented when chronic inflammatory reaction is developed, 
and is typical for implanted biomaterials, considered to be normal. The implanted scaffolds 
did not evidence fibrotic encapsulation. PBS scaffolds showed cell necrosis in all tissue 
locations, which is not a positive indication. These results demonstrated that chitosan 
showed a superior effect in terms of cell behavior, both in vitro as in vivo. After the initial 
screening of the proposed chitosan based materials for bone tissue engineering scaffolding it 
was possible to conclude that chitosan is, indeed, relevant to improve the biological 
performance of the scaffolds both in vitro as in vivo in terms of inflammatory response. 
 In chapter V, chitosan–poly(butylene succinate) scaffolds with a different morphology 
were produced to optimize cell ingrowth in the previous morphology. The scaffolds were 
prepared by a fiber bonding methodology, which allowed obtaining a fiber mesh porous 
structure, with an adequate porosity and interconnectivity. Several studies were conducted to 
conclude about cell adhesion, viability, proliferation and osteogenic differentiation onto these 
scaffolds structure. The developed scaffolds also evidenced cytocompatibility and no signs of 
cytotoxicity by showing excellent cell behavior, in terms of adhesion, proliferation and 
viability. Moreover, hBMSCs seeded and cultured onto the 3D structures in osteogenic 
culture conditions, evidenced successful osteogenic differentiation by expressing osteogenic 
related genes, as well as production of a mineralized ECM. This optimized scaffold 
morphology kept the excellent in vitro biological performance of the scaffolds. The next step 
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was to evaluate the degradation of those scaffolds, both in vitro and in vivo, as reported in 
chapter VI. It is known that biodegradation of the scaffold must be at a similar rate as new 
tissue is developed, which turns the study of the degradation of the scaffolds used in tissue 
engineering a key issue to be analyzed. To study chitosan-PBS degradation in vitro, 
enzymes responsible for the degradation of both scaffold components (lipase and lysozyme, 
respectively) were used, in concentrations similar to those in human serum. The weight loss 
and water uptake results showed that an enzymatic cocktail with lysozyme and lipase 
evidenced a greater effect on the scaffolds degradation in vitro. Moreover, in scanning 
electron microscopy (SEM) micrographs, it was possible to observe cracks in the fibers of the 
scaffold structure, being more pronounced for the condition with lipase and lysozyme 
together. The biodegradation of chitosan-PBS scaffolds was also evaluated in vivo by a 
period of three months. For that, a subcutaneous rat model was used. After 12 weeks all 
scaffolds maintained their structural integrity, denoting a slower degradation kinetics that the 
one observed in vitro. Host tissue response evidenced a normal chronic inflammatory 
response. The host tissue response was also assessed. After one week of implantation, it 
was visible an acute inflammatory reaction with the main cells being neutrophils. The 
evolution to a chronic inflammatory response was observed at the third week, when the 
presence of neutrophils was almost residual and the resident cells were macrophages, 
lymphocytes, plasma cells and foreign body giant cells. Alpha smooth muscle actin (α-SMA) 
immunostaining was visible throughout the implant, indicating that connective tissue was 
growing and the degreed of vascularization increased as a function of time. At the same time, 
collagen was being deposited by fibroblasts, confirmed by Masson´s thricrome staining that 
specifically stains mature collagen. After 12 weeks, the connective tissue became more 
organized, by marked presence of α-SMA and more giant cells were observed. Longer time 
periods of implantation are required to investigate about the biodegradation of these 
scaffolds, both in vitro as in vivo. However, the results obtained showed that the slower rate 
of degradation in vivo, as compared to the studied model in vitro, is positive, since the 
kinetics of biodegradation needs to match to the kinetics of the neotissue formation. Being 
the scaffolds a temporary support for tissue ingrowth, in the specific case of bone tissue, this 
time frame is not fast. 
 In the last chapter of this thesis, the tissue engineering strategy herein described was 
validated in vivo. For that, it was used a critical size defect in calvaria of nude mice, which 
allows to use human MSCs by excluding the immune response mediated by T cells. The 
cranial defects used were considered critical size defects with a diameter of 5 mm and two 
for each animal. The hBMSCs were pre-cultured in osteogenic conditions on chitosan-PBS 
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scaffolds obtained by compression molding followed by salt leaching. After assessing the in 
vitro biological performance of the hBMSCs seeded and cultured onto the scaffolds, in 
osteogenic culture conditions, these constructs were implanted into cranial defects in nude 
mice, demonstrating some bone regeneration with chitosan-PBS scaffolds per se, although 
the most prominent results were observed for in vitro matured constructs. These results 
confirm several reports described in the literature, where cell perform a key role in bone 
formation.  
 The work developed in this PhD thesis leads to the conclusion that chitosan-
poly(butylene succinate) scaffolds in combination with autologous bone marrow MSCs have 
all the requisites in vitro as in vivo to design effective bone tissue engineering strategies.  
 It is, however, important to continue the research on these chitosan based scaffolds. 
One of the hypotheses is to assess the degree of bone regeneration in large animal models, 
combining the scaffolds with autologous cells pre-cultured in osteogenic culture conditions. 
Other hypothesis is to use other source of cells, different from bone marrow. Fetal stem cells 
are in the front line of regenerative medicine field, mostly due to its easy accessibility and 
associated non-immunogenicity, which turns these cells adequate to be used in an allogenic 
setting, avoiding issues of donor morbidity. 
 
 
 
 
 
